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1.1 Introduction 
Photochromism has attracted great attention in materials science[1] and as a tool in 
molecular biology.[2] A variety of applications are found in molecular optoelectronics[3] 
and optical data storage.[4-6] In the field of life sciences, molecular switches have been 
used to control enzyme activity,[7-10] Watson-Crick base pairing,[11-13] the regulation of 
neuronal activity by photochromic ligands for ion channels and receptors,[14-20] antibiotic 
effects[21-22] and even the agility of a living organism[23] by light. This broad applicability is 
one of the reasons why photopharmacology has evolved into a vibrant field of research.[24] 
Various photochromic molecules, like azobenzenes,[25] spiropyrans[26], spirooxazines,[26] 
fulgides[27] and diarylethenes[28-29] have been developed. All these photoswitches can be 
reversible toggled between two isomers using light. The well investigated 
dithienylethenes (DTEs), including dithienylmaleimides, are characterized by a nearly 
quantitative photochemical conversion between the photoisomers, which are often 
thermally stable. Irradiation with light of a specific wavelength switches the DTEs between 
their open and closed photoisomer, which differ in conformational flexibility and 
electronic conjugation (Figure 1). Many DTEs show high fatigue resistance.[28]  
 
Figure 1. Reversible photochemical isomerization of a dithienylmaleimide between the open and closed 
photoisomer by irradiation with light of different wavelength. 
Despite their outstanding photophysical properties the synthesis of DTEs, in particular of 
non-symmetric derivatives, is laborious.[13, 30] Different synthetic routes for the 
preparation of dithienylmaleimides were established. Starting from 3,4-
dibromomaleimides and 3,4-diiodomaleimides, respectively, both thiophene moieties can 
be attached by palladium catalyzed Suzuki coupling.[31-33] However, only nitrogen 
protected maleimides can be used and the synthesis of non-symmetric compounds is 
challenging. Another route uses the reaction of a dithienylmaleic anhydride with amines 
to the corresponding maleimide.[34-36] The synthesis of diarylmaleimides by intramolecular 
Perkin condensation of two independently prepared precursors gives selective access to 
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non-symmetric diarylmaleimides.[10, 37-38] Compared to diarylperfluorocyclopentenes and 
diarylcyclopentenes, diarylmaleimides are more hydrophilic and better water soluble, 
which is valuable for applications in biology and pharmacy. The absorption maxima of 
diarylmaleimides are shifted to higher wavelengths and thus the photoisomerization can 
be induced by light with lower energy reducing potential cell damage.[28] Moreover, the 
biocompatibility of diarylmaleimides is known from bisindolylmaleimides, for instance 
arcyriarubins and arcyriaflavins with antibiotic activities, several other potent protein 
kinase and sirtuin inhibitors.[10, 39-43] However, a better synthetic access to functionalized 
photochromic dithienylmaleimides is desirable in order to extend their applications. 
Herein, we discuss the synthesis of functionalized dithienylmaleimides substituted on 
each thiophene moiety and the maleimide nitrogen atom. 
 
1.2 Results and Discussion 
1.2.1 Synthesis 
Functionalization of the maleimide nitrogen atom 
The transformation of diarylmaleic anhydrides into their corresponding diarylmaleimides 
provides an easy access to compounds with a functionalized maleimide nitrogen atom.[28] 
Complex functionalities or protecting groups can be introduced at the maleimide nitrogen 
by reaction with amines or hydrazines. We used the adapted synthetic approach of 
Scandola et al.[36] for the synthesis of anhydride 4 as precursor (Scheme 1). 
 
Scheme 1. Synthesis of dithienylmaleic anhydride 4. 
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Methyl ester 2 was converted to its potassium salt 3 and condensed in a Perkin reaction 
with carboxylic acid 1 yielding the photochromic maleic anhydride 4. The anhydride 
moiety allows the subsequent functionalization with hydrazines or amines (Scheme 2). 
 
Scheme 2. Synthesis of the functionalized photochromic dithienylmaleimides 6-9 starting from maleic 
anhydride 4. 
Therefore, maleic anhydride 4 was treated with -Cbz protected L-glutamic acid -
hydrazide[44] (5) and -Cbz protected L-lysine to give amino acids 6 and 7 with a 
photochromic dithienylmaleimide on each sidechain. Photochromic tripeptides forming 
hydrogels with different aggregation modes mainly depending on the switch moiety were 
recently reported.[45] The reaction of hydrazine hydrate in acetic acid as solvent and 1,2-
dimethylhydrazine dihydrochloride, respectively, with maleic anhydride 4 afforded the 
maleimide nitrogen protected dithienylmaleimides 8 and 9 in good yields (Scheme 2). 
Remarkably, the formation of any maleic hydrazide or other tautomers was not observed. 
The protected maleimides 8 and 9 could be used for further functionalizations on the 
thiophene moieties by palladium-catalyzed cross coupling reactions or other reactions 
using the reactivity of the heteroaryl chlorides. 
 
Functionalization as photochromic amino acid 
Recently, DTE-based non-natural amino acids were synthesized and successfully 
introduced into small peptides.[46] However, their water-solubility is limited due to the 
diarylperfluorocyclopentene core and therefore, we developed a more polar 
dithienylmaleimide amino acid. Compounds 13a and 13b were prepared by a Perkin 
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condensation[10, 37-38] of the thiophene precursors 10 and 11 bearing a protected primary 
amino or carboxyl group, respectively (Scheme 3).  
 
Scheme 3. Perkin condensation of thiophenes 10 and 11 yielding dithienylmaleimide 12 and after 
deprotection 13a and 13b. 
The Alloc group was chosen as a suitable protection for the amine as it is stable during the 
synthesis of compound 12. Diester thiophene 11 provides in 4-position the carboxylic 
ester giving the maleimide core in the Perkin condensation. The ester in 2-position will 
serve as carboxylate of the amino acid. Both carboxylic acids were protected as methyl 
ester. Alloc group and methyl ester of 12 were cleaved simultaneously with boron 
tribromide giving amino acid 13a in 47% yield, accompanied by 20% of the Alloc amino 
acid 13b as byproduct. A selective non-hydrolytic deprotection of the methyl ester of 12 
is possible in low yield using lithium iodide in a polar aprotic solvent.[47-48] A large excess 
of lithium iodide and reflux were necessary to achieve conversion; several solvents were 
tested with best yields in acetone (see Supporting Information, Table S1). Standard basic 
hydrolytic conditions for the deprotection of the methyl ester afforded the deprotected 
maleic anhydride (see Supporting Information, Scheme S2). The synthesis of thiophene 10 
is depicted in Scheme 4. 
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Scheme 4. Synthesis of thiophene 10. 
Bromination[49] of 2-methyl thiophene (14) and subsequent Rosenmund-von Braun 
reaction[50] giving nitrile 16 were performed according to literature procedures. The 
reduction of nitrile 16 with lithium aluminum hydride followed by immediate protection 
with allyl chloroformate afforded carbamate 17 in good yield. Using Fmoc chloride instead 
led to the respective Fmoc derivative in lower yields and caused the formation of side 
products in the subsequent Friedel-Crafts acylation. The yield of glyoxylester 18 in the 
Friedel-Crafts acylation depends critically on the sequence of the reagent addition. Best 
results were obtained by mixing 17 and methyl chlorooxoacetate before adding aluminum 
chloride in small portions. Quenching the reaction with saturated sodium hydrogen 
carbonate solution avoids the addition of hydrochloric acid to the allyl double bond. 
Aminolysis with aqueous ammonia converted the glyoxylester 18 in high yield into 
compound 10. The overall yield for 10 after six steps is 22%. 
Thiophene 11 was prepared by esterification[51] of methyl thiophene acid 19 in the 
presence of thionyl chloride followed by Friedel-Crafts acylation and finally a thallium 
trinitrate (TTN) mediated oxidative rearrangement[52] (Scheme 5). All intermediates were 
isolated in good to excellent yields with an overall yield of 68% for three steps. Initial 
moderate yields for the Friedel-Crafts acylation of around 40% significantly increased to 
77% after rigorous removal of stabilizers from the solvent chloroform. 
 
Scheme 5. Synthesis of thiophene 11. 
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Functionalization by Suzuki coupling 
Dithienylmaleimides are conveniently synthesized by the Perkin-type condensation. The 
reaction of two precursors yields the maleimide core without the need for protection of 
the maleimide nitrogen. Scheme 6 shows the intermolecular Perkin condensation of the 
two chlorosubstituted precursors 22 and 23. 
 
Scheme 6. Perkin condensation of 22 and 23 yielding dithienylmaleimide 24. 
Both precursors can be differently functionalized by Suzuki coupling before used in the 
Perkin condensation yielding non-symmetric dithienylmaleimides. 
 
Scheme 7. Synthesis of functionalized precursors 25-27 and 32-34. 
Recently, we described the synthesis of symmetric diarylmaleimides, with thiophene 
moieties functionalized by palladium-catalysis prior to the condensation reaction.[10] 
Based on this strategy we prepared a small series of non-symmetric diarylmaleimides 
(Scheme 7). The Perkin condensation to the maleimide core was performed under basic 
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conditions combining the different thiophenes. Scheme 8 summarizes the synthesis of the 
non-symmetric photoswitches 35-37. 
 
Scheme 8. Synthesis of non-symmetric substituted dithienylethenes 35-37 by Perkin condensation. 
1.2.2 Photochromic Properties 
The dithienylmaleimide core structure can be toggled reversibly between a ring-open and 
ring-closed photoisomer (Figure 1). The photochemical properties of photochromic 
compounds 4, 6-9, 12, 13a, 13b, 24 and 35-37 were investigated by UV-Vis spectroscopy.  
 
Figure 2. Changes of the UV-Vis absorption spectra of dithienylmaleimide amino acid 12 (50 µM in MeOH) 
upon light irradiation with 312 nm; arrows indicate the changes of the absorption maxima over 42 s 
irradiation in periods of 6 s (Herolab, 6 W); the cuvettes show the color of the solution before and after 
irradiation. 
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Despite of reports that diarylmaleimides are not able to undergo photoisomerization in 
polar solvents due to a twisted intramolecular charge transfer (TICT),[53-55] we could 
observe reversible photoisomerization of the dithienylmaleimides 6-9, 12, 13a, 13b, 24 
and 35-37 in methanol or dimethyl sulfoxide, respectively. Figure 2 shows the changes of 
the UV-Vis spectra of compound 12 upon irradiation with light of 312 nm (Herolab, 6 W). 
Upon irradiating a methanol solution of the ring-open form of compound 12 with UV light 
(312 nm), the absorption band at 250 nm immediately decreases. Simultaneously, new 
absorption maxima at 232 nm, 378 nm and 550 nm arise (Figure 2) causing the color 
change of the sample from slightly yellow to purple. The isosbestic points indicate a clean 
conversion between two components. Compared to typical DTE-cyclopentenes the 
absorption maxima are red shifted. The photostationary state was reached after 42 s of 
irradiation (Herolab, 312 nm, 6 W) and the open form can be regained by irradiation with 
visible light (> 420 nm) for 5 min. The photoswitchable amino acid 12 is stable over at least 
seven closing/opening cycles (Figure 3). 
 
Figure 3. Cycle performance of the dithienylmaleimide amino acid 12 (50 µM in MeOH). Changes in 
absorption at 554 nm were measured during alternate irradiation with light of 312 nm (Herolab, 6 W) for 
60 s and 530 nm (CREE-XP green, 700 mA) for 5 min. 
The absorption maxima and their corresponding extinction coefficients for the open and 
closed form of all synthesized photochromic compounds are summarized in Table 1. 
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Table 1. UV-Vis spectroscopic data of the open and closed (PSS) form of the synthesized photochromic 
compounds.[a] 
Entry Comp. Solvent 
Conc. 
[µM] 
max open () max closed () 
1 4 MeOH 100 242 (26.0), 298 (9.5) 359 (16.0), 523 (3.7) 
2 6 DMSO 50 387 (4.6) 359 (17.4), 510 (3.2) 
3 7 DMSO 50 381 (5.0) 355 (20.8), 500(4.1) 
4 8 DMSO 50 386 (6.0) 359 (22.7), 508 (4.3) 
5 9 DMSO 50 380 (3.3) 351 (12.9), 498 (2.7) 
6 12 MeOH 50 250 (18.5) 
232 (16.2), 378 (13.6), 
550 (3.9) 
7 13a MeOH 50 252 (13.0) 
231 (11.3), 375 (10.0), 
537 (2.7) 
8 13b MeOH 50 250 (14.3) 
232 (12.6), 378 (10.3), 
549 (2.8) 
9 24 MeOH 50 240 (20.2), 370 (4.5) 
234 (20.6), 352 (13.8), 
497 (2.5) 
10 35 MeOH 100 264 (18.5), 292 (17.1) 369 (9.7), 543 (3.0) 
11 36 MeOH 100 
255 (28.8), 291[b] 
(14.3) 
369 (10.1), 540 (3.7) 
12 37 MeOH 100 262 (26.1), 297 (20.7) 391 (11.5), 586 (5.7) 
[a] UV-Vis spectroscopic data are reported for solutions at 25 °C and reported in nm (max) and 103 cm-1 M-1 
(). The PSS were obtained by irradiation of solutions of the open isomer with light of 312 nm (Herolab, 
6 W). [b] Shoulder. 
Interestingly, the long wavelength absorption maximum of compound 13a is blue shifted 
to 537 nm compared to photoswitches 12 and 13b, which may indicate an interaction of 
the Alloc group with the dithienylmaleimide core. In contrast, the selective removal of the 
methyl ester has almost no influence on the photochromic properties. In comparison to 
bischloro dithienylmaleimide 24 the functionalized maleimides 35-37 show a 
bathochromic shift in their absorption maxima of the closed photoisomer. The enlarged 
-system of the substituted thiophenes can explain this shift to higher wavelengths. 
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1.3 Conclusion 
In summary, we have prepared several photochromic dithienylmaleimides. Maleimide 
nitrogen atom functionalized derivatives were obtained by the reaction of dithienylmaleic 
anhydride with different hydrazines and amines. Using a Perkin-type condensation non-
symmetric dithienylmaleimides were synthesized including a photochromic amino acid 
and dithienylmaleimides with different aromatic substituents on each thiophene moiety. 
Reversible photoisomerization in dimethyl sulfoxide and methanol was observed for all 
synthesized photochromic compounds. 
 
1.4 Experimental 
1.4.1 General Information 
Commercial reagents and starting materials were purchased from Acros Organics, Alpha-
Aesar, Fluka, Sigma Aldrich or VWR and used without further purification. Solvents were 
used in p.a. quality and dried according to common procedures, if necessary. To purify the 
chloroform for Friedel-Crafts acylations, it was washed with sulfuric acid (1 M), dried over 
calcium chloride, filtered through silica, subsequently refluxed with phosphorous 
pentoxide (5-10 g L−1) and distilled under nitrogen atmosphere. Compounds 1[10], 2[10], 
5[44], 15[49], 16[50], 20[51], 22[10], 25[10], 28[10], 29[10] and 32[10] were prepared according to 
previously reported procedures. Flash column chromatography was performed on a 
Biotage Isolera One automated flash purification system with UV/Vis detector using Sigma 
Aldrich MN silica gel 60 M (40-63 µm, 230-400 mesh) for normal phase or pre-packed 
Biotage SNAP cartridges (KP-C18-HS) for reversed phase chromatography. Reaction 
monitoring via TLC was performed on alumina plates coated with silica gel (Merck silica 
gel 60 F254, 0.2 mm). Melting points were determined using a Stanford Research Systems 
OptiMelt MPA 100. NMR spectra were recorded on Bruker Avance 300 (1H: 300 MHz, 
13C: 75 MHz), Bruker Avance 400 (1H: 400 MHz, 13C: 101 MHz) and Avance III 600 
(1H: 600 MHz, 13C: 151 MHz) instrument. The spectra are referenced against the NMR-
solvent, chemical shifts are reported in ppm and coupling constants J are given in Hz. 
Resonance multiplicity is abbreviated as: s (singlet), d (doublet), t (triplet), m (multiplet) 
and b (broad). Carbon NMR signals are reported with (+) for primary/tertiary, (−) for 
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secondary and (q) for quaternary carbons. The assignment resulted from DEPT, HSQC and 
HMBC experiments. Mass spectra were recorded on a Finnigan MAT95 (EI-MS), Agilent Q-
TOF 6540 UHD (ESI-MS, APCI-MS), Finnigan MAT SSQ 710 A (EI-MS, CI-MS) or 
ThermoQuest Finnigan TSQ 7000 (ES-MS, APCI-MS) spectrometer. UV/Vis absorption 
spectroscopy was performed using a Varian Cary BIO 50 UV/Vis/NIR spectrometer. IR-
spectra were recorded with a Specac Golden Gate Diamond Single Reflection ATR System 
in a Bio-Rad FT-IR-Spectrometer Excalibur FTS 3000 and peak positions are reported in 
wavenumbers (cm-1). Standard hand-held lamps were used for visualizing TLC plates and 
to carry out the ring-closure reactions at 312 nm (Herolab, 312 nm, 6 W). The ring-opening 
reactions were performed with the light of a 200 W tungsten light bulb which was passed 
through a 420 nm cut-off filter to eliminate higher energy light or the light of a green LED 
(CREE-XP green, 530 nm, 700 mA). The power of the light is given based on the 
specifications supplied by the company when the lamps were purchased. A light detector 
was not used to measure the intensity during the irradiation experiments. 
 
1.4.2 Synthesis and Characterization of Compounds 
3,4-Bis(5-chloro-2-methylthiophen-3-yl)furan-2,5-dione (4) 
To obtain the potassium salt 3, the ester 2 was dissolved in EtOH (2.5 mL/mmol) and KOH 
(1.0 eq) was added. After stirring overnight, the solvent was removed and the crude 
product 3 was used without further purification. A mixture of the acid 1 (984 mg, 
5.16 mmol), the potassium salt 3 (1.25 g, 5.16 mmol) and acetic anhydride (15 mL) was 
heated to 120 °C for 5 h. The reaction was cooled to room temperature and quenched by 
adding water (20 mL). The aqueous phase was extracted with EtOAc (3 x 15 mL). The 
combined organic phases were dried over MgSO4, filtered and the solvent was removed 
under reduced pressure. The crude product was purified by automated flash column 
chromatography (PE/CH2Cl2: 30-60% CH2Cl2) to yield the maleic anhydride 4 (1.07 g, 58%) 
as gray solid; Rf: 0.45 (PE/CH2Cl2: 1/1); m.p.: 205 °C; 1H-NMR (300 MHz, DMSO-d6):  = 
1.94 (s, 6H, thiophene-CH3), 7.03 (s, 2H, thiophene-H); 13C-NMR (75 MHz, DMSO-d6):  = 
14.1 (+), 125.2 (q), 125.3 (q), 127.2 (+), 134.5 (q), 141.4 (q), 164.5 (q); IR (neat) max: 3108, 
2922, 1843, 1766, 1629, 1539, 1460, 1252, 1047, 1177, 990, 919; HR-MS (ESI): calcd. for 
C14H9Cl2O3S2 (M+H)+ 358.9365; found 358.9362. 
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N2-((Benzyloxy)carbonyl)-N5-(3,4-bis(5-chloro-2-methylthiophen-3-yl)-2,5-dioxo-2,5-
dihydro-1H-pyrrol-1-yl)-L-glutamine (6) 
Maleic anhydride 4 (40 mg, 0.11 mmol) was added to a solution of acid hydrazide 5 
(30 mg, 0.10 mmol) in THF (1 mL) in a crimp top vial. After heating to 85 °C for 16 h the 
reaction was quenched with 1 M aqueous HCl solution (1 mL) and water (1 mL). The 
aqueous phase was extracted with EtOAc (3 x 5 mL). The combined organic phases were 
dried over MgSO4 and the solvent was removed under reduced pressure. Purification by 
automated reversed phase flash column chromatography (MeCN/H2O with 0.05% TFA: 
10-95% MeCN) yielded compound 6 (40 mg, 63%) as orange solid; Rf: 0.01 (EtOAc); m.p.: 
103 °C; 1H-NMR (300 MHz, DMSO-d6):  = 1.74 – 1.88 (m, 1H, CO-(CH2)2-CH), 1.92 (s, 6H, 
thiophene-CH3), 2.00-2.10 (m, 1H, CO-(CH2)2-CH), 2.38-2.48 (m, 2H, CO-(CH2)2-CH), 4.03 
(dt, J = 9.0, 4.8 Hz, 1H, CH2-CH-NH), 5.05 (s, 2H, O-CH2-Ph), 7.03 (s, 2H, thiophene-H), 7.31-
7.40 (m, 5H, Ph-H), 7.68 (d, J = 8.0 Hz, 1H, CH-NH-CO), 10.63 (s, 1H, N-NH-CO), 12.70 (bs, 
1H, COOH); 13C-NMR (75 MHz, DMSO-d6):  = 14.2 (+), 26.1 (−), 29.1 (−), 53.1 (+), 65.4 (−), 
125.0 (q), 125.8 (q), 127.6 (+), 127.6 (+), 127.7 (+), 128.3 (+), 131.2 (q), 136.8 (q), 140.6 
(q), 156.1 (q), 166.9 (q), 170.8 (q), 173.4 (q); IR (neat) max: 3250, 2924, 1789, 1727, 1522, 
1462, 1434, 1215, 1175, 990; HR-MS (ESI): calcd. for C27H24Cl2N3O7S2 (M+H)+ 636.0427; 
found 636.0428. 
 
(S)-2-(((Benzyloxy)carbonyl)amino)-6-(3,4-bis(5-chloro-2-methylthiophen-3-yl)-2,5-
dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoic acid (7) 
Triethylamine (131 µL, 0.95 mmol) was added to a suspension of maleic anhydride 4 
(97 mg, 0.27 mmol) and Cbz-Lys-OH (83 mg, 0.30 mmol) in THF (5 mL) in a crimp top vial. 
After heating to 85 °C for 16 h the reaction was quenched with 1 M aqueous HCl solution 
(3 mL) and water (3 mL). The aqueous phase was extracted with EtOAc (3 x 15 mL). The 
combined organic phases were dried over MgSO4 and the solvent was removed under 
reduced pressure. Purification by automated reversed phase flash column 
chromatography (MeCN/H2O with 0.05% TFA: 50-100% MeCN) yielded compound 7 
(138 mg, 82%) as orange solid; Rf: 0.09 (PE/EtOAc: 1/1); m.p.: 88 °C; 1H-NMR (400 MHz, 
DMSO-d6):  = 1.29-1.43 (m, 2H, CH2-(CH2)3-CH), 1.51-1.65 (m, 3H, CH2-(CH2)3-CH), 1.67-
1.79 (m, 1H, CH2-(CH2)3-CH), 1.91 (s, 6H, thiophene-CH3), 3.49 (t, J = 7.1 Hz, 2H, N-CH2-
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(CH2)3), 3.93 (dt, J = 7.9, 4.6 Hz, 1H, NH-CH-CH2), 5.02 (s, 2H, O-CH2-Ph), 7.00 (s, 2H, 
thiophene-H), 7.28-7.37 (m, 5H, Ph-H), 7.57 (d, J = 8.0 Hz, 1H, CO-NH-CH), 12.55 (s, 1H, 
COOH); 13C-NMR (101 MHz, DMSO-d6):  = 14.1 (+), 22.8 (−), 27.4 (−), 30.2 (−), 37.7 (−), 
53.5 (+), 65.3 (−), 124.6 (q), 126.4 (q), 127.6 (+), 127.7 (+), 127.7 (+), 128.2 (+), 132.3 (q), 
136.9 (q), 139.8 (q), 169.6 (q), 173.8 (q); IR (neat) max: 3351, 3095, 2932, 2870, 1698, 
1526, 1438, 1404, 1211, 989; HR-MS (ESI): calcd. for C28H27Cl2N2O6S2 (M+H)+ 621.0682; 
found 621.0684. 
 
N-(3,4-Bis(5-chloro-2-methylthiophen-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)acetamide (8) 
Hydrazine hydrate (39 µL, 0.81 mmol) was added to a solution of maleic anhydride 4 
(97 mg, 0.27 mmol) in acetic acid (3.5 mL). The reaction mixture was heated to 100 °C for 
20 h and then water (10 mL) was added. The aqueous phase was extracted with EtOAc 
(3 x 10 mL). The combined organic phases were dried over MgSO4 and the solvent was 
evaporated in vacuo. Purification by automated phase flash column chromatography 
(PE/EtOAc: 15-50% EtOAc) yielded compound 8 (81 mg, 72%) as orange solid; Rf: 0.23 
(PE/EtOAc: 2/1); m.p.: 131 °C; 1H-NMR (400 MHz, DMSO-d6):  = 1.96 (s, 6H, 
thiophene-CH3), 2.04 (s, 3H, CO-CH3), 7.01 (s, 2H, thiophene-H), 10.58 (s, 1H, NH); 13C-
NMR (101 MHz, DMSO-d6):  = 14.2 (+), 20.0 (+), 125.0 (q), 125.8 (q), 127.6 (+), 131.3 (q), 
140.6 (q), 166.9 (q), 168.5(q); IR (neat) max: 3328, 3088, 2924, 2359, 1717, 1702, 1510, 
1429, 1255, 1193, 988; HR-MS (ESI): calcd. for C16H13Cl2N2O3S2 (M+H)+ 414.9739; found 
414.9741. 
 
3,4-Bis(5-chloro-2-methylthiophen-3-yl)-1-methyl-1H-pyrrole-2,5-dione (9) 
Maleic anhydride 4 (54 mg, 0.15 mmol) and 1,2-dimethylhydrazine dihydrochloride 
(60 mg, 0.45 mmol) were heated to 160 °C for 12 h in PEG400 (2 mL) in a crimp top vial. 
Then water (15 mL) was added and the aqueous phase was extracted with EtOAc 
(3 x 15 mL). The combined organic phases were washed with brine (50 mL), dried over 
MgSO4 and the solvent was removed under reduced pressure. Purification by automated 
phase flash column chromatography (PE/EtOAc: 3-10% EtOAc) yielded compound 9 
(48 mg, 86%) as orange foam; Rf: 0.32 (PE/EtOAc: 19/1); 1H-NMR (300 MHz, CDCl3):  = 
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1.93 (s, 6H, thiophene-CH3), 3.13 (s, 3H, N-CH3), 6.89 (s, 2H, thiophene-H); 13C-NMR 
(75 MHz, CDCl3):  = 14.9 (+), 24.4 (+), 126.0 (q), 127.2 (+), 127.2 (q), 132.7 (q), 140.2 (q), 
170.2 (q); IR (neat) max: 3098, 2924, 2851, 1765, 1697, 1435, 1386, 1250, 1174, 980; HR-
MS (ESI): calcd. for C15H12Cl2NO2S2 (M+H)+ 373.9649; found 373.9652. 
 
Allyl ((4-(2-amino-2-oxoacetyl)-5-methylthiophen-2-yl)methyl) carbamate (10) 
To a solution of oxoacetate 18 (282 mg, 0.95 mmol) in THF (5 mL) was added a NH4OH 
solution (32% in H2O) (1.18 mL, 9.50 mmol) at 0 °C. The reaction was stirred for 90 min at 
room temperature and then quenched with water (5 mL). The aqueous phase was 
extracted with EtOAc (3 x 10 mL). The combined organic phases were dried over MgSO4 
and the solvent was removed under reduced pressure. Compound 10 (253 mg, 94%) was 
obtained as yellow solid and used without further purification; Rf: 0.21 (PE/EtOAc: 1/1); 
m.p.: 108 °C; 1H-NMR (400 MHz, CDCl3):  = 2.70 (s, 3H, thiophene-CH3), 4.44 (d, J = 6.1 Hz, 
2H, thiophene-CH2NH), 4.59 (d, J = 5.1 Hz, 2H, CH2=CHCH2O), 5.21 (dd, J = 10.4, 0.5 Hz, 1H, 
CH2=CHCH2), 5.24-5.43 (m, 2H, CH2=CHCH2 and NH), 5.90 (ddt, J = 16.2, 10.7, 5.5 Hz, 1H, 
CH2=CHCH2), 6.05 (bs, 1H, NH2), 7.06 (bs, 1H, NH2), 7.86 (s, 1H, thiophene-H); 13C-NMR 
(101 MHz, CDCl3):  = 16.7 (+), 39.8 (−), 65.9 (−), 117.9 (−), 129.0 (+), 130.8 (q), 132.7 (+), 
137.0 (q), 155.7 (q), 156.1 (q), 164.4 (q), 182.1 (q); IR (neat) max: 3402, 3301, 3167, 2962, 
1750, 1686, 1649, 1535, 1460, 1254, 1047, 796; HR-MS (ESI): calcd. for C12H18N3O4S 
(M+NH4)+ 300.1013; found 300.1012. 
 
Methyl 4-(2-methoxy-2-oxoethyl)-5-methylthiophene-2-carboxylate (11) 
Thallium trinitrate (850 mg, 1.91 mmol) and 70% HClO4 (0.30 mL) were added to a 
suspension of 21 (316 mg, 1.59 mmol) in MeOH (3 mL) at room temperature. After stirring 
for 24 h the mixture was concentrated under vacuum and diluted with water (5 mL). The 
aqueous phase was extracted with EtOAc (3 x 5 mL) and the combined organic layers were 
dried over MgSO4. The solvent was evaporated and purification of the crude product by 
automated flash column chromatography (PE/EtOAc: 3-15% EtOAc) yielded compound 11 
(331 mg, 91%) as colorless oil; Rf: 0.34 (PE/EtOAc: 5/1); 1H-NMR (300 MHz, CDCl3):  = 2.43 
(s, 3H, thiophene-CH3), 3.54 (s, 2H, thiophene-CH2C(O)OCH3), 3.70 (s, 3H, thiophene-
CH2C(O)OCH3), 3.85 (s, 3H, C(O)OCH3), 7.61 (s, 1H, thiophene-H); 13C-NMR (75 MHz, 
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CDCl3):  = 13.8 (+), 33.8 (−), 52.0 (+), 52.1 (+), 129.0 (q), 130.7 (q), 135.6 (+), 144.0 (q), 
162.6 (q), 170.9 (q); IR (neat) max: 2997, 2953, 2845, 1736, 1704, 1535, 1457, 1392, 1331, 
1291, 1250, 1194, 1132, 1063, 1006, 927, 874, 785, 751; HR-MS (APCI): calcd. for 
C10H12O4S (M+H)+ 229.0529; found 229.0531. 
 
Methyl 4-(4-(5-((((allyloxy)carbonyl)amino)methyl)-2-methyl-thiophen-3-yl)-2,5-dioxo-
2,5-dihydro-1H-pyrrol-3-yl)-5-methylthiophene-2-carboxylate (12) 
KOtBu (1 M in THF, 0.88 mL, 0.88 mmol) was added to a solution of glyoxylamide 10 
(206 mg, 0.73 mmol) in dry THF (5 mL) at 0 °C under nitrogen atmosphere. After stirring 
for 90 min at 0 °C, diester 11 (200 mg, 0.88 mmol) in THF (2 mL) was added at 0 °C and 
stirred for 3 d at room temperature. Then the reaction was quenched with 1 M aqueous 
HCl solution (3 mL) and diluted with EtOAc (10 mL). The organic phase was washed with 
water (2 x 10 mL), brine (10 mL) and dried over MgSO4. The solvent was removed under 
reduced pressure and purification of the crude product by automated flash column 
chromatography (PE/EtOAc: 25-50% EtOAc) yielded 12 (148 mg, 44%) as yellow foam; Rf: 
0.20 (PE/EtOAc: 2/1); 1H-NMR (400 MHz, CDCl3):  = 1.90 (s, 3H, thiophene-CH3); 1.98 (s, 
3H, thiophene-CH3), 3.87 (s, 1H, OCH3), 4.45 (d, J = 6.0 Hz, 2H, thiophene-CH2NH), 4.60 (d, 
J = 4.9 Hz, 2H, CH2=CHCH2O), 5.13-5.27 (m, 2H, CH2=CHCH2 and CH2NHCO), 5.31 (dd, 
J = 17.2, 1.2 Hz, 1H, CH2=CHCH2), 5.92 (ddt, J = 16.2, 10.8, 5.5 Hz, 1H, CH2=CHCH2), 6.90 (s, 
1H, thiophene-H), 7.74 (s, 1H, thiophene-H), 8.30 (bs, 1H, CONHCO); 13C-NMR (101 MHz, 
CDCl3): = 15.0 (+), 15.3 (+), 39.9 (−), 52.3 (+), 65.9 (−), 117.9 (−), 125.8 (q), 126.7 (+), 
127.5 (q), 130.9 (q), 132.7 (+), 134.8 (q), 134.9 (+), 139.4 (q), 142.1 (q), 148.6 (q), 156.0 
(q), 162.1 (q), 170.0 (q), 170.2 (q); IR (neat) max: 3289, 3070, 2952, 1703, 1540, 1458, 
1339, 1248, 994, 909, 727; HR-MS (ESI): calcd. for C21H21N2O6S2 (M+H)+ 461.0838; found 
461.0836. 
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4-(4-(5-(Aminomethyl)-2-methylthiophen-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-
5-methylthiophene-2-carboxylic acid (13a) 
and 4-(4-(5-((((Allyloxy)carbonyl)amino)methyl)-2-methylthiophen-3-yl)-2,5-dioxo-2,5-
dihydro-1H-pyrrol-3-yl)-5-methylthiophene-2-carboxylic acid (13b) 
A solution of BBr3 (1 M in CH2Cl2) (2.0 mL, 2.00 mmol) was added to a solution of 
compound 12 (92 mg, 0.20 mmol) in dry CH2Cl2 (6 mL) in a crimp top vial. The mixture was 
heated to 40 °C for 5 h. Then water (4 mL) was added via syringe and the suspension was 
stirred at 40 °C for additional 30 min. After cooling to room temperature the solvent was 
removed at the rotary evaporator. Purification by automated reversed phase flash column 
chromatography (MeCN/H2O with 0.05% TFA: 3-100% MeCN) yielded compound 13a 
(34 mg, 47%) as yellow solid and compound 13b (18 mg, 20%) as another yellow solid. 
Analytical data of 13a: Rf: 0.02 (PE/EtOAc: 1/1); m.p.: 173 °C; 1H-NMR (600 MHz, MeOD): 
 = 2.00 (s, 3H, thiophene-CH3), 2.08 (s, 3H, thiophene-CH3), 4.27 (s, 2H, thiophene-
CH2NH), 7.18 (s, 1H, thiophene-H), 7.64 (s, 1H, thiophene-H); 13C-NMR (151 MHz, MeOD): 
 = 14.7 (+), 15.3 (+), 38.5 (−), 128.5 (q), 129.3 (q), 132.2 (+), 132.8 (q), 133.1 (q), 135.0 (q), 
135.7 (q), 136.3 (+), 144.6 (q), 149.7 (q), 164.6 (q), 172.4 (q), 172.6 (q); IR (neat) max: 3008, 
2924, 1766, 1712, 1681, 1545, 1463, 1344, 1188, 1137, 1001, 839, 799, 756, 723; HR-MS 
(ESI): calcd. for C16H15N2O4S2 (M+H)+ 363.0469; found 363.0468. 
Analytical data of 13b: Rf: 0.04 (PE/EtOAc: 1/1); m.p.: 94 °C; 1H-NMR (300 MHz, CD3CN): 
 = 1.93 (s, 3H, thiophene-CH3), 1.97 (s, 3H, thiophene-CH3), 4.33 (d, J = 6.3 Hz, 2H, 
thiophene-CH2NH), 4.52 (d, J = 5.3 Hz, 2H, CH2=CHCH2O), 5.18 (dd, J = 10.5, 1.4 Hz, 1H, 
CH2=CHCH2), 5.27 (dd, J = 17.3, 1.6 Hz, 1H, CH2=CHCH2), 5.74-6.05 (m, 1H, CH2=CHCH2), 
6.14 (bs, 1H, CH2NHCO), 6.79 (s, 1H, thiophene-H), 7.60 (s, 1H, thiophene-H), 8.80 (bs, 1H, 
COOH); 13C-NMR (75 MHz, CD3CN):  = 14.7 (+), 15.1 (+), 40.0 (−), 65.9 (−), 117.4 (−), 
127.2 (q), 127.4 (+), 129.0 (q), 131.3 (q), 134.0 (q), 134.3 (+), 136.0 (+), 136.1 (q), 141.1 
(q), 141.7 (q), 149.5 (q), 157.0 (q), 162.8 (q), 171.5 (q); IR (neat) max: 2926, 1981, 1769, 
1709, 1544, 1459, 1344, 1246, 1185, 1150, 1049, 991, 849, 762; HR-MS (ESI): calcd. for 
C20H18N2O6S2 (M+H)+ 447.0679; found 447.0676. 
Alternative procedure to obtain 13b: Compound 12 (40 mg, 0.09 mmol) was dissolved in 
acetone (10 mL) and LiI (350 mg, 2.60 mmol) was added. The mixture was heated to 
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100 °C overnight. After cooling to room temperature it was quenched with 1 M aqueous 
HCl solution (5 mL) and diluted with CH2Cl2 (5 mL). The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 5 mL). The combined organic phases were 
dried over Na2SO4 and the solvent was removed at the rotary evaporator. Automated 
reversed phase flash column chromatography (MeCN/H2O with 0.05% TFA: 3-100% 
MeCN) yielded compound 13b (14 mg, 35%) as yellow solid. 
 
Allyl ((5-methylthiophen-2-yl)methyl)carbamate (17) 
LAH (2.78 g, 73.2 mmol) was added in portions to a solution of nitrile 16 (3.01 g, 
24.4 mmol) in dry Et2O (250 mL) at 0 °C under nitrogen atmosphere. After stirring for 4 h 
at room temperature the reaction was quenched with water (80 mL) and saturated 
aqueous NaHCO3 solution (50 mL) at 0 °C. The suspension was filtered and the aqueous 
phase was extracted with Et2O (3 x 80 mL). The combined organic phases were dried over 
MgSO4 and concentrated in vacuo. Then the residue was dissolved in dry THF (100 mL) 
and pyridine (2.47 mL, 30.50 mmol) was added at 0 °C. Within 1 h allyl chloroformate 
(4.02 mL, 37.82 mmol) in dry THF (5 mL) was dropped to the solution via a syringe pump 
at 0 °C. After stirring for 14 h at room temperature the reaction was quenched cautiously 
with water (50 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases 
were dried over MgSO4 and the solvent was removed under reduced pressure. 
Purification of the crude product by automated flash column chromatography (PE/EtOAc: 
8-15% EtOAc) yielded 17 (3.40 g, 66%) as yellow oil; Rf: 0.20 (PE/EtOAc: 9/1); 1H-NMR 
(400 MHz, CDCl3):  = 2.44 (s, 3H, thiophene-CH3), 4.44 (d, J = 5.7 Hz, 2H, 
thiophene-CH2NH), 4.59 (d, J = 5.3 Hz, 2H, CH2=CHCH2O), 5.05 (bs, 1H, NH), 5.21 (dd, 
J = 10.4, 0.3 Hz, 1H, CH2=CHCH2), 5.30 (dd, J = 17.1, 1.2 Hz, 1H, CH2=CHCH2), 5.92 (ddt, 
J = 16.4, 10.8, 5.7 Hz, 1H, CH2=CHCH2), 6.57 (dd, J = 3.1, 1.0 Hz, 1H, 4-thiophene-H), 6.74 
(d, J = 3.1 Hz, 1H, 3-thiophene-H); 13C-NMR (101 MHz, CDCl3):  = 15.4 (+), 40.1 (−), 65.6 
(−), 117.8 (−), 124.8 (+), 125.7 (+), 132.8 (+), 138.8 (q), 139.9 (q), 155.9 (q); IR (neat) max: 
3335, 3073, 2922, 1695, 1514, 1426, 1236, 982, 799; HR-MS (ESI): calcd. for C10H14NO2S 
(M+H)+ 212.0740; found 212.0740. 
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Methyl 2-(5-((((allyloxy)carbonyl)amino)methyl)-2-methylthiophen-3-yl)-2-oxoacetate 
(18) 
Carbamate 17 (169 mg, 0.80 mmol) and methyl chlorooxoacetate (81 µL, 0.88 mmol) 
were dissolved in dry CH2Cl2 (6 mL) under nitrogen atmosphere. Then AlCl3 (427 mg, 
3.20 mmol) was added in portions at 0 °C and the suspension was stirred for 20 h at room 
temperature. The reaction was quenched with saturated aqueous NaHCO3 solution (1 mL) 
at 0 °C and diluted with water (5 mL). The aqueous phase was extracted with CH2Cl2 
(3 x 5 mL), the combined organic layers were washed with brine (10 mL) and dried over 
MgSO4. After evaporation of the solvent the crude product was purified by automated 
flash column chromatography (PE/EtOAc: 15-40% EtOAc) to obtain 18 (117 mg, 49%) as 
brown oil; Rf: 0.22 (PE/EtOAc: 3/1); 1H-NMR (400 MHz, CDCl3):  = 2.70 (s, 3H, thiophene-
CH3) 3.91 (s, 3H, OCH3), 4.42 (d, J = 6.1 Hz, 2H, thiophene-CH2NH), 4.58 (d, J = 5.3 Hz, 2H, 
CH2=CHCH2O), 5.16-5.34 (m, 3H, CH2=CHCH2 and NH), 5.90 (ddt, J = 16.3, 10.8, 5.6 Hz, 1H, 
CH2=CHCH2), 7.32 (s, 1H, thiophene-H); 13C-NMR (101 MHz, CDCl3):  = 16.3 (+), 39.7 (−), 
52.8 (+), 65.9 (−), 118.0 (−), 127.5 (+), 131.0 (q), 132.6 (+), 138.0 (q), 154.8 (q), 156.1 (q), 
164.0 (q), 180.0 (q); IR (neat) max: 3395, 2954, 1726, 1670, 1517, 1434, 1242, 1200, 1112, 
984, 757; HR-MS (ESI): calcd. for C13H16NO5S (M+H)+ 298.0744; found 298.0744. 
 
Methyl 4-acetyl-5-methylthiophene-2-carboxylate (21) 
Thiophene 20 (800 mg, 5.12 mmol) and acetyl chloride (550 µL, 7.68 mmol) were 
dissolved in purified anhydrous CHCl3 (10 mL) under nitrogen atmosphere. After cooling 
to 0 °C AlCl3 (2.05 g, 15.4 mmol) was added in small portions. The yellow suspension was 
heated to 45 °C overnight upon turning bright red, then the reaction was quenched with 
ice/water and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined 
organic phases were washed with a saturated aqueous solution of NaHCO3 (10 mL) and 
brine (10 mL). The organic phase was dried over MgSO4 and the solvent was evaporated. 
The crude product was purified by automated flash column chromatography (PE/EtOAc: 
5-25% EtOAc) and compound 21 (781 mg, 77%) was obtained as colorless solid; Rf: 0.41 
(PE/EtOAc: 3/1); m.p.: 84 °C; 1H-NMR (300 MHz, CDCl3):  = 2.52 (s, 3H, thiophene-CH3), 
2.76 (s, 3H, acetyl-CH3), 3.88 (s, 3H, OCH3), 8.03 (s, 1H, thiophene-H); 13C-NMR (75 MHz, 
CDCl3):  = 16.8 (+), 29.6 (+), 52.3 (+),128.5 (q), 135.0 (+), 136.3 (q), 155.8 (q), 162.0 (q), 
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193.7 (q); IR (neat) max: 3007, 2957, 1717, 1678, 1539, 1457, 1439, 1254, 1233, 1074, 
1021, 745; HR-MS (APCI): calcd. for C9H10O3S (M+H)+ 199.0423; found 199.0424. 
 
General procedure A: Suzuki coupling: 
To a suspension of Pd2(dba)3 (5 mol%), XPhos (10 mol%), the appropriate boronic acid 
(1.5 eq.) and K3PO4 (1.5 eq.) in 1,4-dioxane (0.5 M) the appropriate ester (1.0 eq.) was 
added. The resulting mixture was heated to 100 °C and stirred overnight. After cooling to 
room temperature the reaction mixture was diluted with EtOAc and the organic phase 
was washed two times with water. The organic phase was dried over MgSO4, filtered and 
the solvent was removed under reduced pressure. 
 
General procedure B: Aminolysis 
An NH4OH solution (25% in H2O) (10.0 eq.) was added to a solution of the appropriate 
oxoacetate (1.0 eq.) in THF (0.3 M) at 0 °C. The reaction was stirred for 1 h at room 
temperature and then quenched with water. The aqueous phase was extracted with 
EtOAc. The combined organic phases were dried over MgSO4, filtered and the solvent was 
removed under reduced pressure. 
 
General procedure C: Perkin condensation 
KOtBu (1 M in THF) (1.2 eq.) was added to a solution of the appropriate amide (1.0 eq.) in 
THF (0.2 M) at 0 °C. After 90 min stirring at 0 °C the appropriate ester (1.0 eq.) was added 
at 0 °C and stirred overnight at room temperature. The reaction was quenched with 1 M 
HCl and diluted with EtOAc. The organic phase was washed three times with water and 
brine. The organic phase was dried over MgSO4, filtered and the solvent was removed 
under reduced pressure. 
 
2-(5-Chloro-2-methylthiophen-3-yl)-2-oxoacetamide (23) 
Compound 23 was prepared from 28 (800 mg, 3.66 mmol) according to general procedure 
B. The amide 23 (640 mg, 85%) was obtained as light yellow solid and used without further 
purification. m.p.: 183 °C; 1H-NMR (300 MHz, DMSO-d6):  = 2.64 (s, 3H, thiophene-CH3), 
7.49 (s, 1H, thiophene-H), 7.94 (bs, 1H, NH), 8.25 (bs, 1H, NH); 13C-NMR (75 MHz, DMSO-
d6):  = 15.2 (+), 123.9 (q), 128.4 (+), 131.4 (q), 150.9 (q), 166.1 (q), 184.2 (q); IR (neat) 
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max: 3446, 3252, 1996, 1670, 1618, 1296, 1221, 1153; HR-MS (ESI): calcd. for 
C7H10ClN2O2S (M+NH4)+ 221.0146; found 221.0144. 
 
3,4-Bis(5-chloro-2-methylthiophen-3-yl)-1H-pyrrole-2,5-dione (24) 
Compound 24 was prepared from amide 23 (600 mg, 2.95 mmol) and ester 22 (720 mg, 
3.54 mmol) according to general procedure C. Purification by automated flash column 
chromatography (heptane/EtOAc: 5/1) yielded 24 (660 mg, 63%) as orange solid. Rf: 0.18 
(heptane/EtOAc: 5/1); m.p.: 237 °C. 1H-NMR (400 MHz, DMSO-d6):  = 1.87 (s, 6H, 
thiophene-CH3), 6.97 (s, 2H, thiophene-H), 11.25 (bs, 1H, NH); 13C-NMR (101 MHz, DMSO-
d6):  = 14.6 (+), 125.0 (q), 127.0 (q), 128.4 (+), 133.6 (q), 140.0 (q), 171.4 (q); IR (neat) 
max: 3381, 2939, 2818, 1653, 1437, 1002; HR-MS (ESI): calcd. for C14H10Cl2NO2S2 (M+H)+ 
357.9525; found 357.9523. 
 
Methyl 2-(5-(4-(tert-butyl)phenyl)-2-methylthiophen-3-yl)acetate (26) 
Compound 26 was prepared from 22 (200 mg, 0.98 mmol) according to general procedure 
A. Purification by automated flash column chromatography (PE/EtOAc: 0-25% EtOAc) 
yielded 26 (163 mg, 55%) as yellow liquid. Rf: 0.63 (PE/EtOAc: 5/1); 1H-NMR (300 MHz, 
CDCl3):  = 1.33 (s, 9H, tBu), 2.41 (s, 3H, thiophene-CH3), 3.55 (s, 2H, thiophene-
CH2C(O)OCH3), 3.71 (s, 3H, thiophene-CH2C(O)OCH3), 7.08 (s, 1H, thiophene-H), 7.32-7.40 
(m, 2H, Ph), 7.43-7.52 (m, 2H, Ph); 13C-NMR (75 MHz, CDCl3):  =13.3 (+), 31.3 (+) 34.1 (−), 
34.6 (q), 52.1 (+), 124.7 (+), 125.2 (+), 125.7 (+), 130.1 (q), 131.6 (q), 134.8 (q), 140.1 (q), 
150.2 (q), 171.6 (q); IR (neat) max: 2961, 1736, 1609, 1520, 1435, 1364, 1239, 1018, 825; 
HR-MS (ESI): calcd. for C18H23O2S (M+H)+ 303.1413; found 303.1418. 
 
Methyl 2-(5-([1,1'-biphenyl]-3-yl)-2-methylthiophen-3-yl)acetate (27) 
Compound 27 was prepared from 22 (500 mg, 2.44 mmol) according to general procedure 
A. Purification by automated flash column chromatography (PE/EtOAc: 0-15% EtOAc) 
yielded 27 (569 mg, 72%) as yellow liquid. Rf: 0.50 (PE/EtOAc: 5/1); 1H-NMR (300 MHz, 
CDCl3):  = 2.44 (s, 3H, thiophene-CH3), 3.58 (s, 2H, thiophene-CH2C(O)OCH3), 3.72 (s, 3H, 
thiophene-CH2C(O)OCH3), 7.19 (s, 1H, thiophene-H), 7.37-7.45 (m, 3H, Ph), 7.46-7.54 (m, 
3H, Ph), 7.59-7.66 (m, 2H, Ph), 7.74-7.76 (m, 1H, Ph); 13C-NMR (75 MHz, CDCl3):  =2.44 (s, 
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3H, thiophene-CH3), 3.58 (s, 2H, thiophene-CH2C(O)OCH3), 3.72 (s, 3H, thiophene-
CH2C(O)OCH3), 7.19 (s, 1H, thiophene-H), 7.37-7.42 (m, 1H, Ph), 7.43-7.47 (m, 3H, Ph), 
7.48-7.54 (m, 2H, Ph), 7.60-7.65 (m, 2H, Ph), 7.74-7.76 (m, 1H, Ph); 13C-NMR (75 MHz, 
CDCl3):  = 13.3 (+), 34.1 (−), 52.1 (+), 124.3 (+), 124.4 (+), 125.3 (+), 126.0 (+), 127.2 (+), 
127.5 (+), 128.8 (+), 129.2 (+), 130.3 (q), 134.8 (q), 135.5 (q), 139.9 (q), 140.9 (q), 141.9 
(q), 171.5 (q); IR (neat) max: 1707, 1597, 1449, 1262, 1174, 755, 696; HR-MS (EI): calcd. 
for C20H18O2S (M+) 322.1028; found 322.1032. 
 
Methyl 2-(5-(4-(tert-butyl)phenyl)-2-methylthiophen-3-yl)-2-oxoacetate (30) 
Compound 30 was prepared from 28 (500 mg, 2.29 mmol) according to general procedure 
A. Purification by automated flash column chromatography (PE/EtOAc: 0-15% EtOAc) 
yielded 30 (350 mg, 48%) as dark yellow liquid. Rf: 0.67 (PE/EtOAc: 5/1); 1H-NMR 
(300 MHz, CDCl3):  = 1.34 (s, 9H, tBu), 2.78 (s, 3H, thiophene-CH3), 3.96 (s, 3H, thiophene-
CH2C(O)OCH3), 7.39-7.44 (m, 2H, Ph), 7.46-7.51 (m, 2H, Ph), 7.63 (s, 1H, thiophene-H); 13C-
NMR (75 MHz, CDCl3):  =16.3 (+), 31.3 (+) 34.7 (q), 52.8 (+), 124.2 (+), 125.6 (+), 126.0 (+), 
130.3 (q), 132.2 (q), 140.5 (q), 151.3 (q), 153.5 (q), 164.1 (q), 180.2 (q); IR (neat) max: 2961, 
2866, 1732, 1676, 1456, 1191, 1127, 993, 753; HR-MS (EI): calcd. for C18H20O3S (M+) 
316.1133; found 316.1139. 
 
Methyl 2-(5-([1,1'-biphenyl]-3-yl)-2-methylthiophen-3-yl)-2-oxoacetate (31) 
Compound 31 was prepared from 28 (500 mg, 2.29 mmol) according to general procedure 
A. Purification by automated flash column chromatography (PE/EtOAc: 0-15% EtOAc) 
yielded 31 (537 mg, 70%) as yellow oil. Rf: 0.40 (PE/EtOAc: 5/1); 1H-NMR (300 MHz, CDCl3): 
 = 2.81 (s, 3H, thiophene-CH3), 3.98 (s, 3H, thiophene-CH2C(O)OCH3), 7.36-7.43 (m, 1H, 
Ph), 7.45-7.49 (m, 2H, Ph), 7.50-7.57 (m, 3H, Ph), 7.60-7.65 (m, 2H, 4-H, Ph), 7.73-7.76 (m, 
2H, Ph, thiophene-H); 13C-NMR (75 MHz, CDCl3):  = 16.4 (+), 52.9 (+), 124.6 (+), 124.7 (+), 
124.8 (+), 126.9 (+), 127.2 (+), 127.7 (+), 128.9 (+), 129.5 (+), 132.3 (q), 133.5 (q), 140.2 (q), 
140.6 (q), 142.2 (q), 154.0 (q), 164.0 (q), 180.1 (q); IR (neat) max: 3028, 1724, 1668, 1598, 
1464, 1197, 1132, 1000, 748, 695; HR-MS (ESI): calcd. for C20H15O2S (M+H+) − (H2O) 
319.0787; found 319.0787. 
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2-(5-(4-(tert-Butyl)phenyl)-2-methylthiophen-3-yl)-2-oxoacetamide (33) 
Compound 33 was prepared from 30 (312 mg, 0.99 mmol) according to general procedure 
B. The amide 33 (250 mg, 84%) was obtained as light yellow solid and used without further 
purification. m.p.: 202 °C; 1H-NMR (300 MHz, DMSO-d6):  = 1.29 (s, 9H, tBu), 2.71 (s, 3H, 
thiophene-CH3), 7.36-7.48 (m, 2H, Ph), 7.51-7.59 (m, 2H, Ph), 7.74 (s, 1H, thiophene-H), 
7.91 (s, 1H, NH), 8.26 (s, 1H, NH); 13C-NMR (75 MHz, DMSO-d6):  = 15.4 (+), 30.9 (+), 34.3 
(q), 124.4 (+), 125.0 (+), 126.0 (+), 129.7 (q), 133.0 (q), 138.9 (q), 150.5 (q), 150.6 (q), 167.0 
(q), 185.5 (q); IR (neat) max: 3395, 2955, 1712, 1651, 1454, 1191, 575; HR-MS (ESI): calcd. 
for C17H20NO2S (M+H+) 303.1240; found 303.1240. 
 
2-(5-([1,1'-Biphenyl]-3-yl)-2-methylthiophen-3-yl)-2-oxoacetamide (34) 
Compound 34 was prepared from 31 (250 mg, 0.74 mmol) according to general procedure 
B. The amide 34 (224 mg, 94%) was obtained as light yellow solid and used without further 
purification. m.p.: 151 °C; 1H-NMR (300 MHz, DMSO-d6):  = 2.73 (s, 3H, thiophene-CH3), 
7.39-7.44 (m, 1H, Ph), 7.47-7.56 (m, 3H, Ph), 7.58-7.66 (m, 2H, Ph), 7.71-7.75 (m, 2H, Ph), 
7.83-7.85 (m, 1H, NH), 7.93 (bs, 2H, Ph, thiophene-H), 8.28 (bs, 1H, NH); 13C-NMR (75 MHz, 
DMSO-d6):  = 15.4 (+), 123.4 (+), 124.4 (+), 125.5 (+), 126.4 (+), 126.8 (+), 127.7 (+), 128.9 
(+), 129.9 (+), 133.1 (q), 133.2 (q), 138.7 (q), 139.5 (q), 141.1 (q), 151.1 (q), 166.9 (q), 185.6 
(q); IR (neat) max: 3393, 3302, 3184, 1721, 1652, 1597, 1456, 1352, 1196, 747, 689, 608; 
HR-MS (ESI): calcd. for C19H16NO2S (M+H+) 322.0896; found 322.0893. 
 
3-(5-(4-(tert-Butyl)phenyl)-2-methylthiophen-3-yl)-4-(5-chloro-2-methylthiophen-3-yl)-
1H-pyrrole-2,5-dione (35) 
Compound 35 was prepared from amide 23 (100 mg, 0.49 mmol) and ester 26 (178 mg, 
0.59 mmol) according to general procedure C. Purification by automated flash column 
chromatography (PE/EtOAc: 0-25% EtOAc) yielded 35 (62 mg, 28%) as dark green solid. Rf: 
0.47 (PE/EtOAc: 5/1); m.p.: 145 °C; 1H-NMR (300 MHz, DMSO-d6):  = 1.28 (s, 9H, tBu), 
1.88 (s, 3H, thiophene-CH3), 1.99 (s, 3H, thiophene-CH3), 7.02 (s, 1H, thiophene-H), 7.28 
(s, 1H, thiophene-H), 7.40-7.49 (m, 4H, Ph), 11.27 (s, 1H, NH); 13C-NMR (75 MHz, DMSO-
d6):  = 14.0 (+), 14.2 (+), 30.9 (+), 34.2 (q), 124.0 (+), 124.3 (q), 124.7 (+), 125.9 (+), 126.7 
(q), 127.8 (q), 127.9 (+), 130.2 (q), 132.7 (q), 134.1 (q), 139.3 (q), 139.5 (q), 139.8 (q), 150.3 
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(q), 171.0 (q), 171.1 (q); IR (neat) max: 3055, 2961, 1707, 1459, 1338, 1181, 1018, 987, 
825; HR-MS (ESI): calcd. for C24H26ClN2O2S2 (M+NH4)+ 473.1119; found 473.1116. 
 
3-(5-([1,1'-Biphenyl]-3-yl)-2-methylthiophen-3-yl)-4-(5-chloro-2-methylthiophen-3-yl)-
1H-pyrrole-2,5-dione (36) 
Compound 36 was prepared from amide 23 (100 mg, 0.49 mmol) and ester 27 (160 mg, 
0.49 mmol) according to general procedure C. Purification by automated flash column 
chromatography (PE/EtOAc: 0-25% EtOAc) yielded 36 (63 mg, 27%) as dark red solid. Rf: 
0.16 (PE/EtOAc: 5/1); m.p.: 137 °C; 1H-NMR (300 MHz, DMSO-d6):  = 1.91 (s, 3H, 
thiophene-CH3), 2.01 (s, 3H, thiophene-CH3), 7.03 (s, 1H, thiophene-H), 7.37-7.44 (m, 1H, 
Ph), 7.46-7.56 (m, 5H, thiophene-H, Ph), 7.58-7.63 (m, 1H, Ph), 7.69-7.75 (m, 2H, Ph), 7.77-
7.79 (m, 1H, Ph), 11.30 (s, 1H, NH); 13C-NMR (75 MHz, DMSO-d6):  = 14.1 (+), 14.2 (+), 
123.2 (+), 124.1 (+), 124.3 (q), 125.1 (+), 126.1 (+), 126.6 (q), 126.7 (+), 127.7 (+), 127.9 (+), 
128.0 (q), 128.9 (+), 129.8 (+), 132.8 (q), 133.6 (q), 134.0 (q), 139.4 (q), 139.5 (q), 139.6 
(q), 140.2 (q), 141.1 (q), 171.0 (q), 171.1 (q); IR (neat) max: 2736, 1705, 1338, 1022, 1006, 
756, 700; HR-MS (ESI): calcd. for C26H22ClN2O2S2 (M+NH4)+ 493.0806; found 493.0804. 
 
3-(5-([1,1'-Biphenyl]-3-yl)-2-methylthiophen-3-yl)-4-(5-(4-(tert-butyl)phenyl)-2-
methylthiophen-3-yl)-1H-pyrrole-2,5-dione (37) 
Compound 37 was prepared from amide 33 (260 mg, 0.86 mmol) and ester 27 (277 mg, 
0.86 mmol) according to general procedure C. Purification by automated flash column 
chromatography (PE/EtOAc: 0-15% EtOAc) yielded 37 (155 mg, 33%) as purple solid. Rf: 
0.13 (PE/EtOAc: 5/1); m.p.: 145 °C; 1H-NMR (300 MHz, DMSO-d6):  = 1.27 (s, 9H, tBu), 
2.02 (s, 6H, thiophene-CH3, thiophene-CH3), 7.31 (s, 1H, thiophene-H), 7.38-7.43 (m, 3H, 
Ph), 7.44-7.50 (m, 5H, thiophene-H, Ph), 7.50-7.52 (m, 1H, Ph), 7.54-7.56 (m, 1H, Ph), 7.58-
7.61 (m, 1H, Ph), 7.68-7.71 (m, 2H, Ph), 7.76-7.78 (m, 1H, Ph), 11.27 (s, 1H, NH); 13C-NMR 
(75 MHz, DMSO-d6):  = 14.3 (+), 31.0 (+), 34.3 (q), 123.2 (+), 124.1 (+), 124.2 (+), 124.8 
(+), 125.4 (+), 126.0 (+), 126.1 (+), 126.8 (+), 127.7 (+), 128.2 (q), 128.3 (q), 128.9 (+), 129.9 
(+), 130.3 (q), 133.7 (q), 133.9 (q), 134.0 (q), 139.4 (q), 139.5 (q), 139.6 (q), 139.8 (q), 140.1 
(q), 141.1 (q), 150.3 (q), 171.6 (q), 171.7 (q); IR (neat) max: 2921, 2851, 1707, 1334, 831, 
756; HR-MS (ESI): calcd. for C36H32NO2S2 (M+H)+ 576.1879; found 576.1875. 
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1.5 Supporting Information 
Non-hydrolytic methyl ester deprotection of 12 
Table S1. Non-hydrolytic methyl ester deprotection of 12. 
Entry LiI [eq.] Solvent T [°C] Isolated yield[a] 
1 3.0 EtOAc RT -- 
2 3.0 EtOAc reflux -- 
3 30 EtOAc reflux 26% 
4 3.0 acetone reflux -- 
5 30 acetone reflux 35% 
6 30 MeCN reflux -- 
7 30 DMSO 100 °C -- 
[a] If conversion was too low, the product 13b was not isolated. 
 
Synthesis of compounds 11S, 12S, 13S and 21S 
 
Scheme S1. Perkin condensation of 10 and 11S yielding dithienylmaleimide 12 and 12S. 
 
Scheme S2. Hydrolytic ester cleavage yielding maleic anhydride 13S. 
 
Scheme S3. Synthesis of ethyl ester 11S. 
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Ethyl 4-(2-methoxy-2-oxoethyl)-5-methylthiophene-2-carboxylate (11S) 
Thallium trinitrate (2.20 g, 4.94 mmol) and 70% HClO4 (2 mL) were added to a suspension 
of 21S (875 mg, 4.12 mmol) in MeOH (10 mL) at RT. After stirring for 24 h the mixture was 
concentrated under reduced pressure and diluted with water (10 mL). The aqueous phase 
was extracted with CHCl3 (3 x 15 mL) and the combined organic layers were dried over 
MgSO4. The solvent was evaporated and purification of the crude product by automated 
flash column chromatography (PE/EtOAc: 3-15% EtOAc) yielded compound 11S (816 mg, 
82%) as yellowish oil. Rf: 0.23 (PE/EtOAc: 9/1); 1H-NMR (400 MHz, CDCl3):  = 1.35 (t, 
J = 7.1 Hz, 3H, O−CH2−CH3), 2.42 (s, 3H, thiophene-CH3), 3.54 (s, 2H, C−CH2−CO), 3.70 (s, 
3H, CO−O−CH3), 4.31 (q, J = 7.1 Hz, 2H, O−CH2−CH3), 7.60 (s, 1H, thiophene-H); 13C-NMR 
(101 MHz, CDCl3):  = 13.8 (+), 14.4 (+), 33.8 (−), 52.2 (+), 61.0 (−), 129.6 (q), 130.6 (q), 
135.4 (+), 143.8 (q), 162.2 (q), 171.0 (q); IR (neat) max: 3081, 2987, 2922, 1730, 1705, 
1460, 1254, 1201, 1172, 1061; HR-MS (ESI): calcd. for C11H14NaO4S (M+Na)+ 265.0505; 
found 265.0502. 
 
Methyl/Ethyl 4-(4-(5-((((allyloxy)carbonyl)amino)methyl)-2-methyl-thiophen-3-yl)-2,5-
dioxo-2,5-dihydro-1H-pyrrol-3-yl)-5-methylthiophene-2-carboxylate (12/12S) 
KOtBu (1 M in THF, 1.34 mL, 1.34 mmol) was added to a solution of 10 (316 mg, 
1.12 mmol) in anhydrous THF (6 mL) at 0 °C under nitrogen atmosphere. After stirring for 
90 min at 0 °C, diester 11S (326 mg, 1.34 mmol) was added and stirred for 15 h at RT. Then 
the reaction was heated to 60 °C for 1 h, quenched with 1 M HCl solution (4 mL) and 
diluted with EtOAc (10 mL). The organic phase was washed with water (3 x 5 mL), brine 
(5 mL) and dried over MgSO4. The solvent was removed under reduced pressure and 
purification of the crude product by automated reversed phase flash column 
chromatography (H2O/EtOH: 20-45% EtOH) yielded 12S (40 mg, 8%) as orange foam, 12 
(74 mg, 14%) as yellow foam and a mixed fraction of both (65 mg). Analytical data of 12S: 
Rf: 0.25 (PE/EtOAc: 2/1); 1H-NMR (400 MHz, CDCl3):  = 1.36 (t, J = 7.1 Hz, 3H, O−CH2−CH3), 
1.91 (s, 3H, thiophene-CH3), 1.97 (s, 3H, thiophene-CH3), 4.33 (q, J = 7.1 Hz, 2H, 
O−CH2−CH3), 4.45 (d, J = 5.9 Hz, 2H, C−CH2−NH), 4.60 (d, J = 4.8 Hz, 2H, O−CH2−CH), 5.14-
5.26 (m, 2H, CH2=CH−CH2 and CH2−NH−CO), 5.31 (dd, J = 17.2, 1.1 Hz, 1H, CH2=CH−CH2), 
5.92 (ddt, J = 16.3, 10.8, 5.6 Hz, 1H, CH2=CH−CH2), 6.90 (s, 1H, thiophene-H), 7.75 (s, 1H, 
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thiophene-H), 7.97 (bs, 1H, CO−NH−CO); 13C-NMR (101 MHz, CDCl3):  = 14.3 (+), 15.0 (+), 
15.3 (+), 39.9 (−), 61.4 (−), 65.9 (−), 117.9 (−), 125.8 (q), 126.7 (+), 127.4 (q), 131.4 (q), 
132.7 (+), 132.8 (q), 134.7 (+), 139.4 (q), 142.1 (q), 148.4 (q), 156.0 (q), 161.7 (q), 170.0 
(q), 170.1 (q); IR (neat) max: 3288, 3071, 2980, 1710, 1541, 1458, 1252, 995, 916, 760; HR-
MS (ESI): calcd. for C22H23N2O6S2 (M+H)+ 475.0993; found 475.0992; UV/Vis (50 µM in 
MeOH): open isomer: max = 250 nm; closed isomer: max = 232 nm, 378 nm, 554 nm. 
 
4-(4-(5-((((Allyloxy)carbonyl)amino)methyl)-2-methylthiophen-3-yl)-2,5-dioxo-2,5-
dihydrofuran-3-yl)-5-methylthiophene-2-carboxylic acid (13S) 
A mixture of 12 and 12S (62 mg) in 10 mL of H2O/MeOH/THF (2:5:3, v/v/v) was stirred for 
20 h with NaOH (78 mg, 1.95 mmol) at RT. After addition of water (10 mL) the reaction 
mixture was washed with EtOAc (2 x 10 mL) and then acidified with conc. HCl to pH 1. The 
aqueous phase was extracted with EtOAc (3 x 10 mL) and the combined organic phases 
were dried over MgSO4. Evaporation of the solvent and purification of the crude product 
by automated reversed phase flash column chromatography (H2O/MeCN: 20-55% MeCN) 
yielded 13S (29 mg)A as green solid. Rf: 0.02 (PE/EtOAc: 1/1); mp: 84 °C; 1H-NMR 
(400 MHz, DMSO-d6):  = 1.90 (s, 3H, thiophene-CH3), 1.96 (s, 3H, thiophene-CH3), 4.28 (d, 
J = 6.1 Hz, 2H, thiophene-CH2NH), 4.49 (d, J = 5.3 Hz, 2H, CH2=CHCH2O), 5.17 (dd, J = 10.5, 
1.4 Hz, 1H, CH2=CHCH2), 5.27 (dd, J = 17.2, 1.5 Hz, 1H, CH2=CHCH2), 5.90 (ddt, J = 17.2, 
10.6, 5.3 Hz, 1H, CH2=CHCH2), 6.86 (s, 1H, thiophene-H), 7.65 (s, 1H, thiophene-H), 7.92 (t, 
J = 6.0 Hz, 1H, CH2NHCO), 13.30 (bs, 1H, COOH); 13C-NMR (101 MHz, DMSO-d6):  = 14.1 
(+), 14.5 (+), 38.8 (−), 64.4 (−), 116.9 (−), 124.9 (q), 125.5 (+), 126.8 (q), 131.6 (q), 133.5 
(+), 133.9 (q), 134.1 (+), 135.6 (q), 140.8 (q), 141.4 (q), 148.6 (q), 155.9 (q), 162.2 (q), 164.9 
(q), 164.9 (q); IR (neat) max: 3327, 3164, 3020, 2925, 1764, 1702, 1541, 1458, 1254, 931, 
750; HR-MS (ESI): calcd. for C20H18NO7S2 (M+H)+ 448.0519; found 448.0516; UV/Vis 
(50 µM in MeOH): open isomer: max = 246 nm; closed isomer: max = 384 nm, 568 nm. 
 
Ethyl 4-acetyl-5-methylthiophene-2-carboxylate (21S) 
A solution of acetyl chloride (128 µL, 1.80 mmol) in anhydrous CHCl3 (2 mL) was added to 
AlCl3 (480 mg, 3.60 mmol) at RT under nitrogen atmosphere. After stirring for 10 min a 
                                                     
A Yield could not be determined because the ratio of 12 to 12S in the mixture was not calculated. 
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solution of 20S (204 mg, 1.20 mmol) in anhydrous CHCl3 (2 mL) was dropped to the 
suspension. The mixture was heated to 60 °C for 9 h, then the reaction was quenched with 
ice/water and the aqueous phase was extracted with CHCl3 (2 x 30 mL). The combined 
organic phases were washed with saturated aqueous solution of NaHCO3 (50 mL) and 
brine (50 mL). The organic phase was dried over MgSO4 and the solvent was evaporated. 
The crude product was purified by automated flash column chromatography (PE/EtOAc: 
8-30% EtOAc) and 21S (180 mg, 71%) was obtained as colorless solid. Rf: 0.15 
(PE/EtOAc: 9/1); mp: 103 °C; 1H-NMR (400 MHz, CDCl3):  = 1.37 (t, J = 7.1 Hz, 3H, 
O−CH2−CH3), 2.52 (s, 3H, thiophene-CH3), 2.75 (s, 3H, acetyl-CH3), 4.34 (q, J = 7.1 Hz, 2H, 
O−CH2−CH3), 8.02 (s, 1H, thiophene-H); 13C-NMR (101 MHz, CDCl3):  = 14.3 (+), 16.8 (+), 
29.6 (+), 61.4 (−), 129.0 (q), 134.7 (+), 136.3 (q), 155.6 (q), 161.6 (q), 193.7 (q); IR (neat) 
max: 3008, 2985, 2944, 1713, 1670, 1540, 1452, 1250, 1236, 1082, 1021, 747; HR-MS (ESI): 
calcd. for C10H13O3S (M+H)+ 213.0580; found 213.0581. 
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1H- and 13C-NMR spectra 
1H-NMR (300 MHz, DMSO-d6) for compound 4:  
 
 
13C-NMR (75 MHz, DMSO-d6) for compound 4: 
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1H-NMR (300 MHz, DMSO-d6) for compound 6:  
 
13C-NMR (75 MHz, DMSO-d6) for compound 6: 
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1H-NMR (400 MHz, DMSO-d6) for compound 7:  
 
13C-NMR (101 MHz, DMSO-d6) for compound 7: 
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1H-NMR (400 MHz, DMSO-d6) for compound 8:  
 
13C-NMR (101 MHz, DMSO-d6) for compound 8: 
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1H-NMR (300 MHz, CDCl3) for compound 9:  
 
13C-NMR (75 MHz, CDCl3) for compound 9: 
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1H-NMR (400 MHz, CDCl3) for compound 10:  
 
13C-NMR (101 MHz, CDCl3) for compound 10: 
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1H-NMR (400 MHz, CDCl3) for compound 11:  
 
13C-NMR (101 MHz, CDCl3) for compound 11: 
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1H-NMR (400 MHz, CDCl3) for compound 11S:  
 
13C-NMR (101 MHz, CDCl3) for compound 11S: 
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1H-NMR (400 MHz, CDCl3) for compound 12:  
 
13C-NMR (101 MHz, CDCl3) for compound 12: 
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1H-NMR (400 MHz, CDCl3) for compound 12S:  
 
13C-NMR (101 MHz, CDCl3) for compound 12S: 
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1H-NMR (600 MHz, MeOD) for compound 13a:  
 
13C-NMR (151 MHz, MeOD) for compound 13a: 
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1H-NMR (300 MHz, CD3CN) for compound 13b:  
 
13C-NMR (75 MHz, CD3CN) for compound 13b: 
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1H-NMR (300 MHz, DMSO-d6) for compound 13S:  
 
13C-NMR (75 MHz, DMSO-d6) for compound 13S: 
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1H-NMR (400 MHz, CDCl3) for compound 17:  
 
13C-NMR (101 MHz, CDCl3) for compound 17: 
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1H-NMR (400 MHz, CDCl3) for compound 18:  
 
13C-NMR (101 MHz, CDCl3) for compound 18: 
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1H-NMR (300 MHz, CDCl3) for compound 21: 
 
13C-NMR (75 MHz, CDCl3) for compound 21: 
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1H-NMR (400 MHz, CDCl3) for compound 21S:  
 
13C-NMR (101 MHz, CDCl3) for compound 21S: 
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1H-NMR (300 MHz, DMSO-d6) for compound 23:  
 
13C-NMR (75 MHz, DMSO-d6) for compound 23: 
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1H-NMR (400 MHz, DMSO-d6) for compound 24:  
 
13C-NMR (101 MHz, DMSO-d6) for compound 24: 
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1H-NMR (300 MHz, CDCl3) for compound 26:  
 
13C-NMR (75 MHz, CDCl3) for compound 26: 
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1H-NMR (300 MHz, CDCl3) for compound 27:  
 
13C-NMR (75 MHz, CDCl3) for compound 27: 
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1H-NMR (300 MHz, CDCl3) for compound 30:  
 
13C-NMR (75 MHz, CDCl3) for compound 30: 
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1H-NMR (300 MHz, CDCl3) for compound 31:  
 
13C-NMR (75 MHz, CDCl3) for compound 31: 
 
 
53 Functionalization of Photochromic Dithienylmaleimides 
1H-NMR (300 MHz, DMSO-d6) for compound 33:  
 
13C-NMR (75 MHz, DMSO-d6) for compound 33: 
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1H-NMR (300 MHz, DMSO-d6) for compound 34:  
 
13C-NMR (75 MHz, DMSO-d6) for compound 34: 
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1H-NMR (300 MHz, DMSO-d6) for compound 35:  
 
13C-NMR (75 MHz, DMSO-d6) for compound 35: 
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1H-NMR (300 MHz, DMSO-d6) for compound 36:  
 
13C-NMR (75 MHz, DMSO-d6) for compound 36: 
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1H-NMR (300 MHz, DMSO-d6) for compound 37:  
 
13C-NMR (75 MHz, DMSO-d6) for compound 37: 
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2.1 Introduction 
Photopharmacology has recently become a vibrant field of research providing tools for 
the investigation of cellular processes and pathogeneses in life sciences.[1-3] In contrast to 
optogenetics,[4] it aims at the artificial control of biological processes with synthetic 
photoswitches by light.[5] Light as an orthogonal control element towards most cellular 
processes can be applied in very high precision in regard to dose, energy, time and 
space.[6] By now various biological targets and functions could be triggered in a reversible 
manner with light, for instance enzyme activity,[7-19] bacterial growth,[20-22] neuronal 
activity,[23-29] the agility of living organisms,[30-33] oligonucleotides,[34-36] the restoration of 
vision[37, 38] and lipids.[39-41] Numerous photochromic scaffolds like azobenzenes,[42] 
spiropyrans as well as spirooxazines,[43] fulgides/fulgimides[44] and diarylethenes[45] have 
been developed. All these photoswitches can reversibly be interconverted between their 
photoisomers by light. 
Cancer and other human diseases are linked to an abnormal expression and/or function 
of histone deacetylases.[46] Therefore, this family of enzymes became an interesting target 
in anticancer research as well as in the field of epigenetics due to their function as 
epigenetic regulators. These enzymes can be found in various organisms and catalyze 
among others the removal of acetyl groups from acetylated lysine residues of various 
protein substrates. The 18 HDACs identified in humans are subdivided in two families: the 
zinc dependent metalloproteins, composed of classes I (HDAC1-3 and 8), IIa (HDAC4, 5, 7 
and 9), IIb (HDAC6 and 10) and IV; and the nicotinamide adenine dinucleotide (NAD+) 
dependent class III (sirtuins).[47] Besides, HDAC inhibitors (HDACi) showed also 
antiproliferative and antiparasitic activities on major human parasitic diseases such as 
leishmaniasis, malaria, schistosomiasis, toxoplasmosis, and trypanosomiasis by 
addressing the HDACs of the parasites.[48] This new approach was further developed 
against schistosomiasis to overcome the reduced efficiency of praziquantel or even the 
resistance of first schistosome flatworm laboratory strains.[49] Praziquantel is still the only 
drug for mass treatment against schistosomiasis. In particular, the HDAC8 of Schistosoma 
mansoni (smHDAC8), which is one of the main species of medical relevance, was 
successfully identified as potential therapeutic target due to its high abundance and 
expression at all life-cycle stages of the parasite.[50, 51] A dose dependent mortality of 
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schistosome larvae and adult worms could be evoked by treating them with generic HDAC 
inhibitors.[52] The HDAC inhibitors for eukaryotic zinc dependent HDACs are classified by 
their moiety interacting with the zinc cation at the polar bottom of the catalytic pocket: 
Hydroxamic acids, short-chain fatty acids, cyclic tetrapeptides and benzamides.[53, 54] 
Different studies on azobenzene based photochromic HDAC inhibitors bearing aliphatic 
hydroxamic acids or benzamides, respectively, have been published recently.[9, 10, 55, 56] 
However, one major drawback of azobenzenes, which are widely used in biological 
applications, can be their thermal reversibility and possible incomplete photoconversion 
due to an substantial overlap of the absorption maxima of both photoisomers.[57] In 
contrast, DTEs as well as fulgides/fulgimides generally feature high photostationary states 
(PSS) with both photoisomers being thermally stable.[45, 58] Both photochromic scaffolds 
can be interconverted with light of specific wavelengths between their open and closed 
photoisomers, which differ in conformational flexibility and electronic conjugation 
(Scheme 1). 
 
Scheme 1. Photochemical ring-closure and the reverse, ring-opening of a DTE and fulgimide scaffold. The 
required 1,3,5-hexatriene system is highlighted in blue. 
We have chosen these two photoswitchable structures to functionalize them with 
aromatic hydroxamic acids which should allow light controllable inhibitory effects of zinc 
dependent HDACs. Aromatic hydroxamic acids have been selected to address the 
individual pockets observed in HDAC isoforms. Based on available X-ray structures of 
hHDAC6, hHDAC8 and smHDAC8 in complex with aromatic hydroxamic acids it is known 
that this class of compounds can be substituted to get isoselective HDAC inhibitors.[59] 
These photochromic inhibitors could be used as a tool to further investigate the biological 
activity and molecular mechanism of HDACs. The comparison of the inhibitory effect of 
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the more flexible open photoisomer with the rigid and planar closed photoisomer should 
also allow to draw conclusions about the flexibility of the binding pocket of the particular 
HDAC in solution. Furthermore, fulgides and fulgimides are well known for applications in 
optical switching and data storage[60-63] but only few examples of their use in a biological 
context are known so far.[64, 65] Their outstanding photochromic properties in polar 
aqueous systems recommend them as a perfect chromophore for such applications. 
 
2.2 Results and Discussion 
2.2.1 Synthesis of DTE Derivatives 
 
Scheme 2. Synthesis of photochromic mono- and bis-hydroxamic acid dithienylcyclopentenes 3 and 6. 
In a first and straightforward design the zinc chelating hydroxamic acid moiety was 
directly attached at the thiophene group of DTEs. Bis-chlorodithienylethene 1 was 
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synthesized according to the method described in literature.[66] Depending on the reaction 
conditions the chlorine/lithium exchange can be controlled to occur selectively on one or 
both thiophenes, respectively.[66, 67] The further reaction with gaseous carbon dioxide 
afforded the required carboxylic acid moieties in very good yields. The mono-acid 2 was 
further functionalized by activation with thionyl chloride and in situ reaction with aqueous 
hydroxylamine yielding target hydroxamic acid 3 in only 26%. A two-step synthesis 
improved this functionalization step for the symmetric bis-carboxylic acid 4. After 
converting the carboxylic acids into methyl esters, they were reacted with aqueous 
hydroxylamine yielding photoswitch 6 in overall 40%. An overview of the synthesis is 
depicted in Scheme 2. 
 
Scheme 3. Synthesis of dithienylmaleimides 10, 12 and 13. 
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In a second approach we attempted to utilize the higher water solubility of 
dithienylmaleimides compared to dithienylcyclopentenes. Therefore, DTE 9 was 
synthesized by a Perkin type condensation from known precursors 7 and 8 (Scheme 3).[68] 
A subsequent exchange of the ester moiety with the desired hydroxamic acid afforded 
dithienylmaleimide 10 in good yield. Unfortunately, all attempts to synthesize a 
symmetric dithienylmaleimide with a free NH group bearing a methyl ester on each 
thiophene were not successful. The maleimide of DTE 9 was subsequently methylated 
yielding a protected precursor 11 for further functionalization. However, all approaches 
to convert the chlorine of 11 into a carboxylic acid or methyl ester by various methods 
failed. In addition, the methyl ester of 11 could also not selectively be transformed into 
the corresponding hydroxamic acid without an undesired side reaction on the maleimide 
core. Depending on the reaction conditions we could isolate either 12 or 13 as main 
product indicating that the methylated maleimide shows a higher intrinsic reactivity with 
hydroxylamine than the methyl ester on the thiophene. 
 
2.2.2 Photochromic Properties of the DTEs 
The DTEs are a well-known class of photochromic scaffolds. In general, they are 
characterized by their excellent photochromic properties like almost quantitative 
photochemical conversion, high fatigue resistance and thermal stability of both 
photoisomers.[45] All these properties are beneficial for photochromic enzyme inhibitors. 
As dimethyl sulfoxide is a standard solvent for stock solutions in inhibitor screening it was 
used as solvent for the investigations of the photoisomerization of the prepared DTEs by 
UV-Vis absorption spectroscopy. Solutions (100 µM) of 3, 6, 10, 12 and 13 were irradiated 
with UV light of 300 nm or 312 nm, respectively. In contrast to reports in literature that 
dithienylmaleimides cannot undergo photoisomerization in polar solvents like DMSO due 
to a twisted intramolecular charge transfer (TICT),[69-71] we could detect reversible 
photochromism of 10. During irradiation ( = 300 nm), a rapid color change from colorless 
to deep violet was observed. This resulted in new absorption bands at max = 369 nm and 
535 nm. The isosbestic points (Table 1) indicate a clean, two-component switching (see 
Supporting Information, Figure S1). Due to a substantial overlap of the absorption maxima 
of the open and closed isomers a maximum PSS of only 57% at UV-irradiation ( = 300 nm) 
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could be reached. Repetitive cycle measurements of compound 10 showed good fatigue 
resistance (see Supporting Information, Figure S1b). However, compounds 12 and 13 did 
not show photochromic switching properties in DMSO at all. Compound 12 was also 
dissolved in a less polar toluene/THF mixture and irradiated ( = 312 nm). Hardly any 
reversible photoisomerization was detected (see Supporting Information, Figure S2). 
Therefore, we suppose that a hydroxyl substitution of the maleimide nitrogen negatively 
affects the photophysical properties in general. In accordance with a recent report in 
literature[72] we also could not photocyclize dithienylmaleimide 10 by UV-exposure to the 
closed isomer in aqueous solution. In contrast, the closed photoisomer could be opened 
in aqueous solution by irradiation with visible light ( = 530 nm). The solution was 
prepared by dissolving a DMSO stock solution of the closed photoisomer into aqueous 
PBS. 
The photochromic properties of the synthesized dithienylcyclopentenes 3 and 6 differed 
from them of dithienylmaleimide 10. Upon irradiation ( = 312 nm) of 3 a quick color 
change from colorless to orange was observed because of an arising new maximum at 
max = 488 nm. However, the lack of distinct isosbestic points in the spectral evolution as 
well as a fast degradation of 3 at repetitive switching cycle measurements indicate an 
irreversible side reaction (see Supporting Information, Figure S3). Further investigations 
by continuous UV-irradiation ( = 312 nm) supposed the undesired, irreversible formation 
of a byproduct (Scheme 4). 
 
Scheme 4. Irreversible formation of the byproduct of 3 upon continuous UV-irradiation. 
The phenomenon of this annulated isomer has been reported previously, but the 
mechanism of the byproduct formation which has to be related to the substitution pattern 
of the DTEs is not yet fully understood.[73-75] Following the photoisomerization by UV-Vis 
absorption spectroscopy upon continuous irradiation, a decrease of the evolving 
maximum at  max = 488 nm was observed. HPLC traces show that, upon reaching the PSS 
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after 45 s, at which the highest amount of the closed isomer (40%) is generated, 23% of 
the byproduct has already formed and the nearly quantitative formation of it is completed 
after 220 s of irradiation (see Supporting Information, Figure S4 and Figure S5). 
Nevertheless, the undesired byproduct was also used in the biological assays although its 
formation is irreversible and it cannot be reconverted to the open isomer. 
Dithienylcyclopentene 6 showed slightly different photochromic properties. Upon 
irradiation ( = 312 nm) a quick color change from colorless to purple was observed. 
Compound 6 had a much higher fatigue resistance than compound 3 and upon reaching 
the PSS (80% closed isomer) after 60 seconds of irradiation only traces of the 
corresponding byproduct had been formed. However, the byproduct could be formed by 
further continuous irradiation with UV-light requiring a much longer irradiation time of 
640 s compared to DTE 3 (see Supporting Information, Figure S6). The symmetric 
substitution of 3 and consequently a symmetric electron distribution in the DTE seems to 
prevent a quick formation of the byproduct. All photophysical properties of the DTEs 3, 6, 
and 10 are summarized in Table 1. 
Table 1. Photochromic properties of DTEs 3, 6, and 10 (100 µM in DMSO). 
Entry Compound 
max open 
[nm] 
max PSS 
[nm] 
Isosbestic 
points [nm] 
PSS [%]* 
1 3 - 488 - 40:37:23 
2 6 - 348, 523 368, 426 80:17:3 
3 10 367 369, 535 301, 394, 415 57:43:0 
* determined by HPLC measurements (closed isomer:open isomer:byproduct). 
2.2.3 Enzyme Inhibition 
Next, the inhibitory effect of compounds 3 (open and byproduct), 6 (open and PSS), 10 
(open and PSS), 12 and 13 against several HDACs was determined using two different 
assays. On the one hand, a homogenous histone deacetylase assay established by Jung et 
al. was used for hHDAC1 and hHDAC6. The enzymatic conversion was quantified by using 
(S)-[5-acetylamino-1-(4-methyl-2-oxo-2H-chromen-7-ylcarbamoyl)-pentyl]-carbamic acid 
benzyl ester also termed ZMAL[76] as fluorescent substrate for deacetylation followed by 
a tryptic digestion step.[77] On the other hand, the commercially available Fluor de Lys-
HDAC8 Fluorometric Drug Discovery Assay Kit of EnzoLifeScience was used in a modified 
  
70  Results and Discussion 
way for hHDAC8 and smHDAC8. Stock solutions (10 mM) of compounds 3, 6 and 10 in 
DMSO were irradiated with UV-light to generate the corresponding closed isomer or 
byproduct prior to the biological assays, respectively. Table 2 summarizes an initial 
screening of inhibitory effects at two fixed inhibitor concentrations. 
Table 2. Inhibitory effects of the respective isomers of compounds 3, 6, 10, 12 and 13 against hHDAC1, 
hHDAC6, hHDAC8 and smHDAC8. 
Entry Compound 
Conc. 
[µM] 
hHDAC1 
[%] 
hHDAC6 
[%] 
hHDAC8 
[%] 
smHDAC8 
[%] 
1 3 open 50 69 97 92 75 
2 3 byprod. 50 59 83 94 71 
3 3 open 10 25 90 87 65 
4 3 byprod. 10 14 63 89 61 
5 6 open 50 86 100 98 73 
6 6 PSS 50 84 99 98 82 
7 6 open 10 53 99 97 73 
8 6 PSS 10 60 97 99 89 
9 10 open 50 81 97 100 95 
10 10 PSS 50 90 97 100 96 
11 10 open 10 50 92 89 84 
12 10 PSS 10 59 87 99 89 
13 12 50 64 84 99 91 
14 12 10 19 59 95 75 
15 13 50 n.i. 35 23 n.i. 
16 13 10 n.i. 9 11 n.i. 
n.i.: no inhibition 
These preliminary results show strong inhibition for most compound species especially 
for hHDAC6 and hHDAC8. As expected, compound 13 exhibits only low or no inhibition 
effects on all tested zinc dependent HDACs due to the lack of the zinc chelating 
hydroxamic acid moiety. The hydroxylated maleimide does also not bind efficiently to the 
zinc cation because of the restricted size of the HDAC binding pocket. Subsequently, the 
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IC50 values of the most promising photochromic inhibitors 3 and 6 were determined 
(Table 3). 
In general, very potent inhibition of hHDAC6 and hHDAC8 is observed for both isomers of 
compound 6 as well as a preference for the human over the S. mansoni isotype is 
registered. The activity on hHDAC1 is in the lower micromolar range which can be 
explained by the narrow binding pocket which does not allow a favorable coordination of 
the hydroxamic acid group to the zinc ion. Generally, the difference in the observed IC50 
values of all compounds is too small to perform assays with direct irradiation. 
Table 3. IC50 values of the respective isomers of DTEs 3 and 6 against different HDACs. 
Entry Compound 
hHDAC1 
[µM] 
hHDAC6 
[µM] 
hHDAC8 
[µM] 
smHDAC8 
[µM] 
1 3 open 15 ± 1.2 1.8 ± 0.2 1.6 ± 0.6 5.8 ± 1.1 
2 3 byprod. 26 ± 2.5 3.9 ± 0.2 2.7 ± 0.9 22 ± 3.9 
 ratio < 2-fold 2-fold < 2-fold 4-fold 
3 6 open 4.2 ± 0.7 0.213 ± 0.018 0.248 ± 0.029 18 ± 2.1 
4 6 PSS 5.1 ± 0.8 0.297 ± 0.041 0.262 ± 0.036 4.5 ± 0.8 
 ratio no difference no difference no difference 4-fold 
 
 
2.2.4 Synthesis of the Fulgimide Derivatives 
Due to the moderate photochromic properties and small difference in their biological 
inhibitory effects between the isomers of the prepared DTEs we changed the 
photochromic scaffold to fulgimides. They can be prepared by the reaction of the 
anhydride moiety of a fulgide with amines. The synthesis of our fulgimide based 
photochromic HDAC inhibitors is depicted in Scheme 5. Fulgide 16 was prepared by an 
optimized procedure[78] via Stobbe[79-81] condensation from precursors furan 14 and 
diethylsuccinate 15 in 20% yield. Further reaction with two different amines under basic 
conditions and CDI as coupling reagent to form the bisimide, which is the crucial step, 
afforded fulgimides 17 and 19. Interestingly, the reaction with aniline worked best with 
potassium carbonate as base, the reaction of the primary amine with triethylamine. In a 
last step the hydroxamic acid moiety was introduced by treating esters 17 and 19 with 
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aqueous hydroxylamine solution, respectively. Due to the high nucleophilicity of 
hydroxylamine in basic media a lot of side reactions occurred in this step and the desired 
target compounds 18 and 20 could only be isolated in low yields. 
 
Scheme 5. Preparation of fulgimides 18 and 20. 
 
2.2.5 Photochromic Properties of the Fulgimides 
The photochromism of fulgides and fulgimides has its origin in a concerted 
electrocyclization and occurs very fast. Therefore they are widely used in materials 
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science and optical data storage.[58] By introducing a bulky substituent on the 1,3,5 
hexatriene system, like an isopropyl group in our case, the undesired UV-light induced E/Z 
isomerization from the open E-fulgimide isomer to the closed Z-isomer is suppressed 
(Scheme 6).[78] 
 
Scheme 6. Reversible photochemical isomerization of a fulgimide between the E-open and closed 
photoisomer by irradiation with light of different wavelength. The photochemical isomerization from the 
open E-isomer to the open Z-isomer is suppressed by the sterically demanding isopropyl group. 
Only the open E-isomer can undergo a photocyclization to the closed isomer which is 
thermally stable. First, we investigated the photochromic properties of compounds 18 
and 20 in DMSO (100 µM). Upon irradiation ( = 365 nm) a quick color change from 
colorless to pink was observed, resulting in a new broad absorption band with a maximum 
around 520 nm for each compound. The photochromic properties of fulgimides 18 and 20 
are summarized in Table 4. The PSS of both fulgimides exceeds 95% which is beneficial 
and advantageous for photochromic enzyme inhibitors as the interaction with the enzyme 
can be assigned to mainly one photoisomer. 
Table 4. Photochromic properties of fulgimides 18 and 20 (100 µM in DMSO). 
Entry Compound 
max open 
[nm] 
max PSS 
[nm] 
Isosbestic 
points [nm] 
PSS [%]* 
1 18 335 (shoulder) 519 280, 380 98 
2 20 333 (shoulder) 518 293, 312, 388 96 
* Determined by HPLC measurements. 
By way of example, Figure 1a illustrates the spectral evolution (marked with arrows) of 
compound 20 upon irradiation ( = 365 nm). The isosbestic points (Table 4) indicate a 
clear two-component switching. After 30 s of irradiation the PSS was reached and 96% of 
the open isomer were converted to the closed photoisomer. The repetitive cycle 
  
74  Results and Discussion 
performance with light of  = 365 nm for closing and  = 530 nm for opening shows a high 
fatigue resistance over seven cycles (Figure 1b). 
In addition, the photochromic properties of fulgimides 18 and 20 were also investigated 
in aqueous PBS (pH = 7.4) with 1% of DMSO as solvent. Both compounds showed a similar 
reversible photochromic performance like in DMSO with slightly bathochromically shifted 
maxima. Only at the repetition of the photoisomerization a slightly reduced fatigue 
resistance was observed (see Supporting Information, Figure S8 and Figure S9). In 
summary, the outstanding photochromic properties of the prepared fulgimides in polar 
as well as aqueous systems make them perfect candidates for use in biological 
environment. 
 
Figure 1. a) Changes in absorption spectra of fulgimide 20 (100 µM in DMSO) upon continuous irradiation 
for 0, 5, 10, 15, 20, 25, and 30 s with light of  = 365 nm until the PSS is reached. The cuvettes show the 
color of the solution before and after irradiation. b) Cycle performance of the fulgimide 20 (100 µM in 
DMSO). Changes in absorption at 518 nm were measured during alternate irradiation with light of 365 nm 
for 30 s and 530 nm for 5 min. 
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2.2.6 Enzyme Inhibition 
Analogous to the DTE inhibitors, the IC50 values of fulgimides 18 and 20 for hHDAC1, 
hHDAC6, hHDAC8 as well as smHDAC8 were quantified (Table 5). 
For compound 18 low micromolar IC50 values are observed for hHDAC6, hHDAC8 and 
smHDAC8 and there is only little or no difference between the IC50 values of the two 
isomers. Compound 20 displays nanomolar affinity for hHDAC6 but again with a very small 
difference between the two different isomers. As above for the DTE derivatives, the 
difference of IC50 values did not provide a basis to perform assays under irradiation. 
Table 5. IC50 values of the respective isomers of fulgimides 18 and 20 against different HDACs. 
Entry Comp. 
hHDAC1 
[µM] 
hHDAC6 
[µM] 
hHDAC8 
[µM] 
smHDAC8 
[µM] 
1 18 open 28.5 ± 10.9 1.8 ± 0.5 1.1 ± 0.2 1.1 ± 0.2 
2 18 PSS 87.7 ± 53.0 6.1 ± 1.7 0.88 ± 0.07 1.1 ± 0.1 
 ratio 3-fold 3-fold no difference no difference 
3 20 open 6.4 ± 1.0 0.047 ± 0.032 5.6 ± 1.3 8.9 ± 3.1 
4 20 PSS 5.0 ± 1.0 0.075 ± 0.047 3.6 ± 1.0 5.7 ± 2.0 
 ratio no difference < 2-fold < 2-fold < 2-fold 
 
 
2.2.7 Molecular Docking 
In order to rationalize the experimental biological data all the prepared compounds were 
docked to the different enzymes. The available crystal structures of hHDAC1, hHDAC6, 
hHDAC8 and smHDAC8 show the typical fold of zinc-dependent histone 
deacetylases.[51, 82] The catalytic zinc ion is bound by two aspartate and one histidine 
residue. The middle part of the acetyl-lysine binding pocket is formed by two conserved 
phenylalanine residues whereas the rim of the pocked is composed by flexible loops that 
are different in the various HDAC isoforms. As consequence the shape of the binding 
pocket of individual HDAC isoforms is rather different which enabled the development of 
isoform selective inhibitors.[83] HDACs have been cocrystallized with several hydroxamic 
acids that showed a bidental chelating of the zinc ion. In case of hHDAC6 the recently 
reported structures[84, 85] showed a slightly different binding mode of hydroxamic acids. 
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Here, a water molecule is bridging the interaction of the terminal hydroxy group to the 
zinc ion. 
The hHDAC1 binding pocket is rather narrow and the docking of the bulky DTEs and 
fulgimides resulted generally in less favorable docking complexes. Due to the narrow 
pocket the distances between the hydroxamic acid carbonyl and hydroxy group are above 
3 Å. In addition, the docking scores for all compounds are rather weak (see Supporting 
Information, Table S1). For compound 3 byproduct no docking pose that showed a binding 
of the hydroxamic acid nearby the zinc ion was obtained. 
Docking of the DTE inhibitors to hHDAC6 and hHDAC8 binding pockets showed that the 
hydroxamic acids are showing the favorable coordination to the zinc ion as observed for 
the cocrystallized inhibitors. The methylthiophene ring attached to the hydroxamic acid is 
embedded between two conserved phenylalanine residues of the HDAC binding pocket 
(F152 and F208 in hHDAC8, F620 and F680 in hHDAC6). In case of hHDAC6 and hHDAC8 
the second hydroxamic acid groups of 6 open and 6 closed are making a hydrogen bond 
to S568 (hHDAC6) and D101 (hHDAC8) that are located on a flexible loop of the enzyme 
(Figure 2). S568 of hHDAC6 is interacting with the carbonyl group, whereas D101 of 
hHDAC8 is interacting with the NH group of the hydroxamic acid. These hydrogen bonds 
might explain the good inhibitory activity for both isoforms. The hydrogen bonds were 
observed for the open and the closed form. In case of 3 open the lipophilic 
chlorothiophene is adopting a different conformation and is sticking out of the pocket 
(see Supporting Information, Figure S10). The less favorable interaction is also supported 
by the weaker docking scores compared to 6 open and 6 closed (see Supporting 
Information, Table S2 and Table S3). The bulky compound 3 byproduct could not be 
docked into the hHDAC8 crystal structure used for the other inhibitors. However, docking 
into the hHDAC8 crystal structure complexed with an amino acid derivative (PDB ID 
3SFF)[86] was resulting in a docking pose that showed coordination between the 
hydroxamic acid and the zinc ion. Due to the observed switch of Y306 in this hHDAC8 
crystal structure the binding pocket becomes wider and accessible for the bulky 3 
byproduct. Enzyme smHDC8 shows a different form of the binding pocket due to the 
flipping of one of the conserved phenylalanine residues (F151). Therefore, the favorable 
binding of the methylthiophene between two conserved phenylalanine (like in hHDAC6 
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and hHDAC8) is not possible resulting in lower inhibitory activities. In addition, D100 
(which corresponds to D101 in hHDAC8) is not able to form a hydrogen bond to the NH of 
the second hydroxamic acid group of 6 open and 6 closed (see Supporting Information, 
Figure S11). The docking of the open form of 3 gave an unfavorable interaction of the 
hydroxamic acid with the zinc ion (distance CO-Zn 3.30 Å). Due to D100 the second 
thiophene-hydroxamic acid cannot adopt a similar conformation as observed for the 
docking pose at hHDAC8 (see Supporting Information, Figure S10b and Figure S11c). For 
compound 3 byproduct no docking pose that showed a binding of the hydroxamic acid 
nearby the zinc ion was obtained (see Supporting Information, Table S4). 
 
Figure 2. Docking poses of DTE 6 for hHDAC6 (a, b) and hHDAC8 (c, d) (6 open colored dark green, 6 closed 
(R,R) colored cyan and 6 closed, (S,S) colored brown). Only the interacting residues of the binding pockets 
are displayed. The zinc ion is shown as brown ball, the water molecule bridging the coordination to the zinc 
ion for hHDAC6 in a and b is shown as red ball. Distances of the metal coordination and hydrogen bonds are 
given in Å and are shown as lines colored in magenta. 
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Docking of the fulgimides to hHDAC1 showed that 18 open and 18 closed (results not 
shown) are not able to coordinate to the zinc ion whereas in case of 20 open and 20 closed 
(see Supporting Information, Figure S12) the additional methylene group and the 
movement of the bulky fulgimide group from meta to the para position of the 
benzohydroxamic acid is resulting in more favorable docking solutions (see Supporting 
Information, Table S1). The fulgimide part of 18 open and 18 closed is interacting with 
L271. Since the fulgimide part is located at the open part of the binding pocket it is obvious 
that both open and closed forms are tolerated by the enzyme. 
In case of hHDAC6 the two compounds 20 open and 20 closed showed the best docking 
scores and the best shape complimentary (Figure 3a-d). The interaction of the highly 
active compounds is comparable to the reported and crystallized hHDAC6 inhibitor 
Nexturastat A[85] which has a reported IC50 of 5 nM (Figure 3e). The fulgimide part is 
located in the so called side pocket and interacts with H500, F620 and L749 at the rim of 
the pocket. In addition, a hydrogen bond to S568 is observed for both forms of 20. Also 
here, both forms show favorable interactions with the enzyme (see Supporting 
Information, Table S2). For the more rigid compounds 18 open and 18 closed the L749 
side chain is hindering an optimal interaction of the compounds with the zinc ion 
(Figure 3f) resulting in less favorable docking scores and a significantly lower inhibitory 
activity. 
Docking of the fulgimides to hHDAC8 showed a comparable binding mode as observed for 
hHDAC6 (see Supporting Information, Figure S13). However, due to the substitution of 
L749 (hHDAC6) to M274 (hHDAC8) the side pocket is larger and the fulgimide side chain 
of 18 open and 18 closed can be nicely accommodated (see Supporting Information, 
Figure S13d-f). In case of 20 open and 20 closed the sidechain of D100 is restricting the 
size of the pocket for the para-substituted benzohydroxamic acid (see Supporting 
Information, Figure S13a-c). Similar observations and docking poses were obtained for 
smHDAC8 (results not shown). 
In general, the docking poses derived for the individual HDAC isoforms show a good 
agreement with the biological data. For example the strong inhibition of hHDAC6 by both 
isomers of fulgimide 20 could be supported by the observed shape complimentary and 
the calculated docking scores. 
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Figure 3. Docking poses of the fulgimides (20 open colored green, a and c; 20 closed (S) colored blue and 
20 closed (R) colored light grey, b and d; 18 open colored yellow, f) for hHDAC6 in comparison to the 
cocrystallized inhibitor Nexturastat A (colored cyan, e). The zinc ion is shown as brown ball and the water 
molecule bridging the coordination to the zinc ion is shown as red ball. Distances of the metal coordination 
and hydrogen bonds are given in Å and are shown as lines colored in magenta. The molecular surface of the 
hHDAC6 binding pocket in c and d are colored according to the hydrophobicity (hydrophobic region are 
colored green, polar region are colored magenta). 
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2.3 Conclusion 
In summary, we functionalized the two established photochromic scaffolds of DTEs and 
fulgimides with hydroxamic acid moieties to obtain photoswitchable inhibitors for zinc 
dependent HDACs. The two different classes of prepared DTEs, dithienylcyclopentenes 
and dithienylmaleimides, showed only moderate photochromic properties in DMSO and 
aqueous media. In contrast, the fulgimides provided excellent reversible photochromic 
performance in DMSO as well as aqueous PBS with very high photostationary states. 
These properties recommend them as perfect photochromic groups for biological 
applications. All target compounds showed an inhibitory effect of the tested hHDAC1, 
hHDAC6, hHDAC8 and smHDAC8 with IC50 values in the range of 50 nM to 90 µM. We 
achieved a maximum four-fold difference in inhibitory ability between two corresponding 
photoisomers. This provides a good basis for the development of more efficient 
photochromic inhibitors with higher difference in activity triggered by light, which is 
necessary to beneficially utilize photopharmacology for HDACs. The in vitro activities of 
our photochromic inhibitors were rationalized by molecular dockings showing that while 
potency could be explained well, the lack of selectivity between the open and closed 
forms was hard to predict. This might probably be due to the flexibility of HDACs that is 
documented by different crystal structures showing the plasticity of the binding pocket 
but is difficult to use in prospective analysis of photoswitchable HDAC inhibitors. Still, very 
potent HDAC inhibitors with new scaffolds especially for hHDAC6 could be realized. 
 
2.4 Experimental 
2.4.1 Chemistry 
Compounds 1,[66] 2,[67] 4,[66] 7,[68] 8,[68] 14[78] and 15[78] were prepared according to 
previously reported procedures. Commercial reagents and starting materials were 
purchased from Acros Organics, Alfa-Aesar, Fisher Scientific, Sigma Aldrich or VWR and 
used without any further purification. Solvents were used in p.a. quality and dried 
according to common procedures, if necessary. Dry nitrogen was used as inert gas 
atmosphere. Automated flash column chromatography was performed on a Biotage 
Isolera flash purification system with UV/Vis detector using Sigma Aldrich MN silica gel 60 
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M (40-63 µm, 230-400 mesh) for normal phase or pre-packed Biotage SNAP cartridges (KP 
C18 HS) for reversed phase chromatography. Reaction monitoring via TLC was performed 
on alumina plates coated with silica gel (Merck silica gel 60 F254, 0.2 mm). Melting points 
were determined using a Stanford Research Systems OptiMelt MPA 100 and are 
uncorrected. NMR spectra were measured on Bruker Avance 300 (1H 300.13 MHz, 13C 
75.48 MHz), Bruker Avance 400 (1H 400.13 MHz, 13C 100.61 MHz), Bruker Avance III 600 
(1H 600.25 MHz, 13C 150.95 MHz) and Bruker Avance 800 (1H 800.20. MHz, 13C 
201.21 MHz) instruments. The spectra are referenced against the NMR-solvent (CDCl3: 
H = 7.26 ppm, C = 77.16 ppm, DMSO-d6: H = 2.50 ppm, C = 39.52 ppm) and chemical 
shifts  are reported in ppm. Resonance multiplicity is abbreviated as: s (singlet), d 
(doublet), t (triplet), quint (quintet), sept (septet) and m (multiplet). Carbon NMR signals 
are reported using DEPT 135 and 1H-13C HSQC spectra with (+) for primary/tertiary, (−) for 
secondary and (q) for quaternary carbons. Mass spectra were recorded on an Agilent Q-
TOF 6540 UHD (ESI-MS) instrument. UV/Vis absorption spectroscopy was performed using 
a Varian Cary BIO 50 UV/Vis spectrometer in 10 mm quartz cuvettes. IR-spectra were 
measured with an Agilent Cary 630 FT-IR spectrometer and the peak positions are 
reported in wavenumbers (cm-1). Analytical HPLC measurements were performed on an 
Agilent 1290 series UHPLC-MS system (column: Phenomenex Luna C18(2), 3 µM, 100 Å, 
150 x 2.00 mm; flow: 0.3 mL/min at 25 °C or 40 °C; solvent A: MilliQ water with 
0.059 wt. % TFA; solvent B: MeCN) and an Agilent 1220 Infinity LC (column: Phenomenex 
Luna 3 µM C18(2) 100 Å, 150 x 2.00 mm; flow: 0.3 mL/min at 30 °C; solvent A: MilliQ water 
with 0.05 % vol. TFA; solvent B: MeCN). The ratios in the PSSs were determined at the 
isosbestic points. An Agilent 1260 system (column: Phenomenex Luna 10 µM C18(2) 
100 Å, 250 x 21.2 mm; flow: 22.0 mL/min; solvent A: MilliQ water with 0.05 % vol. TFA; 
solvent B: MeCN) was used for preparative HPLC purification. Light sources for irradiation: 
 = 300 nm (NIKKISO UV LED, 150 mA, 25 mW),  = 312 nm (Herolab hand-held lamp UV-
6 M, 6 W),  = 365 nm (Herolab hand-held lamp UV-6 L, 6 W),  = 470 nm (OSRAM Oslon 
SSL 80 LED, 700 mA, 1.12 W),  = 530 nm (CREE-XP green LED, 700 mA, 3.7 W). The power 
of the light is given based on the specifications supplied by the company when the lamps 
were purchased. All tested final compounds possess a purity ≥95% determined by HPLC 
measurements with detection at 220 nm or 254 nm, respectively.  
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4-[2-(5-Chloro-2-methylthiophen-3-yl)-cyclopent-1-en-1-yl]-N-hydroxy-5-methylthio-
phene-2-carboxamide (3) 
To a stirred solution of 2 (100 mg, 0.28 mmol, 1.0 eq.) in CH2Cl2 (3 mL) SOCl2 (64.2 µL, 
0.85 mmol, 3.0 eq.) was added slowly at 0°C. After complete addition the solution was 
stirred at 40°C for 3 h. The mixture was cooled to room temperature and concentrated in 
vacuo. The residue was dissolved in THF/MeOH (1:1, 5 mL). Afterwards a solution of NaOH 
(90 mg, 2.24 mmol, 8.0 eq.) in an aqueous hydroxylamine solution (50 wt. %, 0.72 mL) was 
added dropwise to the mixture at 0°C. The resulting solution was stirred at room 
temperature overnight. The reaction was quenched with AcOH (1.50 mL) and 
concentrated in vacuo. Purification by automated flash column chromatography 
(CH2Cl2/MeOH, 5% - 10% MeOH) and subsequent preparative HPLC (60% - 98% MeCN in 
10 min, tR = 7.3 min) yielded 3 (28 mg, 26%) as colorless solid. Rf 0.29 (PE/EtOAc 1:1); m.p. 
128 °C; 1H-NMR (400 MHz, DMSO-d6) = 11.05 (s, 1H), 9.01 (s, 1H), 7.35 (s, 1H), 6.83 (s, 
1H), 2.73 (t, J = 7.5 Hz, 4H), 2.03 - 1.92 (m, 5H), 1.79 (s, 3H); 13C-NMR (151 MHz, DMSO-
d6) = 159.4 (q), 138.6 (q), 135.9 (q), 134.9 (q), 134.4 (q), 133.9 (q), 133.0 (q, 2C) 128.4 
(+), 127.3 (+), 123.6 (q), 38.0 (−), 37.8 (−), 22.2 (−), 14.1 (+), 13.7 (+); HRMS (ESI) calcd. for 
C16H15ClNO2S2 (M-H)- m/z = 352.0238; found: 352.0251. 
 
Dimethyl-4,4’-(cyclopent-1-ene-1,2-diyl)bis(5-methylthiophene-2-carboxylate) (5) 
SOCl2 (0.52 mL, 7.20 mmol, 10.0 eq.) was added dropwise to a solution of 4 (250 mg, 
0.72 mmol, 1.0 eq.) in anhydrous MeOH (15 mL) at 0°C under nitrogen atmosphere and 
stirred for 5 h at 65°C. The mixture was cooled to room temperature and concentrated in 
vacuo. The residue was suspended in EtOAc (15 mL) and washed with water (3 x 10 mL) 
and brine (10 mL). The organic layer was dried over Na2SO4, filtered and the solvent was 
removed under reduced pressure. Purification by automated flash column 
chromatography (PE/EtOAc, 5% - 30% EtOAc) yielded 5 (180 mg, 66%) as colorless solid. 
Rf 0.72 (PE/EtOAc 1:1); m.p. 163 °C; 1H-NMR (400 MHz, CDCl3) = 7.50 (s, 2H), 3.84 (s, 6H), 
2.78 (t, J = 7.5 Hz, 4H), 2.06 (quint, J = 7.5 Hz, 2H) 1.90 (s, 6H); 13C-NMR (101 MHz, CDCl3) 
= 162.7 (q), 142.9 (q), 136.7 (q), 134.9 (q), 134.6 (+), 129.4 (q), 52.2 (+), 38.8 (−), 23.0 (−), 
14.9 (+); HRMS (ESI) calcd. for C19H21O4S2 (M+H)+ m/z = 377.0880; found: 377.0876. 
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N-Hydroxy-4-(2-[5-(hydroxycarbamoyl)-2-methylthiophen-3-yl]cyclopent-1-en-1-yl)-5-
methylthiophene-2-carboxamide (6) 
NaOH (135 mg, 3.38 mmol, 8.0 eq.) was dissolved in an aqueous hydroxylamine solution 
(50 wt. %, 1.1 mL). The solution was added dropwise to a solution of 5 (160 mg, 
0.42 mmol, 1.0 eq.) in THF/MeOH (1:1, 7 mL) at 0°C. The resulting solution was stirred 
overnight at room temperature. The reaction was quenched with AcOH (1.5 mL) and 
concentrated in vacuo. Purification by automated reversed phase flash column 
chromatography (H2O/MeOH, 5% - 100% MeOH) and subsequent preparative HPLC 
(20% - 98% MeCN in 12 min, tR = 6.8 min) yielded 6 (100 mg, 61%) as colorless solid. Rf 
0.05 (PE/EtOAc 1:1); m.p. 182 °C; 1H-NMR (400 MHz, DMSO-d6) = 11.04 (s, 2H), 9.01 (s, 
2H), 7.35 (s, 2H), 2.74 (t, J = 7.4 Hz, 4H), 2.00 (quint, J = 7.4 Hz, 2H), 1.87 (s, 6H); 13C-NMR 
(101 MHz, DMSO-d6) = 159.4 (q), 138.5 (q), 135.9 (q), 134.2 (q), 132.9 (q), 128.4 (+), 38.0 
(−), 22.3 (−), 14.1 (+); HRMS (ESI) calcd. for C17H19N2O4S2 (M+H)+ m/z = 379.0635; found:. 
379.0640. 
 
Methyl-4-[4-(5-chloro-2-methylthiophen-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-5-
methylthiophene-2-carboxylate (9) 
KOtBu (1 M in THF, 1.45 mL, 1.45 mmol, 1.2 eq.) was added to a solution of amide 7 
(277 mg, 1.21 mmol, 1.0 eq.) in anhydrous THF (6 mL) at 0°C under nitrogen atmosphere. 
After stirring for 90 min ester 8 (296 mg, 1.45 mmol, 1.2 eq.) was added at 0°C and the 
mixture was stirred overnight at room temperature. The reaction was quenched with 
aqueous HCl solution (1 M, 15 mL) and diluted with EtOAc (15 mL). The organic phase was 
separated, washed with water (3 x 15 mL), brine (1 x 30 mL) and dried over MgSO4. The 
solvent was removed under reduced pressure. Purification of the crude product was 
performed by automated flash column chromatography (PE/EtOAc, 5% - 30% EtOAc) 
yielding 9 (210 mg, 45%) as yellow solid. Rf 0.68 (PE/EtOAc 1:1); m.p. 183 °C; 1H-NMR 
(400 MHz, DMSO-d6) = 11.29 (s, 1H), 7.70 (s, 1H), 6.99 (s, 1H), 3.81 (s, 3H), 2.00 (s, 3H), 
1.85 (s, 3H); 13C-NMR (101 MHz, DMSO-d6) = 171.0 (q), 171.0 (q), 161.3 (q), 148.0 (q), 
139.6 (q), 135.2 (+), 133.4 (q), 133.1 (q), 129.3 (q), 128.0 (q), 127.9 (+), 126.6 (q), 124.6 
(q), 52.3 (+), 14.6 (+), 14.1 (+); HRMS (ESI) calcd. for C16H13ClNO4S2 (M+H)+ m/z = 381.9969; 
found: 381.9978. 
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4-[4-(5-Chloro-2-methylthiophen-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-N-
hydroxy-5-methylthiophene-2-carboxamide (10) 
NaOH (75 mg, 1.88 mmol, 8.0 eq.) was dissolved in an aqueous hydroxylamine solution 
(50 wt. %, 0.60 mL). This solution was added dropwise to a solution of 9 (90 mg, 
0.24 mmol, 1.0 eq.) in THF/MeOH (1:1, 5 mL) at - 20°C. The resulting solution was stirred 
for 20 min at - 20°C and was then warmed to - 3°C in 20 min. The reaction was quenched 
with AcOH (1.5 mL) and concentrated in vacuo. Purification by automated flash column 
chromatography (CH2Cl2/MeOH, 5% - 10% MeOH) and subsequent preparative HPLC 
(30% - 70% MeCN in 15 min, tR = 9.4 min) yielded 10 (68 mg, 76%) as orange solid. Rf 0.25 
(PE/EtOAc 1:1); m.p. 175 °C; 1H-NMR (400 MHz, DMSO-d6) = 11.27 (s, 2H), 9.09 (s, 1H), 
7.51 (s, 1H), 6.99 (s, 1H), 2.00 (s, 3H), 1.84 (s, 3H); 13C-NMR (101 MHz, DMSO-d6) = 171.1 
(q), 158.9 (q), 144.6 (q), 139.5 (q), 134.1 (q), 133.5 (q), 133.3 (q), 128.9 (q), 128.9 (+), 128.0 
(+), 127.4 (q), 126.6 (q), 124.5 (q), 14.5 (+), 14.1 (+); HRMS (ESI) calcd. for C15H12ClN2O4S2 
(M+H)+ m/z = 382.9922; found: 382.9925. 
 
Methyl-4-[4-(5-chloro-2-methylthiophen-3-yl)-1-methyl-2,5-dioxo-2,5,-dihydro-1H-
pyrrol-3-yl]-5-methylthiophene-2-carboxylate (11) 
Methyl iodide (13 µL, 0.21 mmol, 2.0 eq.) was added dropwise to a solution of 
dithienylmaleimide 9 (40 mg, 0.11 mmol, 1.0 eq.) in anhydrous DMF (6 mL) at 0°C under 
nitrogen atmosphere. The solution was stirred overnight at room temperature and then 
diluted with water (5 mL) and EtOAc (5 mL). The aqueous phase was extracted with EtOAc 
(3 x 5 mL). The combined organic phases were dried over MgSO4, filtered and the solvent 
was removed under reduced pressure. Dithienylmaleimde 11 was obtained as yellow solid 
(30 mg, 76%) and was used without further purification. Rf 0.78 (PE/EtOAc 1:1); m.p. 
187 °C; 1H-NMR (400 MHz, CDCl3) = 7.75 (s, 1H), 6.88 (s, 1H), 3.88 (s, 3H), 3.14 (s, 3H), 
2.04 (s, 3H), 1.88 (s, 3H); 13C-NMR (201 MHz, CDCl3) = 170.3 (q), 170.2 (q), 162.2 (q), 
148.5 (q), 140.3 (q), 135.0 (+), 133.3 (q), 132.8 (q), 131.1 (q), 127.6 (q), 127.5 (q), 127.2 
(+), 126.1 (q), 52.4 (+), 24.6 (+), 15.5 (+), 15.0 (+); HRMS (ESI) calcd. for C17H15ClNO4S2 
(M+H)+, m/z = 396.0126; found: 396.0131. 
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4-[4-(5-Chloro-2-methylthiophen3-yl)-1-hydroxy-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-
N-hydroxy-5-methylthiophene-2-carboxamide (12) 
NaOH (32 mg, 0.81 mmol, 8.0 eq.) was dissolved in an aqueous hydroxylamine solution 
(50 wt. %, 0.26 mL). The solution was added dropwise to a solution of 11 (40 mg, 
0.10 mmol, 1.0 eq.) in THF/MeOH (1:1, 5 mL) at 0°C. The resulting solution was stirred 
overnight at room temperature. The reaction was quenched with AcOH (1.5 mL) and 
concentrated in vacuo. Purification by automated reversed phase flash column 
chromatography (H2O/MeOH, 5% - 100% MeOH) and subsequent preparative HPLC 
(25% - 80% MeCN in 15 min, tR = 9.1 min) yielded 32 (21 mg, 50%) as yellow solid. Rf 0.05 
(PE/EtOAc 1:1); m.p. 140 °C; 1H-NMR (400 MHz, DMSO-d6) = 11.29 (s, 1H), 10.69 (s, 1H), 
9.11 (s, 1H), 7.52 (s, 1H), 7.01 (s, 1H), 2.00 (s, 3H), 1.85 (s, 3H); 13C-NMR (101 MHz, DMSO-
d6) = 166.3 (q), 166.3 (q), 158.8 (q), 145.1 (q), 140.1 (q), 134.3 (q), 130.2 (q), 130.0 (q), 
128.7 (+), 127.8 (+), 127.1 (q), 126.2 (q), 124.7 (q), 14.5 (+), 14.1 (+); HRMS (ESI) calcd. for 
C15H10ClN2O5S2 (M-H)-, m/z = 396.9725; found: 396.9732. 
 
Methyl-4-[4-(5-chloro-2-methylthiophen-3-yl)-1-hydroxy-2,5-dioxo-2,5-dihydro-1H-
pyrrol-3-yl]-5-methylthiophene-2-carboxylate (13) 
NaOH (25.0 mg, 0.63 mmol, 8.0 eq.) was dissolved in an aqueous hydroxylamine solution 
(50 wt. %, 0.20 mL). The solution was added dropwise to a solution of 11 (30 mg, 
0.08 mmol, 1.0 eq.) in THF/MeOH (1:1, 3 mL) at - 20°C. The resulting solution was stirred 
for 10 min at - 20°C and was warmed to - 8°C in 10 min afterwards. The reaction was 
quenched with AcOH (1.5 mL) and concentrated in vacuo. Purification by automated flash 
column chromatography (CH2Cl2/MeOH, 5% - 10% MeOH) and subsequent preparative 
HPLC (60% - 98% MeCN in 10 min, tR = 6.5 min) yielded 13 (8 mg, 26%) as yellow solid. 
Rf 0.31 (PE/EtOAc 1:1); m.p. 193 °C; 1H-NMR (600 MHz, DMSO-d6) = 10.73 (s, 1H), 7.71 
(s, 1H), 7.01 (s, 1H), 3.82 (s, 3H), 2.01 (s, 3 H), 1.86 (s, 3H); 13C-NMR (151 MHz, DMSO-d6) 
= 166.3 (q), 166.3 (q), 161.3 (q), 148.4 (q), 140.2 (q), 135.1 (+), 130.1 (q), 129.9 (q), 129.5 
(q), 127.8 (+), 127.7 (q), 126.2 (q), 124.8 (q), 52.4 (+), 14.7 (+), 14.1 (+); HRMS (ESI) calcd. 
for C16H13ClNO5S2 (M+H)+ m/z = 397.9918; found: 397.9929. 
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(E)-3-(1-(2,5-dimethylfuran-3-yl)-2-methylpropylidene)-4-(propan-2-ylidene) dihydro-
furan-2,5-dione (16) 
A solution of succinate 15 (2.55 g, 11.91 mmol, 1.0 eq.) in anhydrous THF (15 mL) was 
cooled to -105°C under N2-atmosphere and a freshly prepared solution of LDA by adding 
a solution of nBuLi (1.6 M in hexane, 7.4 mL, 11.91 mmol, 1.0 eq.,) to a solution of 
diisopropylamine (1.7 mL, 11.91 mmol, 1.0 eq.) in anhydrous THF (6 mL) at -78°C under 
N2-atmosphere was added dropwise at -105°C. After stirring for 30 min a precooled 
solution of furan 14 (1.98 g, 11.91 mmol, 1.0 eq.) in anhydrous THF (5 mL) was added 
dropwise. The reaction mixture was warmed to room temperature und stirred overnight. 
The solution was acidified with aqueous HCl (2 M) and the aqueous layer was extracted 
with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (100 mL), 
dried over MgSO4, and the solvent was evaporated under reduced pressure. The residue 
was dissolved in EtOH (60 mL) and a saturated aqueous solution of KOH (5 mL) was added. 
After stirring at 70°C for 24 h, the reaction mixture was poured onto ice and acidified with 
aqueous HCl (2 M). The aqueous layer was extracted with EtOAc (3 x 50 mL), and the 
combined organic layers were washed with brine (100 mL), dried over MgSO4, and the 
solvent was removed in vacuo. The dark-brown residue was dissolved in acetyl chloride 
(20 mL) and the mixture was heated to 40°C overnight. The solvent was evaporated under 
reduced pressure and the crude product was purified by automated flash column 
chromatography (PE/EtOAc, 5% EtOAc) to obtain fulgide 16 (688 mg, 20%) as a pink solid. 
The analytical data were in accordance with data from literature.[78] 
 
Methyl (E)-3-(3-(1-(2,5-dimethylfuran-3-yl)-2-methylpropylidene)-2,5-dioxo-4-(propan-
2-ylidene)pyrrolidin-1-yl)benzoate (17) 
A suspension of fulgide 16 (98 mg, 0.34 mmol, 1.0 eq.), methyl 3-aminobenzoate (154 mg, 
1.02 mmol, 3.0 eq.) and K2CO3 (235 mg, 1.70 mmol, 5.0 eq.) in anhydrous CH2Cl2 (5 mL) 
was refluxed for 3 d. After filtration CDI (83 mg, 0.51 mmol, 1.5 eq.) was added and the 
mixture was stirred at room temperature for 1 d. The reaction mixture was acidified with 
aqueous HCl (1 M) and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were washed with brine (10 mL), dried over MgSO4 and the 
solvent was evaporated under reduced pressure. Purification by automated flash column 
chromatography (PE/EtOAc, 3% - 15% EtOAc) afforded fulgimide 17 (17 mg, 12%) as 
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orange oil. Rf 0.30 (PE/EtOAc 9:1); 1H-NMR (400 MHz, CDCl3) = 8.08 (t, J = 1.9 Hz, 1H), 
8.05 (dt, J = 7.6, 1.5 Hz, 1H), 7.61 (dt, J = 8.0, 1.6 Hz, 1H), 7.55 (t, J = 7.8 Hz, 1H), 5.96 (s, 
1H), 4.48 (sept, J = 7.0 Hz, 1H), 3.92 (s, 3H), 2.29 (s, 3H), 2.27 (s, 3H), 1.95 (s, 3H), 1.41 (s, 
3H), 1.33 (d, J = 7.1 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3) = 167.2 
(q), 167.1 (q), 166.4 (q), 154.1 (q), 150.2 (q), 149.6 (q), 146.9 (q), 132.5 (q), 131.6 (+), 131.1 
(q), 129.2 (+), 129.0 (+), 128.3 (+), 123.2 (q), 123.1 (q), 119.8 (q), 106.4 (+), 52.4 (+), 30.2 
(+), 27.4 (+), 23.2 (+), 22.2 (+), 20.8 (+), 13.5 (+), 13.1 (+); IR (neat) = 3437, 2960, 1703, 
1588, 1491, 1446, 1368, 1275, 1167, 1133, 958, 910, 850, 809, 753, 682 cm-1; HRMS (ESI) 
calcd. for C25H38NO5 (M+H)+ m/z = 422.1962; found 422.1969. 
 
(E)-3-(3-(1-(2,5-Dimethylfuran-3-yl)-2-methylpropylidene)-2,5-dioxo-4-(propan-2-
ylidene)pyrrolidin-1-yl)-N-hydroxybenzamide (18) 
A solution of NaOH (42 mg, 1.04 mmol, 8.0 eq.) in aqueous hydroxyl amine (50 wt. %, 
335 µL) was added dropwise to a solution of fulgimide 17 (55 mg, 0.13 mmol, 1.0 eq.) in 
MeOH/THF (1:1, 2 mL) at – 15 °C. Then the mixture was stirred for 20 min at - 15 °C. The 
reaction was quenched with AcOH (744 µL) and concentrated in vacuo. Purification by 
preparative HPLC (50% - 98% MeCN in 20 min, tR = 15.0 min) yielded 18 (10 mg, 18%) as 
slightly pink solid. Rf 0.51 (CH2Cl2/MeOH 9:1); m.p. 93 °C; 1H-NMR (400 MHz, DMSO-d6) 
= 11.29 (s, 1H), 9.11 (s, 1H), 7.85 – 7.70 (m, 2H), 7.64 – 7.46 (m, 2H), 6.17 (s, 1H), 4.42 
(sept, J = 7.0 Hz, 1H), 2.25 (s, 3H), 2.22 (s, 3H), 1.93 (s, 3H), 1.36 (s, 3H), 1.29 (d, J = 7.1 Hz, 
3H), 0.82 (d, J = 6.9 Hz, 3H); 13C-NMR (151 MHz, DMSO-d6) = 166.4 (q), 166.4 (q), 163.3 
(q), 152.1 (q), 149.8 (q), 148.1 (q), 146.5 (q), 133.3 (q), 132.3 (q), 130.4 (+), 128.8 (+), 126.3 
(+), 126.3 (+), 122.9 (q), 122.8 (q), 119.2 (q), 106.3 (+), 29.2 (+), 26.7 (+), 22.8 (+), 21.4 (+), 
20.5 (+), 13.0 (+), 12.5 (+); IR (neat) = 3258, 2926, 2855, 1752, 1700, 1584, 1525, 1484, 
1439, 1368, 1282, 1170, 1129, 1088, 995, 801, 693 cm-1; HRMS (ESI) calcd. for C24H27N2O5 
(M+H)+ m/z = 423.1914; found 423.1920.  
 
Methyl (E)-4-((3-(1-(2,5-dimethylfuran-3-yl)-2-methylpropylidene)-2,5-dioxo-4-(propan 
-2-ylidene)pyrrolidin-1-yl)methyl)benzoate (19) 
A solution of fulgide 16 (98 mg, 0.34 mmol, 1.0 eq.), methyl 4-(aminomethyl)benzoate 
hydrochloride (274 mg, 1.36 mmol, 4.0 eq.) and triethylamine (189 µL, 1.36 mmol, 
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4.0 eq.) in anhydrous CH2Cl2 (2 mL) was refluxed for 3 d. Then CDI (276 mg, 1.70 mmol, 
5.0 eq.) was added and the mixture was refluxed for 1 d. The reaction mixture was 
acidified with aqueous HCl (1 M) and the aqueous layer was extracted with EtOAc 
(3 x 10 mL). The combined organic layers were washed with brine (20 mL), dried over 
MgSO4 and the solvent was evaporated under reduced pressure. Purification by 
automated flash column chromatography (PE/EtOAc, 3% - 15% EtOAc) afforded fulgimide 
19 (70 mg, 47%) as orange oil. Rf 0.31 (PE/EtOAc 9:1); 1H-NMR (400 MHz, CDCl3) = 7.98 
(d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 5.92 (s, 1H), 4.79 (d, J = 8.5 Hz, 2H), 4.48 (sept, 
J = 7.0 Hz, 1H), 3.89 (s, 3H), 2.24 (s, 6H), 1.84 (s, 3H), 1.33 (s, 3H), 1.28 (d, J = 7.1 Hz, 3H), 
0.83 (d, J = 6.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3) = 168.1 (q), 168.0 (q), 167.0 (q), 153.1 
(q), 150.1 (q), 148.7 (q), 146.9 (q), 142.0 (q), 130.1 (+), 129.6 (q), 128.5 (+), 123.5 (q), 123.4 
(q), 119.7 (q), 106.5 (+), 52.2 (+), 41.1 (-), 30.0 (+), 27.2 (+), 23.1 (+), 22.1 (+), 20.8 (+), 13.5 
(+), 12.9 (+); IR (neat) = 3422, 2960, 2874, 1692, 1633, 1435, 1387, 1342, 1275, 1219, 
1178, 1100, 1021, 958, 924, 872, 835, 805, 757, 708 cm-1; HRMS (ESI) calcd. for C26H30NO5 
(M+H)+ m/z = 436.2118; found 436.2120. 
 
(E)-4-((3-(1-(2,5-Dimethylfuran-3-yl)-2-methylpropylidene)-2,5-dioxo-4-(propan-2-
ylidene)pyrrolidin-1-yl)methyl)-N-hydroxybenzamide (20) 
A solution of NaOH (37 mg, 0.91 mmol, 8.0 eq.) in aqueous hydroxyl amine (50 wt. %, 
309 µL) was added dropwise to a solution of fulgimide 19 (50 mg, 0.11 mmol, 1.0 eq.) in 
MeOH/THF (1:1, 2 mL) at 0 °C. Then the mixture was stirred for 25 min at 0 °C. The 
reaction was quenched with AcOH (652 µL) and concentrated in vacuo. Purification by 
preparative HPLC (50% - 97% MeCN in 25 min, tR = 15.6 min) afforded 20 (13 mg, 27%) as 
slightly pink solid. Rf 0.59 (CH2Cl2/MeOH 9:1); m.p. 92 °C; 1H-NMR (600 MHz, DMSO-d6) 
= 11.16 (s, 1H), 9.01 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 6.14 (s, 1H), 
4.71 (d, J = 2.5 Hz, 2H), 4.44 (sept, J = 7.1 Hz, 1H), 2.23 (s, 3H), 2.19 (s, 3H), 1.82 (s, 3H), 
1.30 (s, 3H), 1.25 (d, J = 7.3 Hz, 3H), 0.77 (d, J = 6.9 Hz, 3H); 13C-NMR (151 MHz, DMSO-d6) 
= 167.2 (q), 167.2 (q), 163.9 (q, HMBC), 151.5 (q), 149.8 (q), 147.7 (q), 146.3 (q), 139.9 
(q), 131.9 (q), 127.2 (+), 123.0 (q), 122.7 (q), 119.1 (q), 106.4 (+), 40.3 (−), 29.0 (+), 26.6 
(+), 22.6 (+), 21.3 (+), 20.5 (+), 13.0 (+), 12.4 (+); IR (neat) = 3258, 2960, 2930, 2874, 1744, 
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1688, 1632, 1498, 1424, 1387, 1342, 1167, 1133, 1100, 962, 924, 902, 801 cm-1; HRMS 
(ESI) calcd. for C25H29N2O5 (M+H)+ m/z = 437.2071; found 437.2072. 
 
2.4.2 Biological Investigations 
Compounds 3 ( = 312 nm, 36.5 min), 6 ( = 312 nm, 11 min), 10 ( = 365 nm, 7.5 min, 
resulting PSS: 30%), 18 ( = 365 nm, 11 min) and 20 ( = 365 nm, 11 min) were irradiated 
in a 10 mM stock solution in DMSO to form the closed or byproduct isomers prior to the 
biological assays, respectively. In vitro assays were performed as previously described.[51] 
 
2.4.3 Molecular Docking 
Crystal structures of hHDAC1 (PDB ID 5ICN),[87] hHDAC6 (PDB ID 5G0I),[84] hHDAC8 (PDB ID 
2V5X)[88] and smHDAC8 (PDB 5FUE)[50] were downloaded from the Protein Data Bank 
PDB.[89] Protein preparation was done using Schrödinger's Protein Preparation Wizard[90] 
by adding hydrogen atoms, assigning protonation states and minimizing the protein. 
Ligands were prepared in MOE[91] from smiles in neutral form. Multiple low energy 
starting conformations were generated with MOE within an energy window of 5 kcal/mol. 
Molecular docking was performed using the program Glide. The same protocol was 
applied successfully in previous studies.[92] Water molecules were removed from the 
protein structures beside one water molecule in HDAC6 that is bridging the interaction of 
the hydroxamate and the zinc ion in PDB 5G0I. Compounds 3 byproduct, 6 closed, 18 
closed and 20 closed were generated in the possible stereoisomeric forms and were 
docked in the neutral form. 
In our previous study we found that rescoring the docking poses by using a MM-GB/SA 
protocol resulted in a significant correlation between calculated interaction energies and 
in vitro inhibition data. Therefore, the same protocol was applied to the compounds under 
study. To calculate the binding free energy, we used the AMBER12EHT force field 
implemented in the MOE program together with the continuum solvation model GB/SA. 
The experimentally observed geometries of the zinc-hydroxamate complexes were best 
reproduced using this setup. Partial charges were fixed using the MOE Protonate3D tool 
according to the used force-field followed by a short minimization. To estimate the 
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binding free energy a minimizing of the protein-ligand complexes derived from the 
docking was carried out. During complex minimization the heavy atoms of the protein 
were tethered with a deviation of 0.5 Å (force constant (3/2) kT / (0.5)²). The complex 
showing the lowest binding free energy was chosen for each inhibitor and HDAC isoform. 
Using this docking and rescoring protocol the experimentally derived structures of the 
cocrystallized inhibitors of hHDAC6 (PDB ID 5G0I), hHDAC8 (PDB 2V5X) and smHDAC8 
(PDB ID 5FUE) could be reproduced with an RMSD value below 1.00 Å. 
 
2.5 Supporting Information 
Photochemical data 
 
Figure S1. a) Changes in absorption spectra of DTE 10 (100 µM in DMSO) upon continuous irradiation for 0, 
30, 60, 100 and 140 s with light of  = 300 nm until the PSS is reached. b) Cycle performance of DTE 10 
(100 µM in DMSO). Changes in absorption at 535 nm were measured during alternate irradiation with light 
of 300 nm for 140 s and 530 nm for 1 min. 
 
Figure S2. Absorption spectra of DTE 12 (100 µM in toluene/THF) open, after irradiation with  = 312 nm 
for 60 s and subsequent irradiation with  = 530 nm for 60 s. 
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Figure S3. a) Changes in absorption spectra of DTE 3 (100 µM in DMSO) upon continuous irradiation for 0, 
6, 12, 18, 24, 36 and 48 s with light of  = 312 nm until the PSS is reached. b) Cycle performance of DTE 3 
(100 µM in DMSO). Changes in absorption at 488 nm were measured during alternate irradiation with light 
of 312 nm for 48 s and 470 nm for 1 min. 
 
Figure S4. a) Changes in absorption spectra of DTE 3 (100 µM in DMSO) upon continuous irradiation for 48, 
60, 92, 112, 132, 162, 192, 202 and 222 s with light of  = 312 nm until the byproduct is completely formed. 
b) Comparison of the absorption spectra of the three occurring states/isomers of 3: open (black), PSS 
(orange) and byproduct (red). 
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Figure S5. HPLC-MS traces recorded at 275 nm of the three different states/isomers of 3 (tR open isomer: 
15.05 min, m/z=354.1; tR closed isomer: 13.42 min, m/z=353.9; tR byproduct: 13.02 min, m/z=354.0; black: 
open isomer without irradiation; orange: PSS after 45 s of irradiation; red: byproduct after 220 s of 
irradiation). Upon reaching the PSS (orange) approximately 23% of the byproduct has already formed and 
its formation is completed after 220 s (red). 
 
Figure S6. a) Changes in absorption spectra of DTE 6 (100 µM in DMSO) upon continuous irradiation for 0, 
30, 60 (PSS), 80, 120, 300, 480 and 640 s (byproduct) with light of  = 312 nm. b) Cycle performance of DTE 
6 (100 µM in DMSO). Changes in absorption at 523 nm were measured during alternate irradiation with 
light of 312 nm for 60 s and 530 nm for 3 min. 
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Figure S7. a) Changes in absorption spectra of fulgimide 18 (100 µM in DMSO) upon continuous irradiation 
for 0, 5, 10, 15, 20, 25, 30 and 35 s with light of  = 365 nm until the PSS is reached. b) Cycle performance 
of fulgimide 18 (100 µM in DMSO). Changes in absorption at 519 nm were measured during alternate 
irradiation with light of 365 nm for 35 s and 530 nm for 5 min. 
 
Figure S8. a) Changes in absorption spectra of fulgimide 20 (100 µM in PBS with 1% of DMSO, pH=7.4) upon 
continuous irradiation for 0, 5, 10, 15, 20 and 25 s with light of  = 365 nm until the PSS is reached. b) Cycle 
performance of fulgimide 20 (100 µM in in PBS with 1% of DMSO, pH=7.4). Changes in absorption at 532 nm 
were measured during alternate irradiation with light of 365 nm for 25 s and 530 nm for 10 min. 
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Figure S9. a) Changes in absorption spectra of fulgimide 18 (100 µM in PBS with 1% of DMSO, pH=7.4) upon 
continuous irradiation for 0, 5, 10, 15, 20 and 25 s with light of  = 365 nm until the PSS is reached. b) Cycle 
performance of fulgimide 18 (100 µM in in PBS with 1% of DMSO, pH=7.4). Changes in absorption at 536 nm 
were measured during alternate irradiation with light of 365 nm for 25 s and 530 nm for 10 min. 
 
Docking results and additional docking poses 
Table S1. Docking scores calculated for hHDAC1 (PDB ID 5ICN). 
Entry Compound IC50 hHDAC1 [µM] pIC50 hHDAC1 
E GBSA 
[kcal/mol] 
1 3 open 15 ± 1 .2 4.82 -38.54 
2 3 byproduct (R,R) 26 ± 2.5 4.59 - 
3 3 byproduct (S,S) 26 ± 2.5 4.59 - 
4 6 open 4.2 ± 0.7 5.38 -35.05 
5 6 closed (R,R) 5.1 ± 0.8 5.29 -37.25 
6 6 closed (S,S) 5.1 ± 0.8 5.29 -37.05 
7 18 open 28.5 ± 10.9 4.55 -37.48 
8 18 closed (R) 87.5 ± 53.0 4.06 -29.52 
9 18 closed (S) 87.5 ± 53.0 4.06 -31.83 
10 20 open 6.4 ± 1.0 5.19 -41.57 
11 20 closed (R) 5.0 ± 1.0 5.30 -42.80 
12 20 closed (S) 5.0 ± 1.0 5.30 -44.16 
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Table S2. Docking scores calculated for hHDAC6 (PDB ID 5G0I). 
Entry Compound IC50 hHDAC6 [µM] pIC50 hHDAC6 
E GBSA 
[kcal/mol] 
1 3 open 1.8 ± 0.2 5.74 -41.90 
2 3 byproduct (R,R) 3.9 ± 0.2 5.41 -30.82 
3 3 byproduct (S,S) 3.9 ± 0.2 5.41 -30.12 
4 6 open 0.213 ± 0.018 6.67 -45.20 
5 6 closed (R,R) 0.297 ± 0.041 6.53 -47.75 
6 6 closed (S,S) 0.297 ± 0.041 6.53 -47.86 
7 18 open 1.8 ± 0.5 5.74 -40.08 
8 18 closed (R) 6.1 ± 1.7 5.21 -40.48 
9 18 closed (S) 6.1 ± 1.7 5.21 -41.77 
10 20 open 0.047 ± 0.032 7.33 -73.55 
11 20 closed (R) 0.075 ± 0.047 7.12 -72.90 
12 20 closed (S) 0.075 ± 0.047 7.12 -71.91 
 
Table S3. Docking scores calculated for hHDAC8 (PDB ID 2V5X). 
Entry Compound IC50 hHDAC8 [µM] pIC50 hHDAC8 
E GBSA 
[kcal/mol] 
1 3 open 1.6 ± 0.6 5.80 -60.59 
2 3 byproduct (R,R) 2.7 ± 0.9 5.57 - 
3 3 byproduct (S,S) 2.7 ± 0.9 5.57 - 
4 6 open 0.248 ± 0.29 6.61 -67.62 
5 6 closed (R,R) 0.262 ±  0.36 6.58 -65.18 
6 6 closed (S,S) 0.262 ± 0.36 6.58 -65.47 
7 18 open 1.1 ± 0.2 5.96 -63.56 
8 18 closed (R) 0.88 ± 0.07 6.06 -63.49 
9 18 closed (S) 0.88 ± 0.07 6.06 -63.13 
10 20 open 5.6 ± 1.3 5.25 -58.40 
11 20 closed (R) 3.6 ± 1.0 5.44 -60.62 
12 20 closed (S) 3.6 ± 1.0 5.44 -60.26 
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Table S4. Docking scores calculated for smHDAC8 (PDB ID 5FUE). 
Entry Compound IC50 smHDAC8 [µM] pIC50 smHDAC8 
E GBSA 
[kcal/mol] 
1 3 open 1.6 ± 0.6 5.80 -60.59 
2 3 byproduct (R,R) 2.7 ± 0.9 5.57 - 
3 3 byproduct (S,S) 2.7 ± 0.9 5.57 - 
4 6 open 0.248 ± 0.29 6.61 -67.62 
5 6 closed (R,R) 0.262 ±  0.36 6.58 -65.18 
6 6 closed (S,S) 0.262 ± 0.36 6.58 -65.47 
7 18 open 1.1 ± 0.2 5.96 -63.56 
8 18 closed (R) 0.88 ± 0.07 6.06 -63.49 
9 18 closed (S) 0.88 ± 0.07 6.06 -63.13 
10 20 open 5.6 ± 1.3 5.25 -58.40 
11 20 closed (R) 3.6 ± 1.0 5.44 -60.62 
12 20 closed (S) 3.6 ± 1.0 5.44 -60.26 
 
 
 
Figure S10. Docking poses of DTE 3 open for hHDAC6 (a) and hHDAC8 (b). Only the interacting residues of 
the binding pocket are displayed. The zinc ion is shown as brown ball. The water molecule bridging the 
coordination to the zinc ion in a) is shown as red ball. Distances of the metal coordination and hydrogen 
bonds are given in Å and are shown as lines colored in magenta. 
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Figure S11. Docking poses of DTEs for smHDAC8. a) 6 open colored dark green, b) 6 closed (R,R) colored 
cyan and 6 closed (S,S) colored brown, c) 3 open colored magenta. Only the interacting residues of the 
binding pocket are displayed. The zinc ion is shown as brown ball. Distances of the metal coordination and 
hydrogen bonds are given in Å and are shown as lines colored in magenta. 
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Figure S12. Docking poses of the fulgimide 20 for hHDAC1. a) 20 open colored green, b) 20 closed (R) colored 
blue and 20 closed (S) colored light grey. The zinc ion is shown as brown ball. Distances of the metal 
coordination and hydrogen bonds are given in Å and are shown as lines colored in magenta. 
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Figure S13. Docking poses of the fulgimides (20 open colored green, 20 closed (R) colored blue, 20 closed 
(S) colored light grey, 18 open colored yellow, 18 closed (R) colored cyan and 18 closed (S) colored salmon) 
for hHDAC8. The zinc ion is shown as brown ball and the water molecule bridging the coordination to the 
zinc ion is shown as red ball. Distances of the metal coordination and hydrogen bonds are given in Å and are 
shown as lines colored in magenta. The molecular surface of the hHDAC8 binding pocket in c) and f) is 
colored according to the hydrophobicity (hydrophobic regions are colored green, polar regions are colored 
magenta).  
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1H- and 13C-NMR spectra  
Compound 3A 
 
  
                                                     
A 13C-NMR-spectrum contains traces of acetone and CH2Cl2; signals are marked with * 
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Compound 5 
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Compound 9 
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Compound 11 
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Compound 12B  
 
 
  
                                                     
B NMR-spectra contain traces of CHCl3 and CH2Cl2; signals are marked with * 
 
107 Photochromic Histone Deacetylase Inhibitors based on Dithienylethenes and Fulgimides 
Compound 13 
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Compound 18 
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3.1 Introduction 
The two amino acids -aminobutyric acid (GABA) and glycine act as the major inhibitory 
neurotransmitters of the central nervous system by addressing their respective ionotropic 
chloride channel receptors to control the input-output relationship of excitatory drives 
impinging on neurons.[1] The ionotropic GABA receptors (GABAA and GABAC receptors) are 
mainly present in synapses in the brain while glycine-receptors (GlyRs) dominate in the 
spinal cord and brainstem.[2] Both of these receptors belong to the pentameric ligand-
gated ion channel “Cys-loop” family.[3] The GABAA-receptor (GABAAR) is composed of five 
hetero-oligomeric subunits selected from different subunit classes forming a central ion 
conductive pore. The subunit composition determines the individual function and 
pharmacological properties.[4] Most GABAARs in the brain are composed of two alpha 
subunits subtype 1, two beta subunits subtype 2, and one gamma subunit subtype 2.[5] 
When two molecules of GABA bind to the receptor at the neighboring interfaces of the  
and subunits the channel opens and allows the influx of chloride ions into the cell which 
results in membrane hyperpolarization.[6] As their dysfunction is related to various 
neuronal diseases the GABAARs became an important drug target in pharmaceutical and 
clinical research. Benzodiazepines (BZDs), which are an important class of compounds 
among the variety of tranquilizers, bind at the extracellular interface of the  and  
subunit of GABAARs and act as positive allosteric modulators of these receptors.[7] They 
cause highly anxiolytic, sedative, hypnotic, anticonvulsant and muscle relaxant effects.[8] 
However, their long-term use is controversial due to undesired side effects, abuse and 
most importantly drug addiction.[9-11] Interestingly, BZDs can also interact with central 
nervous GlyRs.[12] 
Also the GlyRs are assembled of five subunits arranged symmetrically around a central 
chloride selective pore. There are five different classes of subunits, four alpha and one 
beta. The alpha subunits can form homo- or heterogenic receptors in combination with 
the beta subunit.[13] The glycine binding sites are located at the interfaces of two alpha 
subunits or between an alpha and beta subunit. The binding properties of the beta-beta 
interface are unknown.[14] Like the ionotropic GABA receptors the GlyRs are chloride-
permeable pores which open when an agonist like glycine is binding. This leads to a 
hyperpolarization of the membrane potential and inhibition of neuronal firing.[15] 
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Whereas strychnine is a very potent and famous antagonist of GlyRs, nicardipine, which 
belongs to the class of dihydropyridines, acts mainly as calcium channel blocker[16] but can 
also have a biphasic potentiating as well as an inhibitory effect on GlyRs.[17] 
Light can be a powerful tool for the investigation of biological systems due to its high 
spatial and temporal controllability.[18] Different approaches of photocontrol have been 
developed and investigated: optogenetics,[19-20] the release of caged compounds by 
light,[18] photoswitchable tethered ligands (PTLs)[21-24] and photochromic ligands (PCLs).[25] 
The latter principle is most-common and the use of synthetic photoswitches to control 
biological activity with light has developed in a new vibrant field of research called 
photopharmacology.[26-28] Azobenzenes and dithienylethenes (DTEs) are the two main 
classes of photoswitches used in biological environment. Both scaffolds have a light-
induced reversible conversion between two isomers in common. The isomers of the 
azobenzenes differ in geometry and dipole moment and for the DTEs in conformational 
flexibility and electronic properties.[28] Both classes of switches show high fatigue 
resistance. The open and closed form of DTEs are thermally stable[29] whereas the cis 
isomer of an ordinary azobenzene underlies a thermal relaxation with characteristic half-
life, which can be advantageous depending on the particular application.[30] Another 
benefit of azobenzenes is their relatively easy synthesis by well-known methods like azo 
coupling or Mills reaction.[31] In the last years a lot of effort was made to successfully shift 
the wavelengths for the isomerization of azo compounds to the visible region, which is 
preferable for biological applications due to a higher tissue penetration of visible 
light.[32-33] 
Among other ion channels[34-40] also the GABAA-channel has been photocontrolled by PCLs 
based on propofol or gabazine.[41-43] We envisioned that merging azo switches with 
different known and highly biologically active pharmacophores as the benzodiazepine 
nitrazepam and the dihydropyridine nicardipine, (Figure 1) would lead to photochromic 
ligands for GABAARs and GlyRs, respectively, which have not been targeted yet. For our 
target structure design the tertiary amine moiety of nicardipine had to be modified into 
an aniline for the functionalization with an azobenzene. The nitro group of nitrazepam 
was reduced and then used as reactive counterpart for Mills reactions with various 
aromatic nitroso compounds to generate the azo moiety. Herein, we report the synthesis, 
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photophysical characterization, initial biological evaluations and preliminary results of 
molecular docking studies for these photochromic ion channel ligands. 
 
Figure 1. Molecular structures of the pharmacophores nitrazepam and nicardipine as well as general target 
structures of our photochromic azo ligands based on these pharmacophores. 
 
3.2 Results and Discussion 
3.2.1 Synthesis 
Synthesis of the benzodiazepine core 
First, a published synthesis[44] of nitrazepam starting from commercial benzophenone 1 
was attempted but surprisingly afforded isomeric quinolone 4 as the main product 
(Scheme 1). Already the crude mixture of the reaction contained compounds 3 and 4 
approximately in a 1:1 ratio. Trying to further purify compound 3 after column 
chromatography by recrystallization from toluene selectively transformed nitrazepam (3) 
into the undesired isomer 4. This rearrangement of nitrazepam to quinolone 4 in highly 
boiling solvents is known,[45] but also seems to occur already during the reaction in 
refluxing ethanol efficiently. 
 
Scheme 1. Undesired synthesis of quinolone 4. 
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Therefore, another published synthesis[46] for nitrazepam was accomplished and afforded 
the desired compound in two steps also starting from benzophenone 1. The nitro group 
of 3 was subsequently reduced by hydrogenation with palladium on charcoal as catalyst 
providing aniline 6[47] which can be used for further functionalization (Scheme 2). 
However, our analytical NMR data were in discrepancy with published ones,[48] but we 
could validate and prove our structure by X-ray crystallography. 
 
Scheme 2. Synthesis of nitrazepam (3) and subsequent reduction to 7-amino nitrazepam (6) with its 
corresponding X-ray structure. 
Nitrazepam (3) was further functionalized with quaternary amine 7[49] to increase its 
water solubility and introduce a positive charge (Scheme 3). For this purpose, it was 
alkylated on the amide group in an adapted heterogeneous microwave supported 
reaction[50] to compound 8 and then also hydrogenated to aniline 9 which was not 
isolated. 
 
Scheme 3. Preparation of benzodiazepines 8 and 9.  
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Synthesis of nitroso compounds 
A variety of aromatic nitroso compounds bearing polar groups were synthesized according 
to known procedures (Scheme 4). Sulfanilic acid (10) was converted into its 
tetrabutylammonium salt 11 which is soluble in organic solvents to prevent it from 
overoxidation by oxone in a biphasic system in the next step (Scheme 4a).[51] Nevertheless, 
only a 1:1 mixture of nitroso compound 12 and its corresponding nitro compound 13 could 
be isolated. All attempts to purify this mixture and enrich compound 12 were not 
successful due to the instability and high reactivity of the nitroso group. Hence, this 
obtained mixture was used for further reactions. Two different nitrosobenzsulfonamides 
15 and 18 were synthesized. Aniline 14 was reacted to its corresponding nitroso 
compound 15 by an oxone oxidation in a biphasic water/dichloromethane system in very 
low yield (Scheme 4b).[52]  
 
Scheme 4. Synthesis of nitroso compounds 12 (a), 15 (b), 18 (c), 21 (d) and 25 (e). 
Sulfonyl chloride 16 was reacted with aqueous methylamine to gain sulfonamide 17[53] 
which was further converted to nitrosobenzenesulfonamide 18 by a reduction with zinc 
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and subsequent oxidation with potassium dichromate (Scheme 4c).[54] Nitrosopyridine 21 
was synthesized by an oxidation with meta-chloroperoxybenzoic acid of sulfilimine 20, 
which was obtained starting from commercial aminopyridine 19 (Scheme 4d).[55] A 
microwave assisted 1,3-dipolar cycloaddition of acetylene 22 and diazo compound 23 
yielded pyrazole 24.[56] A further transformation with sodium nitrite in trifluoroacetic acid 
afforded nitrosopyrazole 25 in low yield (Scheme 4e).[57]  
 
Synthesis of 7-azo benzodiazepines. 
The Mills reaction was used as key step to form a photoisomerizable azo moiety between 
the prepared aromatic nitroso compounds 12, 15, 18, 21 as well as 25 and the 7-amino 
benzodiazepines 6 and 9. Therefore, each of the nitroso precursors was reacted with 
aniline 6 affording target structures 26 - 30 in a range of low (15%) up to good (73%) yields 
(Scheme 5).  
 
Scheme 5. Synthesis of target 7-azo benzodiazepines 26 - 31 by Mills reactions.  
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As solvent either pure acetic acid or a mixture of acetic acid and dichloromethane was 
used, which was beneficial for the solubility of the reagents. Under the biological testing 
conditions in aqueous buffer at pH-values around 7 sulfonic acid 26 is completely 
deprotonated bearing an overall negative charge (pKa of benzenesulfonic acid = 0.7)[58]. 
To study the influence and potentially unfavorable interaction of the negative charge of 
compound 26 on chloride anion selective ion channels compound 31 which is also 
functionalized with a sulfonic acid moiety was synthesized by a Mills reaction being overall 
neutral under these conditions (Scheme 5). 
Unfortunately, azo compound 28 showed very poor water solubility, which is essential for 
biological testing. Introducing a highly polar and charged group by post-functionalization 
solved this problem. Sulfonamide 28 was consequently alkylated with a tertiary amine. 
Because of the high reactivity and the use of two equivalents of the alkylating agent, it 
reacted also with its own tertiary amine group and accordingly azo benzodiazepine 32 was 
isolated as main product in 29% yield (Scheme 6). 
 
Scheme 6. Post-functionalization by alkylation of sulfonamide 28 to azo benzodiazepine 32. 
 
Attempt to synthesize fulgimide substituted benzodiazepines. 
We also wanted to take advantage of the very good photochromic properties of 
fulgides/fulgimides and therefore attempted to attach them to benzodiazepine 9 
(Scheme 7). In the first step fulgides 33 and 34 were reacted under basic conditions with 
benzodiazepine 9. The aniline group of 9 efficiently attacked and opened the anhydride 
moieties of the fulgides which was investigated by LC-MS analysis. However, after adding 
CDI to the reaction with furan 33 and PyBOP to the reaction with benzothiophene 34 as 
coupling reagents to build the maleimide ring only traces of desired compounds 35 and 
36 could be detected by LC-MS analysis besides a lot of other compounds. Additionally, 
we were also not able to recover any starting material and therefore suppose that the 
coupling reagents decompose the benzodiazepine scaffold. In a next attempt, the 
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coupling reagents have to be screened and carefully selected to avoid decomposition in 
order to succeed with the preparation of target compounds 35 and 36. 
 
Scheme 7. Attempted synthesis of fulgimide substituted benzodiazepines 35 and 36. 
 
Synthesis of nicardipine based photoswitches. 
For the preparation of a series of nicardipine based photochromic compounds different 
azobenzenes equipped with an aliphatic primary alcohol as linking group to the 
dihydropyridine pharmacophore were synthesized (Scheme 8). Azo compound 40 was 
generated by an adapted diazotization[59] of aniline 37 and subsequent coupling with 
aniline 39 yielded azo switch 40 in two steps with an overall yield of 11% (Scheme 8a). 
Commercially available azo dye 41 was reduced with sodium sulfide.[60] Betaine 43[61] was 
activated by oxalyl chloride and then coupled with amine 42 under basic conditions 
obtaining compound 44 (Scheme 8b). Another diazotization reaction of pyridine 45 and 
subsequent azo coupling with aniline 39 yielded photoswitch 46.[62] Further 
functionalization by alkylation with iodomethane and quaternary ammonium 7[49] 
provided azo compounds 47 and 48 in quantitative and 56% yield, respectively 
(Scheme 8c). Interestingly, the proton NMR spectrum of compound 47 shows four sharp 
doublets each with an integral of two for the eight aromatic protons, but for one of the 
signals the corresponding cross-peak in the HSQC as well as the signal from the 
corresponding pair of carbons in the carbon NMR is missing. This unusual fact that a sharp 
proton signal does not give a cross-peak in the HSQC spectrum with a missing carbon 
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signal could be explained by the positive charge of the pyridinium ion which leads to a fast 
exchange in the aromatic system. The situation for pyridinium 48 is similar for the 
aromatic protons, but in this case two doublets in the proton NMR are sharp, one is broad 
and the last one very broad. Consequently, the corresponding carbon NMR signals for 
both pairs of carbons bound to the protons with the broad signals could not be detected. 
 
Scheme 8. Synthesis of azo compounds 40 (a), 44 (b) and 46 - 48 (c) with the X-ray structure of 46. 
Finally, commercially available dihydropyridine 49 was activated with thionyl chloride and 
then esterified with azo switches 40, 44 and 46 - 48 in low to moderate yields affording 
azo nicardipines 50 - 53 (Scheme 9). Modified nicardipine 54 was synthesized by the same 
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type of reaction and should serve as a reference and model compound for biological 
testing to investigate the effect of the structural change we made compared to the 
original nicardipine scaffold. 
 
Scheme 9. Synthesis of modified nicardipine based compound 54 and azo derivatives 50 - 53. 
However, compound 54 as well as azo switches 50 and 52 unfortunately showed 
insufficient water solubility for biological testing. The desired product of the reaction of 
compound 49 with photoswitch 48 could be detected by LC-MS and NMR analysis but 
could not sufficiently be purified and isolated. Compound 53 shows the same 
phenomenon like already described for compound 47 of a missing cross-peak and a 
missing carbon signal in the NMR analysis despite sharp proton signals. In addition, 
determining the purity of compound 53 by analytical HPLC measurements revealed a 
specific impurity of about 10%. Further investigations by LC-MS analysis combined with 
the observation that also azo switch 52 showed an increasing decomposition tendency 
with decreasing pH value in aqueous solution suppose that compound 53 is also somehow 
decomposing. According to LC-MS measurements the impurity has to be uncharged with 
a molecular weight of 601 grams per mole and exhibits no absorption at 550 nm unlike 
azo dye 53. Therefore, we suppose decomposition of 53 as depicted in Scheme 10. 
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Scheme 10. Assumed formation of decomposition product of azo nicardipine 53. 
The first step is a protonation of compound 53 forming the hydrazine tautomer which is 
well known for such kind of azo systems.[63-64] A reduction of the hydrazine would then 
afford a compound which has no longer an absorption at 550 nm due to the interruption 
of the conjugated -system and with the required molecular weight. However, we were 
not able to isolate, characterize or finally prove the structure of the impurity. 
 
3.2.2 Photochromic Properties 
The choice of the photochromic scaffold is crucial for the design of photoswitchable 
ligands. Beside their relatively easy preparation azobenzenes also exhibit efficient 
photoswitching, a low rate of photobleaching and outstanding fatigue resistance.[25,30] 
Upon irradiation with light of an appropriate wavelength the in general thermally more 
stable trans isomer of azobenzenes is converted to the corresponding cis isomer with a 
huge change in geometry and dipole moment. The trans isomer can be regenerated either 
by thermal back relaxation or by irradiation with light.[30] The photochromic properties of 
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our prepared photoswitchable ligands 26 - 32 and 50 - 53 dissolved in DMSO and aqueous 
PBS if sufficiently soluble are summarized in Table 1. 
Table 1. Photochromic data of the synthesized ligands 26 - 32 and 50 - 53. 
Entry Comp. 
Conc.
[µM] 
Solvent 
max 
trans 
[nm] 
max 
cis 
[nm] 
t1/2 
25 °C 
PSS 
cis[a]
[%]* 
PSS 
tra.[b] 
[%]* 
1 26 50 DMSO 361 440 17.4 h 88 82 
2 26 50 PBS + 0.1% DMSO 347 429 55.6 h n.d. n.d. 
3 27 50 DMSO 365 442 21.1 h 88 82 
4 27 30 PBS + 3% DMSO 348 427 30.4 h n.d. n.d. 
5 28 50 DMSO 364 438 28.5 h n.d. n.d. 
6 29 50 DMSO 357 435 7.8 h 80 84 
7 29 50 PBS + 0.1% DMSO 348 425 82 min n.d. n.d. 
8 30 50 DMSO 350 none 2.7 h 88 71 
9 30 50 PBS + 0.1% DMSO 339 none -[c] n.d. n.d. 
10 31 50 DMSO 359 436 36.9 h 92 85 
11 31 50 PBS + 1% DMSO 340 425 171 h n.d. n.d. 
12 32 50 DMSO 352 451 34.3 h 82 89 
13 32 50 PBS + 1% DMSO 342 437 78.1 h n.d. n.d. 
14 50 10 DMSO 463 358 74 s 83[d] n.d. 
15 51 25 DMSO 434 376 0.3 s -[e] -[e] 
16 51 25 PBS + 1% DMSO 422 none <0.3 s[f] -[e] -[e] 
17 52 25 DMSO 450 376 38 s n.d. n.d. 
18 53 15 DMSO 552 -[g] -[g] -[g] -[g] 
19 53 15 PBS + 1% DMSO 566 -[g] -[g] -[g] -[g] 
n.d.: not determined; * determined by HPLC measurements with detection at isosbestic points; [a] PSS at 
photoconversion from the trans to the cis isomer; [b] PSS at photoconversion from the cis to the trans isomer; 
[c] could not be determined due to decomposition or precipitation after 5 h in PBS solution; [d] determined 
by direct irradiation in the NMR tube during proton NMR analysis (200 µM in DMSO-d6); [e] was not 
determined due to very fast thermal back isomerization; [f] could only be estimated due to aggregation 
effects in aqueous solution and moreover a very fast thermal relaxation; [g] photoisomerization could not 
be detected at all due to very short thermal half-life beyond time resolution of UV-Vis spectroscopy. 
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All our photochromic ligands featured excellent photochromic properties with a high 
photostationary state (PSS) of ≥80% of the cis isomer at the trans to cis photoconversion. 
This fact is beneficial because a biological effect can then be assigned to mainly one 
photoisomer. All the benzodiazepine derivatives 26 - 32 show a similar photochromic 
behavior. They can be photoisomerized to the cis isomer by UV-light of 365 nm. The back 
isomerization to the trans isomer can most efficiently be triggered by blue light of 455 nm 
except for compound 30. Due to the lack of a distinct absorption band for the cis isomer 
of 30 and an overlap of the UV-Vis spectra of both isomers light of a longer wavelength 
(530 nm) was used for back conversion to mostly avoid an absorption of the trans isomer. 
By way of example, Figure 2a illustrates the UV-Vis spectra of the trans isomer and the 
two PSSs of azo benzodiazepine 26 (50 µM in DMSO). Figure 2b shows the repetitive cycle 
performance with light of 365 nm and 455 nm at which no fatigue could be detected over 
ten measured cycles. Photochromic ligands 26 - 32 exhibit thermal half-lives in the range 
from 1.4 h to several days which can be advantageous due to the avoidance of continuous 
UV-irradiation for generating the cis isomer. 
 
 
Figure 2. a) UV-Vis spectra of azo benzodiazepine 26 (50 µM in DMSO) from the trans isomer, the PSS at 
irradiation with UV-light of 365 nm and the PSS at irradiation with blue light of 455 nm. b) Cycle 
performance of azo benzodiazepine 26 (50 µM in DMSO). Changes in absorption at 361 nm were measured 
during alternate irradiation with light of 365 nm for 15 s and 455 nm for three seconds. 
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Photochromic ligands 50 - 53 differ in photochromic properties compared to the azo 
benzodiazepines, because they all belong to the class of so called “push-pull” 
azobenzenes.[30] For compounds 51 - 53 it is quite obvious that the aniline acts as the 
donor part and the second aromatic moiety consisting of a pyridine, pyridinium or 
substituted with an electron withdrawing group as the acceptor part, respectively. 
Compound 50 can be transformed in such a system by simple protonation of one of the 
anilines.[40] These azobenzenes with a “push-pull” substitution generally show a red-shift 
in the absorption and shorter thermal half-lives.[30] We assume, but could not prove that 
the thermal relaxation of the cis isomer of 53 has to be really fast, because we were not 
able to detect any photoisomerization of azo switch 53 under continuous irradiation 
either in DMSO or aqueous phosphate buffer by standard UV-Vis spectroscopy. This is in 
accordance with a report of a related pyridinium switch.[40] The photoisomerization could 
be monitored by flash laser photolysis[65-66] or other readouts like biological effects. It has 
been shown that ion channels are able to recognize such a fast isomerization.[40]  
The azo nicardipines 50 - 52 were isomerized to the corresponding cis isomers by 
irradiation with blue light of 455 nm. The back isomerization of compound 52 was 
achieved with light of 385 nm and for compound 50 with visible light of 590 nm. The 
thermal relaxation of the cis isomer of 51 is so fast that the use of irradiation for back 
isomerization is unnecessary. After stopping irradiation with 455 nm it just takes about 
three seconds to completely recover the trans isomer, which can be repeated without 
fatigue (Figure 3).  
Due to this very short thermal half-life of about 0.3 s in DMSO it was also not possible to 
quantify the PSS under continuous irradiation in the NMR spectrometer, because it was 
beyond the time scale for NMR spectroscopy. Only by irradiating ( = 455 nm) a sample 
of 51 dissolved in methanol at 200 K a second set of signals belonging to the cis isomer 
started to arise, which was detectable by NMR spectroscopy due to the longer half-life of 
the cis isomer at lower temperatures. 
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Figure 3. a) UV-Vis spectra of azo benzodiazepine 51 (25 µM in DMSO) from the trans isomer, the PSS at 
irradiation with blue light of 455 nm and the spectral evolution at thermal cis to trans relaxation which is 
completed after approximately three seconds. b) Cycle performance of azo benzodiazepine 51 (25 µM in 
DMSO). Changes in absorption at 434 nm were measured during alternating irradiation with light of 455 nm 
for three seconds and thermal relaxation for five seconds. 
By investigating the photochromic properties of 51 in aqueous PBS (see Supporting 
Information, Figure S9) a much lower molar extinction coefficient at the maximum 
absorption of the trans isomer was observed. It dropped from 31.7·103 cm-1 M-1 in DMSO 
to 14.4·103 cm-1 M-1 in phosphate buffer with 1% of DMSO as solvent. This significant 
change could be explained by aggregation of 51 in aqueous solution, which is already 
known for other azobenzenes functionalized with a quaternary ammonium moiety due to 
their structure similarity with surfactants (so called azo surfactants).[67] In order to 
investigate the aggregation of compound 51 UV-Vis spectra in PBS as well as DMSO at 
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different concentrations were recorded and the concentration was plotted against the 
absorbance at the maximum absorption of the trans isomer in both solvents (Figure 4). 
 
Figure 4. a) Absorbance versus concentration plot at the absorption maximum of compound 51 in DMSO 
(blue) and aqueous PBS + 1% of DMSO (red) with linear extrapolations. The marked area is shown magnified 
in b. b) CMC determination of azo nicardipine 51 in PBS + 1% of DMSO by intersection of the linear 
extrapolations. 
As depicted in Figure 4a the absorbance at the maximum absorption of 51 in DMSO is 
increasing linearly with the concentration of 51 over the whole examined range of 
concentrations from 0.075 µM up to 10 µM. In contrast, the absorbance of 51 in the 
aqueous system is initially also increasing linearly from a concentration of 0.01 µM up to 
a concentration of almost 0.1 µM and then increasing further linearly with a flatter slope 
up to a 10 µM concentration (Figure 4a and 4b). The concentration at which the two 
extrapolated line segments are intersecting represents the onset of a micellization or 
aggregation process and is generally called critical micelle concentration (CMC).[68] The 
determined CMC value of around 0.1 µM for 51 is quite low compared to other related 
cationic azo surfactants which have critical micelle concentrations in the range from 0.1 
to 10 mM.[67] Therefore, we assume that the large organic and nonpolar nicardipine based 
part of compound 51 is further facilitating an aggregation in aqueous solution already at 
very low concentrations. 
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3.2.3 Biological Investigations and Molecular Docking 
ElectrophysiologyA 
The activity of the synthesized photochromic ligands 26, 29 and 30 was investigated by 
patch-clamp recordings with transfected CHO-cells expressing the respective ion channel. 
First, the effect of azo benzodiazepine 26 on heteromeric 122 GABAARs was studied. 
The sensitivity of the expressed GABAA-receptors to GABA was analyzed and a mean EC50 
of 8 ± 3 µM (data from 6 cells) was determined as depicted in Figure5a. 
 
Figure 5. a) Dose-response curve for GABAA. Mean EC50 for GABA comprised 8 ± 3 µM (n = 6 cells). b) Relative 
amplitudes of GABAA-mediated currents in control (white column), during application of 50 µM of 
photochromic benzodiazepine 26 (GABA 5 µM – gray column, GABA 300 µM – yellow column) and upon UV 
illumination (violet columns). c) Representative trace of the current induced by 5 µM of GABA, application 
of a mixture of GABA 5 µM + compound 26 50 µM started at the 5th second of registration and finished at 
the 20th second. Duration of UV illumination from the 10th until the 15th second of registration is indicated 
by the violet rectangle. d) Representative trace of the current induced by 300 µM of GABA, application of 
mixture GABA 300 µM + compound 26 50 µM started at the 5th second of registration and finished at the 
20th. Duration of UV illumination from the 10th until the 15th second of registration is indicated by the violet 
rectangle. 
Therefore, GABA concentrations of 5 µM (below EC50) and 300 µM (saturating 
concentration) were used to activate the GABAA-receptors in the next experiments. The 
application of 26 (50 µM) induced an inhibition of GABAA-mediated currents to 59 ± 2% 
                                                     
A All electrophysiological investigations were performed in the group of Prof. Dr. Piotr Bregestovski by 
Galyna Maleeva at the Aix-Marseille University, France. 
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(n = 6 cells; Figure 5b and c) when the channels were activated by 5 µM concentration of 
GABA and to 41 ± 3% (n = 8 cells; Figure 5b and d) when the channels were activated by 
300 µM of GABA. This inhibitory effect is contrary to the general mode of action of 
benzodiazepines as positive allosteric modulators of GABAARs. Upon UV illumination in 
both cases the inhibitory action of azo benzodiazepine 26 was abolished. 
The effect of azo benzodiazepine 26 on GlyRs was studied on 1 zebrafish, 1 human, 2 
zebrafish, 2 mouse, 3 human and 1 human G254A mutant homomeric receptors. 
Initially, we determined the sensitivity of 1 zebrafish GlyRs to glycine and found a mean 
EC50 of 35 ± 10 µM (n = 6 cells) as depicted in Figure 6a. 
 
Figure 6. a) Averaged dose-response curves for 1 and 2 zebrafish GlyRs. b) Relative amplitudes of currents 
mediated by 1 zebrafish GlyRs in control (glycine 20 µM), during application of 50 µM of photochromic 
benzodiazepine 26 in visible light (orange column) and in UV light (violet column). c) Representative trace 
of the current induced by 20 µM of glycine, application of a mixture of glycine 20 µM + compound 26 50 µM 
started at the 5th second of registration and finished at the 15th second. Duration of UV illumination from 
the 10th until the 15th second of registration is indicated by the violet rectangle. d) Representative trace of 
the current induced by 300 µM of glycine, application of a mixture of glycine 300 µM + compound 26 50 µM 
started at the 5th second of registration and finished at the 15th second. Duration of UV illumination from 
the 10th until the 15th second of registration is indicated by the violet rectangle. 
The application of azo benzodiazepine 26 (50 µM) caused an inhibition of currents evoked 
by 20 µM of glycine to 66 ± 2% (n = 6). UV illumination provoked an additional decrease 
of the current amplitude to 53 ± 2% (n = 6) (Figure 6b and c). However, the effect of 26 
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was not observed during the activation of 1 zebrafish GlyRs with a saturating 
concentration of glycine (300 µM) shown in Figure 6d. 
As depicted in Figure 6a the mean glycine EC50 for 2 zebrafish Gly-receptors comprised 
70 ± 11 µM (n = 6). Under visible light benzodiazepine 26 inhibited 2 mediated currents. 
The amplitude of currents evoked by 50 µM of glycine decreased to 9 ± 5% (n = 3, Figure 
7a and c). The current evoked by 300 µM of glycine decreased to 24 ± 9% (n = 3, Figure 7b 
and c). Upon UV illumination the inhibitory effect of compound 26 was completely 
abolished. 
 
Figure 7. a) Representative trace of the current induced by 50 µM of glycine at 2 zebrafish GlyRs, 
application of a mixture of glycine 50 µM + compound 26 50 µM started at the 5th second of registration 
and finished at the 15th second. Duration of UV illumination from the 10th until the 15th second of registration 
is indicated by the violet rectangle. b) Representative trace of the current induced by 300 µM of glycine, 
application of a mixture of glycine 300 µM + compound 26 50 µM started at the 5th second of registration 
and finished at the 15th second. Duration of UV illumination from the 10th until the 15th second of registration 
is indicated by the violet rectangle. d) Relative amplitudes of glycine-mediated currents in control (white 
column), during application of 50 µM of photochromic benzodiazepine 26 (50 µM of glycine – gray column, 
300 µM of glycine – yellow column) and upon UV illumination (violet columns). 
The action of benzodiazepine 26 on 2 mouse GlyRs was similar to its action on 2 
zebrafish GlyRs. Currents induced by 30 µM of glycine were inhibited to 34 ± 3% (n = 9) by 
application of 50 µM of compound 26. Upon UV illumination the inhibitory effect of 26 
was abolished. Also the effect of 26 on 3 human Gly-receptors was similar to its action 
on 2 zebrafish and 2 mouse GlyRs. The currents which were induced by 30 µM of glycine 
were inhibited to 38 ± 3% (n = 7) by application of 26 (50 µM). The inhibitory action was 
also abolished upon UV illumination. 
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Photochromic ligand 26 showed also similar effects on 1 human GlyRs like described for 
1 zebrafish GlyRs. The currents evoked by 30 µM of glycine were inhibited to 85 ± 4% 
under visible light and to 72 ± 2% upon UV illumination (n = 4, Figure 8a and c). 
 
Figure 8. a) Representative trace of the current mediated by wild type 1 human GlyRs. The current was 
evoked by application of 30 µM of glycine, application of a mixture of glycine 30 µM + compound 26 50 µM 
started at 5th second of the registration and finished at the 15th second. Duration of UV illumination from 
the 8th until the 10th second of registration is indicated by the violet rectangle. b) Representative trace of 
the current mediated by mutant G254A 1 human GlyRs. The current was evoked by application of 20 µM 
of glycine, application of a mixture of glycine 20 µM + compound 26 50 µM started at the 5th second of 
registration and finished at the 20th second. Duration of UV illumination from the 10th until the 15th second 
of registration is indicated by the violet rectangle. c) Relative amplitudes of the currents mediated by WT 
and mutant 1 GlyRs in control (white column), during application of BZD 26 50 µM (gray columns) and upon 
UV illumination (violet columns). d) IC50 values of azo benzodiazepine 26 for 1 human (91 µM, filled 
rectangle, dashed/dotted line); 1 zebrafish (76 µM, empty rectangle, dashed/dotted/dotted line); 2 
mouse (22 µM, empty circle, dashed line); 2 zebrafish (10 µM, filled circle, dotted line) and 3 human 
(29 µM, triangle, solid line) GlyRs. 
Interestingly, compound 26 exhibited opposite effects on 1 and 2 GlyRs upon UV 
illumination. Moreover, it was active at 2 receptors activated by a saturating 
concentration of the agonist glycine whereas it was not active at 1 receptors activated 
by a saturating concentration of the agonist. This fact suggests that azo benzodiazepine 
26 acts as a pore blocker of 2 GlyRs and as a competitive antagonist of 1 human 
receptors. To further prove this hypothesis the effect of compound 26 on 1 human 
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mutant G254A GlyRs was investigated. The mutation is located in the TM2 domain of the 
receptor which forms the pore of the ion channel and the mutation transforms the ion 
pore of 1 receptors to the ion pore of the 2 receptors. 
The receptors formed by the mutant G254A 1 GlyRs responded to the application of 
compound 26 and UV illumination similarly to 2 GlyRs (Figure 8b) and in a different way 
compared to 1 wild type GlyRs (Figure 8c). As depicted, the currents mediated by 1 wild 
type GlyRs were inhibited to 85 ± 4% under visible light and to 72 ± 2% upon UV 
illumination (n = 4) whereas the currents mediated by mutant 1 G254A GlyRs were 
inhibited by photochromic benzodiazepine 26 (50 µM) in visible light to 70 ± 3% (n = 7) 
and this effect was completely abolished upon UV illumination. The dose response curves 
to determine the IC50 values of azo benzodiazepine 26 for 1 human (91 µM), 1 zebrafish 
(76 µM), 2 mouse (22 µM), 2 zebrafish (10 µM) and 3 human (29 µM) Gly-receptors 
are shown in Figure 8d. 
In summary, photochromic ligand 26 inhibits the pore of GABAA as well as 2 zebrafish, 2 
mouse, 2 human and 3 human Gly-receptors in trans configuration. In cis configuration 
compound 26 loses this ability and its inhibitory effect. Apart from that compound 26 acts 
as a competitive antagonist on 1 zebrafish as well as 1 human GlyRs and its inhibitory 
activity increases upon UV illumination. 
Azo benzodiazepine 29 showed similar effects on all subunits of the tested Gly-receptors 
(1 human, 2 mouse and 3 human). In trans configuration it inhibited the glycine 
induced currents. For 1 GlyRs it was reduced by 9 ± 4% (n = 3), for 2 by 38 ± 7% (n = 4) 
and for 3 by 22 ± 7% (n = 2). Upon UV illumination the strength of the inhibition 
increased and comprised. The currents were reduced by 33 ± 6% for 1 GlyRs, by 73 ± 6% 
for 2 and by 41 ± 9% for 3 compared to the control (Figure 9). With increasing glycine 
concentration the inhibitory effect of compound 29 decreased, suggesting a competitive 
mechanism of the antagonistic action. 
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Figure 9. a) Mean amplitudes of glycine (100 µM) induced currents mediated by 1 GlyRs in control (black), 
upon application of 50 µM azo benzodiazepine 29 (green) and during UV illumination (orange, n = 3). b) 
Mean amplitudes of glycine (30 µM) induced currents mediated by 1 GlyRs in control (black), upon 
application of 50 µM azo benzodiazepine 29 (green) and during UV illumination (orange, n = 4). c) 
Representative trace of the current mediated by 1 GlyRs. The durations of glycine (100 µM) and compound 
29 (50 µM) applications are indicated by bars above the trace. The UV illumination is indicated by the violet 
rectangle. d) Representative trace of the current mediated by 2 GlyRs. The durations of glycine (30 µM) 
and compound 29 (50 µM) applications are indicated by bars above the trace. The UV illumination is 
indicated by the violet rectangles. 
Compound 29 showed also an inhibitory effect on the currents evoked by GABA in 122 
GABAA-receptors. However, irradiation with UV light led to a decreased inhibition in 
contrast to all the GlyRs (Figure 10a and b). Figure 10c summarizes the mean inhibition 
values of azo benzodiazepine 29 for all investigated receptors both with and without UV 
illumination. Further electrophysiological investigations with compound 29 are still 
ongoing. 
Azo benzodiazepine 30 had a minor inhibitory effect on GABAARs and showed almost no 
UV-dependent activity (Figure 11). It was not active at 1 human GlyRs but further 
investigations are accomplished. 
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Figure 10. a) Mean amplitudes of GABA (5 µM) induced currents mediated by 122 GABAA-receptors in 
control (black), upon application of 50 µM azo benzodiazepine 29 (green) and during UV illumination 
(orange, n = 3). b) Representative trace of the current mediated by 122 GABAA-receptors. The durations 
of GABA (5 µM) and compound 29 (50 µM) applications are indicated by bars above the trace. The UV 
illumination is indicated by the violet rectangles. c) Comparison of the mean inhibition (percentage) of 1 
Gly (black column), 2 Gly (light gray), 3 Gly (gray) and GABAA (white) receptors mediated currents by azo 
benzodiazepine 29 in trans configuration and upon UV irradiation (violet columns). 
 
 
Figure 11. Representative trace of the current mediated by 122 GABAA-receptors. The durations of GABA 
(5 µM) and compound 30 (50 µM) applications are indicated by the bars above and below the trace. The UV 
illumination is indicated by the violet rectangle. 
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Preliminary investigations with benzodiazepine 27 resulted in a much lower detected 
activity on all tested ion channels. Therefore, it is supposed that the sulfonic acid group 
of compound 26 plays a crucial role for the interaction with the pores, but further 
experiments with compound 27 are necessary to confirm the obtained results. The 
electrophysiological effects of photochromic ligands 31, 32, 51, and 53 are also currently 
investigated. 
 
In vivo characterizationB 
Next, the photochromic ligands were tested in living animals to evaluate light-dependent 
responses in their behavior. First, we chose zebrafish larvae (Danio rerio, Tupfel long 
strain) as model animal and a behavioral assay to monitor the zebrafish activity was 
developed. The activity was measured as swum distance in millimeters during large 
activity periods in which the animal speed is higher than six millimeters per second. The 
distances or activity in all data and graphs are given as cumulative intense activity periods 
within one minute. Zebrafish larvae have naturally cyclic periods of low and high speed 
movements when they are unstressed. After applying the respective treatment with the 
photochromic ligands (100 µM diluted stock solutions of the trans isomers in DMSO) to 
the animals they were kept in the dark for 20 minutes without light changes or external 
mechanic stimuli (relaxation period). Then they were exposed to UV and blue light cycles 
for in total twelve minutes with alternating continuous illumination with 365 nm and 
455 nm for two minutes, respectively. The corresponding tracking of the activity over time 
is depicted in Figure 12. 
  
                                                     
B All in vivo experiments were carried out in the group of Prof. Dr. Pau Gorostiza by Alexandre Gomila and 
Dr. Núria Camarero at the Institute of Bioengineering of Catalonia, Barcelona, Spain. 
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Figure 12. Experimental zebrafish activity over time for control (without any treatment, black), DMSO (1%, 
gray) and treatments with azo benzodiazepines 26 (100 µM, green), 27 (100 µM, blue) and 29 (100 µM, red). 
Dark conditions are drawn with gray background, UV illumination with violet and blue light illumination with 
blue background. 
Among the three tested photochromic ligands 26, 27 and 29 only compound 29 shows a 
clear excitatory effect onto zebrafish behavior. During the initial relaxation period under 
dark conditions the animals do not return to their natural activity levels and remain in an 
excitatory state (Figure 13a). Therefore, we assume that the trans isomer of azo 
compound 29 has an overall antagonistic effect to the inhibitory pathways in zebrafish. 
Under UV illumination (365 nm) an overreaction with permanent high speed movements 
during the first minute of irradiation is observed in every cycle due to the blockade of the 
inhibitory pathways by the trans isomer of compound 29. This excitatory state decreased 
during the second minute of UV illumination because most of the trans isomer is 
converted to the cis isomer (PSS of 80% at 365 nm see Table 1, entry 6) which seems to 
be inactive in vivo. This behavior in the second minute under UV illumination is reversed 
to the activity observed for the control animals as they get continuously more active in 
the two minutes of UV illumination. Under each cycle of blue light irradiation all animals 
return to levels of their basal activity while compound 29 isomerizes back from its cis to 
the active trans isomer (PSS of 84% at 455 nm see Table 1, entry 6). Therefore, the animals 
under treatment of 29 again overreact in the next cycle of UV illumination. However, the 
overall activity from the second UV cycle is always reduced compared to the first one until 
a plateau (approximately in the third UV cycle) is reached because the back isomerization 
with visible light to the trans isomer is always incomplete. Nevertheless, the maintaining 
  
146  Results and Discussion 
levels of overreaction in the following UV cycles are significantly higher than the control 
levels. Combining the higher inhibitory effect of the trans isomer in vivo with the results 
from electrophysiological measurements supposes that the in vivo activity of compound 
29 results mainly from acting on the zebrafish glycine-receptors. Interestingly, by reducing 
the concentration of compound 29 to 50 µM (not shown in Figure 12) its excitatory effect 
completely vanished and activity levels were similar to them of treatments with 100 µM 
of 26 or 27. The total activities under UV as well as blue light illumination of all investigated 
treatments are depicted in Figure 13b and c indicating with Figure 13a that compounds 
26 and 27 do not have an in vivo activity as their activity levels are always in the range of 
the activity of the control animals. 
 
Figure 13. Total activity during the 20 minutes of relaxation period (a), six minutes of UV illumination (three 
cycles of two minutes illumination with 365 nm, b) and six minutes of blue light illumination (three cycles 
of two minutes illumination with 455 nm, c) for control (without any treatment, black), DMSO (1%, gray) 
and treatments with azo benzodiazepines 26 (100 µM, green), 27 (100 µM, blue) and 29 (100 µM, red). 
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The in vivo inactivity of azo benzodiazepine 26 which is in contradiction to its determined 
electrophysiological effects in vitro could be explained by its opposite effects under UV 
light to the main inhibitory ligand-gated receptors GABAA and 1 Gly. Further experiments 
are performed to investigate this discrepancy. Due to the moderate effects of compound 
30 in electrophysiology and a similar inactivity in zebrafish larvae like compound 26 in 
preliminary assays it was neglected for further experiments. The light-dependent effect 
of photochromic ligands 31, 32, 51 and 53 will also be investigated in zebrafish larvae after 
their electrophysiological evaluation is completed. In addition, further and more complex 
zebrafish assays for the investigation of other changes in behavior than the swum distance 
by treatment with our photochromic ligands will be developed. 
In a second approach the photochromic ligands 26, 29 and 30 were also investigated in 
tadpoles from Xenopus tropicalis in the same manner like described for zebrafish larvae. 
However, all treatments caused no significant effect in the behavior and activity of the 
tadpoles. 
 
Molecular dockingC 
In order to rationalize the observed in vitro activities docking of benzodiazepine 26 in two 
different conformations[69] of the seven membered ring each in trans and cis configuration 
of the azo group to GABAAR and the different subtypes of GlyRs was carried out. 
First, the trans isomer of compound 26 was docked in the classical benzodiazepine binding 
site between the  and  subunits of a GABAAR homology model[70] to compare its binding 
with diazepam. As depicted in Figure 14 the binding of 26 on this site is very unfavored 
and therefore the docking also suggests another mode of action as pore blocker like 
already assumed from the electrophysiological data. 
  
                                                     
C All molecular docking experiments were performed in the group of Prof. Dr. Carme Rovira by Alba Nin-Hill 
and Dr. Mercedes Alfonso-Prieto at the University of Barcelona, Spain. 
  
148  Results and Discussion 
 
Figure 14. Comparison of the binding mode of the trans isomer of azo benzodiazepine 26 (cyan) and 
diazepam (black) in the classical benzodiazepine binding site between the  and  subunits of the GABAA-
receptor. 
Azo benzodiazepine 26 was then docked to the human 1 and 3 GlyRs whose crystal 
structures were recently solved and published.[15, 71] The dockings on the closed 1 and 3 
human GlyRs revealed that both photoisomers of benzodiazepine 26 are able to bind to 
the pores and block them, occupying the T6’, G2’ or A2’ and P-2’ region of the receptor, 
respectively. However, the binding of the cis isomer of azo benzodiazepine 26 is less 
favored because the negatively charged sulfonic acid moieties are located in the nonpolar 
G2’ and A2’ position, respectively. In contrast, the trans isomer is able to form hydrogen 
bonds in the T6’ position and the charge of the sulfonic acid group points to the solvent 
(Figure 15). On the one hand these results for the 1 subtype are in accordance with the 
experimental in vitro data that both trans and cis isomer of azo benzodiazepine show 
inhibitory effects on this receptor. On the other hand they cannot explain the loss of 
inhibition on the 3 subtype of the cis isomer of compound 26. We can only hypothesize 
that the extra methyl group being present in 3-Ala2' compared to 1-Gly2' makes this 
position more apolar and thus the binding of the sulfonic acid moiety of azo 
benzodiazepine 26 less favored which could unblock the closed pore. 
A docking of the two photoisomers of compound 26 to the open human 1 and 3 GlyRs 
showed that at least two molecules of 26 are needed to block the pore. For the 1 subtype 
all possible poses with two cis isomers of 26 block the pore whereas only some possible 
poses for the trans isomers. These findings are in good agreement with the experimental 
results. For the human 3 subtype the preliminary results are not so clear because there 
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are possible poses for two molecules of both isomers which block as well as do not block 
the pore. Further simulations for the open receptors are ongoing. 
 
Figure 15. Dockings of azo benzodiazepine 26 to the 1 human glycine-receptor (a: trans isomer; b: cis 
isomer) as well as to the 3 human glycine-receptor (c: trans isomer; d: cis isomer). 
Finally, a docking in which azo benzodiazepine 26 was allowed to explore all the 3 GlyR 
(both the extracellular and the transmembrane domains) was performed. Thereby some 
poses of trans as well as cis azo benzodiazepine 26 are located in the novel pocket recently 
found by Huang et al. (Figure 16).[72] However, their calculated docking scores are much 
worse compared to reference compound AM3607 and therefore we suppose that the 
most favorable binding mode is in the T6’, A2’ and P-2’ region of the 3 receptor. 
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Figure 16. Comparison of the binding of azo benzodiazepine 26 and reference compound AM3607 at the 
recently discovered novel binding site of the 3 GlyR.[72] 
 
3.3 Conclusion 
In summary, we merged structural elements of nitrazepam and nicardipine, which are 
well-known pharmacophores, with photoswitchable azobenzenes to yield photochromic 
ligands for modulation of GABAA and glycine-receptors by light. A small series of azo 
benzodiazepines was synthesized by using Mills reactions of 7-amino nitrazepam with 
different nitroso precursors as the synthetic key step. The low water solubility of one of 
the obtained target compounds could successfully be increased by post-functionalization. 
The azo nicardipines were synthesized by esterification of the basic dihydropyridine core 
with different hydroxyl substituted azo switches. The photochromic properties of all 
prepared ligands were excellent with very good fatigue resistance and high 
photostationary states in DMSO as well as aqueous phosphate buffer. The 
electrophysiological investigations of the first benzodiazepine derivatives identified one 
very promising compound. It acts as an UV sensitive blocker of GABAA-receptors which 
loses its inhibitory effect upon irradiation. Simultaneously, it shows subtype specific 
effects on glycine-receptors. On the one hand it lost also its ability to block the channels 
under illumination on all tested 2 and 3 glycine-receptors from different species. On the 
other hand the inhibitory effect on subtype 1 glycine-receptors was even increased 
under irradiation. A further molecule showed weaker, but similar effects in 
electrophysiology, but no subtype specific effects on the different glycine-receptors. 
However, only the latter compound exhibited significant influence on the activity of 
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zebrafish larvae in vivo. Preliminary assays indicate that the trans isomer operates as an 
excitatory drug with an overall antagonistic effect on the inhibition pathways of zebrafish. 
Therefore, the fishes overreact to external stimuli which can be measured by their higher 
activity and faster movements. This overreaction is lost by photoisomerizing the 
compound to the cis isomer. Molecular dockings could partly rationalize the in vitro 
activity of the most active compound, but more detailed calculations have to be carried 
out to get a better insight into the mode of action on the particular receptors.  
 
3.4 Experimental 
3.4.1 Chemistry 
Compounds 2,[47] 3,[46] 5,[59] 6,[47] 11,[51] 12,[51] 15,[52] 17,[53] 18,[54] 20,[55] 21,[55] 24,[56] 25,[57] 
38,[59] 42[60] and 46[62] were synthesized according to reported or adapted procedures. 
Commercial reagents and starting materials were purchased from Acros Organics, Alfa-
Aesar, Fisher Scientific, Sigma Aldrich or VWR and used without any further purification. 
Solvents were used in p.a. quality and dried according to common procedures, if 
necessary. Commercially PBS (pH = 7.4) was used for investigations of the photochromic 
properties. Dry nitrogen was used as inert gas atmosphere. Microwave-assisted reactions 
were performed in an Anton Paal Monowave 400 microwave. A Biotage Isolera flash 
purification system with UV/Vis detector using Sigma Aldrich MN silica gel 60 M (40-
63 µm, 230-400 mesh) for normal phase or pre-packed Biotage SNAP cartridges (KP C18 
HS) for reversed phase chromatography was used for automated flash column 
chromatography. Reaction monitoring via TLC and determination of Rf values was 
accomplished on alumina plates coated with silica gel (Merck silica gel 60 F254, 0.2 mm). 
Melting points were measured with a Stanford Research Systems OptiMelt MPA 100 
device and are uncorrected. NMR spectra were measured on Bruker Avance 300 (1H 
300.13 MHz, 13C 75.48 MHz), Bruker Avance 400 (1H 400.13 MHz, 13C 100.61 MHz) and 
Bruker Avance III 600 (1H 600.25 MHz, 13C 150.95 MHz) instruments. The spectra are 
referenced against the NMR-solvent (DMSO-d6: H = 2.50 ppm, C = 39.52 ppm, MeOH-d4: 
H = 4.87 ppm, C = 49.00 ppm, D2O: H = 4.79 ppm) and chemical shifts  are reported in 
ppm. Resonance multiplicity is abbreviated as: s (singlet), d (doublet), t (triplet), q 
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(quartet), m (multiplet) and b (broad). Carbon NMR signals are reported using DEPT 135 
and 1H-13C HSQC spectra with (+) for primary/tertiary, (−) for secondary and (q) for 
quaternary carbons. An Agilent Q-TOF 6540 UHD (ESI-MS) instrument was used for 
recording mass spectra. UV/Vis absorption spectroscopy was accomplished using a Varian 
Cary BIO 50 UV/Vis spectrometer in 10 mm quartz cuvettes. IR-spectra were recorded on 
an Agilent Cary 630 FT-IR spectrometer and the peak positions are reported in 
wavenumbers (cm-1). Analytical HPLC measurements were performed on an Agilent 1220 
Infinity LC (column: Phenomenex Luna 3 µM C18(2) 100 Å, 150 x 2.00 mm; flow: 
0.3 mL/min at 30 °C; solvent A: MilliQ water with 0.05 % vol. TFA; solvent B: MeCN). The 
ratios in the PSSs were determined by HPLC measurements with a detection wavelength 
at the isosbestic points or by 1H-NMR-spectroscopy with direct irradiation inside the NMR 
tube during the measurements. For determination of the thermal half-lives the solutions 
were irradiated until the photostationary state was reached. Then the solutions were left 
at 25 °C and the recovery of the absorbance of the trans isomer at max was measured. 
Consequently, the thermal half-life was calculated by fitting the data with a single 
exponential function. An Agilent 1260 system (column: Phenomenex Luna 10 µM C18(2) 
100 Å, 250 x 21.2 mm; flow: 22.0 mL/min at room temperature; solvent A: MilliQ water 
with 0.05 % vol. TFA; solvent B: MeCN) was used for preparative HPLC purification. Light 
sources for irradiation:  = 365 nm (Herolab hand-held lamp UV-6 L, 6 W), = 385 nm 
(NICHIA NCSU034B, 500 mA, 21 mW)  = 455 nm (OSRAM Oslon SSL 80 LED, 700 mA, 
1.12 W),  = 530 nm (CREE-XP green LED, 700 mA, 3.7 W),  = 590 nm (OSRAM Oslon SSL 
80 LED, 700 mA, 1.12 W). The power of the light is given based on the specifications 
supplied by the company when the lamps were purchased. If not otherwise stated, final 
compounds for biological testing possess a purity ≥95% determined by HPLC 
measurements with detection at 220 nm and 254 nm. 
 
7-Amino-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (6) 
Nitrazepam (3) (149 mg, 0.53 mmol) was dissolved in MeOH (15 mL) and hydrogenated 
using Pd/C (9 mg, 10 wt. % Pd) in an autoclave (2 bar of H2) at room temperature for 
45 min. The mixture was centrifuged, filtered over celite and the solvent was removed in 
vacuo. The residue was purified by automated reversed phase flash column 
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chromatography (PE/CH2Cl2 with 1% Et3N, 70% - 100% CH2Cl2 with 1% Et3N) yielding 6 
(130 mg, 99%) as yellow solid. An analytical sample was crystallized from Et2O with a 
minimal amount of MeOH. Samples for biological testing were further purified by 
preparative HPLC (2% - 30% MeCN in 15 min, tR = 9.1 min) affording the corresponding 
trifluoroacetate salt. 1H-NMR (300 MHz, DMSO-d6) = 10.03 (s, 1H), 7.56 – 7.36 (m, 5H), 
6.93 (d, J = 8.6 Hz, 1H), 6.77 (dd, J = 8.6, 2.5 Hz, 1H), 6.39 (d, J = 2.4 Hz, 1H), 5.16 (s, 2H), 
4.05 (bs, 2H); 13C-NMR (75 MHz, DMSO-d6) = 170.0 (q), 169.6 (q), 144.0 (q), 139.4 (q), 
129.9 (+), 129.2 (+), 128.1 (+), 127.2 (+), 122.0 (+), 118.0 (+), 113.5 (+), 57.0 (−); HRMS (ESI) 
calcd. for C15H14N3O (M+H)+ m/z = 252.1131; found 252.1134. 
 
N,N,N-Triethyl-3-(7-nitro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl) 
propan-1-aminium (8) 
Nitrazepam (101 mg, 0.36 mmol, 1.0 eq.), 49 (164 mg, 0.54 mmol, 1.5 eq.) and K2CO3 
(159 mg, 1.15 mmol, 3.2 eq.) were suspended in DMF (3.3 mL) and heated to 80 °C for 
7.5 min in a microwave reactor. After removing K2CO3 by filtration the solvent was 
evaporated in vacuo. The residue was purified by automated flash column 
chromatography (CH2Cl2/MeOH, 3% - 30% MeOH) and subsequent preparative HPLC 
(70% - 98% MeCN in 9 min, 98% MeCN for further 6 min, tR = 10.3 min) yielding compound 
8 bromide (119 mg, 66%) as yellow solid. Rf 0.07 (CH2Cl2/MeOH 9:1); m.p. 144 °C; 1H-NMR 
(300 MHz, MeOH-d4) = 8.52 (dd, J = 9.1, 2.7 Hz, 1H), 8.17 (d, J = 2.7 Hz, 1H), 7.86 (d, J = 
9.1 Hz, 1H), 7.73 – 7.66 (m, 2H), 7.65 – 7.57 (m, 1H), 7.57 – 7.46 (m, 2H), 4.73 (d, J = 
11.0 Hz, 1H), 4.34 (dt, J = 13.7, 6.6 Hz, 1H), 4.08 – 3.87 (m, 2H), 3.27 – 2.96 (m, 8H), 2.15 
(dtt, J = 6.2 Hz, 1H), 1.96 (dtt, J = 6.1 Hz, 1H), 1.12 (t, J = 7.2 Hz, 9H); 13C-NMR (75 MHz, 
MeOH-d4) = 171.3 (q), 171.2 (q), 148.9 (q), 145.1 (q), 138.6 (q), 132.9 (+), 131.0 (q), 130.8 
(+), 130.0 (+), 127.8 (+), 127.1 (+), 125.1 (+), 57.7 (−), 55.6 (−), 54.0 (−), 46.2 (−), 21.9 (−), 
7.5 (+); IR (neat) = 3086, 2997, 1774, 1737, 1681, 1610, 1525, 1484, 1450, 1420, 1346, 
1185, 1133, 1003, 913, 842, 783, 701 cm-1; HRMS (ESI) calcd. for C24H31N4O3 M+ m/z = 
423.2391; found 423.2401. 
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(E)-4-((2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-yl)diazenyl)benzene-
sulfonic acid (26) 
A 1:1 mixture of tetrabutylammonium 4-nitrosobenzenesulfonate and its corresponding 
nitro derivative (236 mg, 0.54 mmol, 1.0 eq. of nitroso compound) was added to a 
solution of benzodiazepine 6 (68 mg, 0.27 mmol, 1.0 eq.) in acetic acid (2 mL) and CH2Cl2 
(1 mL). After stirring the mixture for 24 h at room temperature the solvent was removed 
in vacuo. Purification by automated flash column chromatography (CH2Cl2/MeOH, 
3% - 25% MeOH) and subsequent preparative HPLC (2% - 65% MeCN in 10 min, tR = 
7.2 min) yielded 26 (69 mg, 61%) as yellow solid. Rf 0.03 (CH2Cl2/MeOH 9:1); m.p. 280 °C 
(decomposition); 1H-NMR (600 MHz, DMSO-d6) = 11.32 (s, 1H), 8.23 (dd, J = 8.8, 2.4 Hz, 
1H), 7.81 – 7.78 (m, 2H), 7.77 – 7.73 (m, 3H), 7.68 (t, J = 7.4 Hz, 1H), 7.64 (dd, J = 8.3, 1.3 
Hz, 2H), 7.57 (t, J = 7.7 Hz, 2H), 7.52 (d, J = 8.9 Hz, 1H), 4.34 (s, 2H); 13C-NMR (151 MHz, 
DMSO-d6) = 172.5 (q), 168.9 (q), 151.4 (q), 151.1 (q), 146.5 (q), 143.0 (q), 135.8 (q),132.5 
(+), 130.7 (+), 128.8 (+), 128.6 (+), 126.8 (+), 126.2 (+), 124.4 (q), 122.9 (+), 122.2 (+), 54.6 
(−); IR (neat) = 3489, 3135, 2930, 1715, 1614, 1484, 1435, 1387, 1342, 1230, 1163, 1115, 
1029, 1006, 846, 742, 697 cm-1; HRMS (ESI) calcd. for C22H16N4O4S (M+H)+ m/z = 421.0965; 
found 421.0964. 
 
(E)-4-((2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-yl)diazenyl)benzene-
sulfonamide (27) 
Freshly prepared 4-nitrosobenzenesulfonamide (238 mg, 1.38 mmol, 3.0 eq.) was added 
to a solution of benzodiazepine 6 trifluoroacetate salt (168 mg, 0.46 mmol, 1.0 eq.) in 
CH2Cl2 (6 mL) and acetic acid (2 mL). After stirring the mixture for 24 h at 40 °C the solvent 
was removed in vacuo. The residue was purified by automated flash column 
chromatography (CH2Cl2/MeOH, 3% - 10% MeOH) yielding compound 27 (140 mg, 73%) 
as orange solid. Material for analytical characterization as well as for biological testing was 
further purified by preparative HPLC (10% - 75% MeCN in 18 min, tR = 11.1 min). Rf 0.14 
(CH2Cl2/MeOH 97:3); m.p. 207 °C; 1H-NMR (400 MHz, DMSO-d6) = 11.08 (s, 1H), 8.16 
(dd, J = 8.8, 2.3 Hz, 1H), 7.98 (s, 4H), 7.79 (d, J = 2.3 Hz, 1H), 7.58 – 7.46 (m, 8H), 4.27 (s, 
2H); 13C-NMR (101 MHz, DMSO-d6) = 170.1 (q), 169.8 (q), 153.2 (q), 146.2 (q), 146.0 (q) 
143.0 (q), 138.0 (q), 131.1 (q), 129.7 (+), 128.5 (+), 127.8 (+), 127.1 (+), 126.1 (q), 124.9 (+), 
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123.0 (+), 122.6 (+), 56.5 (−); IR (neat) = 3243, 3071, 1700, 1674, 1610, 1484, 1390, 1334, 
1200, 1163, 1014, 902, 842, 798, 746, 697 cm-1; HRMS (ESI) calcd. for C21H18N5O3S (M+H)+ 
m/z = 420.1133; found 420.1125. 
 
(E)-N-Methyl-4-((2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-7-yl)diazenyl) 
benzenesulfonamide (28) 
N-Methyl-4-nitrosobenzenesulfonamide (120 mg, 0.60 mmol, 2.0 eq.) was added to a 
solution of benzodiazepine 6 trifluoroacetate salt (110 mg, 0.30 mmol, 1.0 eq.) in CH2Cl2 
(3 mL) and acetic acid (1 mL). After stirring the mixture for 24 h at room temperature the 
solvent was removed in vacuo. The residue was purified by automated flash column 
chromatography (CH2Cl2/MeOH, 3% - 10% MeOH) and subsequent preparative HPLC 
(10% - 98% MeCN in 15 min, tR = 9.4 min) affording compound 28 (85 mg, 65%) as orange 
solid. Rf 0.24 (CH2Cl2/MeOH 97:3); m.p. 252 °C; 1H-NMR (300 MHz, DMSO-d6) = 11.08 (s, 
1H), 8.17 (dd, J = 8.8, 2.3 Hz, 1H), 8.05 – 7.89 (m, 4H), 7.79 (d, J = 2.3 Hz, 1H), 7.64 (q, J = 
4.9 Hz, 1H), 7.59 – 7.54 (m, 3H), 7.53 – 7.44 (m, 3H), 4.27 (s, 2H), 2.44 (d, J = 4.9 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) = 170.1 (q), 169.7 (q), 153.5 (q), 146.2 (q), 143.1 (q), 141.2 
(q), 138.0 (q), 131.0 (q), 129.7 (+), 128.5 (+), 128.1 (+), 127.8 (+), 126.1 (q), 124.9 (+), 123.2 
(+), 122.5 (+), 56.5 (−), 28.6 (+); IR (neat) = 3094, 2937, 1674, 1610, 1484, 1390, 1331, 
1234, 1200, 1163, 1092, 1014, 842, 783, 742, 697 cm-1; HRMS (ESI) calcd. for C22H20N5O3S 
(M+H)+ m/z = 434.1288; found 434.1281. 
 
(E)-5-Phenyl-7-(pyridin-2-yldiazenyl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (29) 
2-Nitrosopyridine (108 mg, 1.00 mmol, 2.0 eq.) was added to a solution of benzodiazepine 
6 (126 mg, 0.50 mmol, 1.0 eq.) in CH2Cl2 (3 mL) and acetic acid (1 mL). After stirring the 
mixture for 24 h at room temperature the solvent was removed in vacuo. The residue was 
purified by automated reversed phase flash column chromatography (MeCN/H2O with 
0.05% TFA, 5% - 100% MeCN) and subsequent preparative HPLC (10% - 60% MeCN in 
20 min, tR = 13.4 min) yielding compound 29 (125 mg, 73%) as yellow solid. Rf 0.63 
(CH2Cl2 + 1% Et3N/MeOH 9:1); m.p. 222 °C; 1H-NMR (600 MHz, DMSO-d6) = 10.98 (s, 1H), 
8.67 (ddd, J = 4.7, 1.8, 0.8 Hz, 1H), 8.17 (dd, J = 8.7, 2.3 Hz, 1H), 8.00 (ddd, J = 8.1, 7.4, 1.8 
Hz, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.68 (dt, J = 8.0, 1.0 Hz, 1H), 7.56 – 7.51 (m, 4H), 7.48 – 
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7.44 (m, 3H), 4.25 (s, 2H); 13C-NMR (151 MHz, DMSO-d6) = 170.1 (q), 169.3 (q), 162.6 (q), 
149.4 (+), 146.1 (q), 143.0 (q), 138.9 (+), 138.8 (q), 130.5 (+), 129.3 (+), 128.4 (+), 126.8 (+), 
126.7 (q), 125.8 (+), 125.1 (+), 122.4 (+), 113.3 (+), 57.2 (−); IR (neat) = 3105, 3058, 2930, 
2881, 1707, 1610, 1487, 1424, 1327, 1245, 1174, 1111, 936, 846, 790, 753, 701 cm-1; 
HRMS (ESI) calcd. for C20H16N5O (M+H)+ m/z = 342.1349; found 342.1358. 
 
(E)-7-((1H-Pyrazol-4-yl)diazenyl)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 
(30) 
4-Nitroso-1H-pyrazole (71 mg, 0.73 mmol, 1.2 eq.) was added to a solution of 
benzodiazepine 6 (153 mg, 0.61 mmol, 1.0 eq.) in glacial acetic acid (8 mL). Then the 
mixture was stirred 3 d at room temperature, quenched by adding a saturated aqueous 
solution of NaHCO3 (30 mL) and diluted with EtOAc (30 mL). After separation of the layers, 
the aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic layers 
were dried over Na2SO4, filtered and the solvent was removed under reduced pressure. 
Purification by preparative HPLC (15% - 45% MeCN in 25 min, tR = 18.8 min) afforded 30 
(30 mg, 15%) as yellow solid. Rf 0.55 (CH2Cl2/MeOH 9:1); m.p. 133 °C; 1H-NMR (600 MHz, 
DMSO-d6) = 13.21 (bs, 1H), 10.86 (s, 1H), 8.22 (bs, 2H), 7.98 (dd, J = 8.7, 2.3 Hz, 1H), 7.56 
(d, J = 2.3 Hz, 1H), 7.55 – 7.51 (m, 3H), 7.48 – 7.43 (m, 2H), 7.39 (d, J = 8.8 Hz, 1H), 4.21 (s, 
2H); 13C-NMR (151 MHz, DMSO-d6) = 170.0 (q), 169.7 (q), 158.1 (+), 157.9 (+), 146.7 (q), 
141.2 (q), 140.8 (q), 138.6 (q), 130.6 (+), 129.4 (+), 128.4 (+), 126.4 (q), 125.0 (+), 124.4 (+), 
122.2 (+), 56.9 (−); IR (neat) = 3138, 2866, 1707, 1674, 1614, 1487, 1439, 1394, 1346, 
1200, 1133, 995, 839, 798, 723 cm-1; HRMS (ESI) calcd. for C18H15N6O (M+H)+ m/z = 
331.1302; found 331.1303. 
 
(E)-N,N,N-Triethyl-3-(2-oxo-5-phenyl-7-((4-sulfophenyl)diazenyl)-2,3-dihydro-1H-
benzo[e][1,4]diazepin-1-yl)propan-1-aminium (31) 
Compound 8 bromide (111 mg, 0.22 mmol) was dissolved in MeOH (5 mL) and 
hydrogenated to the corresponding amino derivative using Pd/C (8 mg, 10 wt. % Pd) in an 
autoclave (2 bar of H2) at room temperature for 45 min. The mixture was centrifuged, 
filtered over celite and the solvent was removed in vacuo. The amino derivative bromide 
(103 mg) was used without further purification. 
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A 1:1 mixture of tetrabutylammonium 4-nitrosobenzenesulfonate and its corresponding 
nitro derivative (192 mg, 0.44 mmol, 1.0 eq. of nitroso compound) was added to a 
solution of freshly prepared amino derivative of 8 (103 mg, 0.22 mmol, 1.0 eq.) in acetic 
acid (2 mL) and CH2Cl2 (1 mL). After stirring the mixture for 24 h at room temperature the 
solvent was removed in vacuo. Purification by preparative HPLC (3% - 55% MeCN in 
15 min, tR = 10.6 min) had to be performed twice to afford 31 trifluoroacetate salt (62 mg, 
42%) as yellow solid. Rf 0.02 (CH2Cl2/MeOH 9:1); m.p. 210 °C; 1H-NMR (400 MHz, 
DMSO-d6) = 8.14 (dd, J = 8.9, 2.4 Hz, 1H), 7.87 (d, J = 9.0 Hz, 1H), 7.83 – 7.79 (m, 2H), 
7.78 – 7.74 (m, 3H), 7.74 – 7.67 (m, 2H), 7.59 – 7.54 (m, 1H), 7.53 – 7.46 (m, 2H), 4.63 (d, 
J = 10.7 Hz, 1H), 4.25 (dt, J = 13.7, 6.7 Hz, 1H), 3.95 – 3.85 (m, 2H), 3.17 – 2.99 (m, 7H), 
2.94 (dt, J = 13.0, 4.6 Hz, 1H), 1.96 (dtt, J = 6.3 Hz, 1H), 1.84 (dtt, J = 6.3 z, 1H), 0.99 (t, J = 
7.1 Hz, 9H); 13C-NMR (101 MHz, DMSO-d6) = 169.2 (q), 169.0 (q), 158.3 (q, quartet), 
151.4 (q), 151.2 (q), 147.4 (q), 144.5 (q), 131.1 (+), 129.5 (q), 129.4 (+), 128.6 (+), 126.8 
(+), 125.1 (+), 124.7 (+), 123.9 (+), 122.3 (+), 115.3 (q, quartet), 56.7 (−), 53.8 (−), 52.2 (−), 
43.9 (−), 20.3 (−), 6.9 (+); IR (neat) = 3440, 2989, 1677, 1607, 1484, 1454, 1398, 1334, 
1189, 1118, 1029, 846, 783, 701 cm-1; HRMS (ESI) calcd. for C30H36N5O4S M+ m/z = 
562.2483; found 562.2490. 
 
(E)-N1,N1,N2,N2-Tetramethyl-N1-(2-((N-methyl-4-((2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-7-yl)diazenyl)phenyl)sulfonamido)ethyl)ethane-1,2-diaminium 
(32) 
A suspension of benzodiazepine 28 (27 mg, 0.06 mmol, 1.0 eq.), 2-chloro-N,N-
dimethylethylamine hydrochloride (18 mg, 0.13 mmol, 2.0 eq.) and K2CO3 (87 mg, 
0.63 mmol, 10.0 eq.) in DMF (1 mL) was stirred overnight at room temperature. Then a 
saturated aqueous solution of NaHCO3 (10 mL) was added and the mixture extracted with 
EtOAc (3 x 5 mL) and CH2Cl2 (3 x 5 mL). The combined organic layers were dried over 
Na2SO4, filtered and the solvent was removed under reduced pressure. The residue was 
purified by preparative HPLC (3% - 70% MeCN in 15 min, tR = 8.9 min) affording 32 bis-
trifluoroacetate salt (14 mg, 29%) as orange solid. Rf 0.02 (CH2Cl2/MeOH 9:1); m.p. 90 °C; 
1H-NMR (400 MHz, DMSO-d6) = 10.08 (bs, 1H), 9.75 (bs, 1H), 8.22 (dd, J = 8.9, 2.4 Hz, 
1H), 8.11 – 8.05 (m, 2H), 8.05 – 7.99 (m, 2H), 7.93 (d, J = 9.0 Hz, 1H), 7.78 (d, J = 2.4 Hz, 
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1H), 7.71 – 7.64 (m, 2H), 7.59 – 7.52 (m, 1H), 7.51 – 7.47 (m, 2H), 4.68 (d, J = 10.8 Hz, 1H), 
4.50 (dt, J = 14.6, 7.3 Hz, 1H), 4.23 (dt, J = 14.1, 6.8 Hz, 1H), 3.92 (d, J = 10.8 Hz, 1H), 3.33 
(s, 6H), 2.86 (s, 6H), 2.76 (s, 6H), 2.74 (s, 3H); 13C-NMR (101 MHz, DMSO-d6) = 169.2 (q), 
168.9 (q), 158.3 (q, quartet), 154.1 (q), 147.5 (q), 144.5 (q), 138.0 (q), 137.8 (q), 130.8 (+), 
130.1 (q), 129.3 (+), 128.9 (+), 128.5 (+), 125.5 (+), 125.0 (+), 123.7 (+), 123.5 (+), 116.5 (q, 
quartet), 56.7 (−), 53.3 (−), 53.0 (−), 44.9 (−), 42.4 (+, 2C), 41.8 (−), 35.0 (+); IR (neat) = 
3038, 2650, 2326, 1670, 1465, 1413, 1342, 1163, 1122, 969, 902, 831, 798, 705 cm-1; 
HRMS (ESI) calcd. for C30H38N7O3S M+ m/z = 576.2751; found 576.2752. 
 
(E)-2-((4-((4-(Diethylamino)phenyl)diazenyl)phenyl)(ethyl)amino)ethan-1-ol (40) 
N,N-Diethyl-p-phenylenediamine was converted into its diazonium tetrafluoroborate 
using an adapted procedure from Abrahamian et al.[59] HBF4 (48%, 1.7 mL) was added 
dropwise to a mixture of N,N-diethyl-p-phenylenediamine (559 mg, 3.40 mmol, 1.0 eq.) in 
water (1 mL) at 0 °C. After stirring for 30 min at 0 °C, a precooled aqueous solution (1 mL) 
of NaNO2 (235 mg, 3.40 mmol, 1.0 eq.) was added dropwise within 15 min. The mixture 
was then stirred for 3 h at room temperature. The precipitate was collected by filtration, 
washed several times with a minimum amount of cold Et2O and was dried in vacuo at 
ambient temperature. The crude diazonium tetrafluoroborate (662 mg, 74%) was 
obtained as a brown yellowish solid and used without further purification. 
2-(N-Ethylanilino)ethanol (681 mg, 4.56 mmol, 1.2 eq) and NaOAc trihydrate (181 mg, 
1.33 mmol, 0.35 eq) were added to a solution of the previously prepared diazonium 
tetrafluoroborate (1.00 g, 3.80 mmol, 1.0 eq.) in MeOH (20 mL) and water (10 mL). After 
stirring the mixture for 3 d at room temperature, the precipitate was collected by filtration 
and purified by recrystallization from MeCN affording azo compound 40 (454 mg, 15%) as 
red solid. Rf 0.12 (CH2Cl2/Et3N 99:1); m.p. 166 °C; 1H-NMR (300 MHz, DMSO-d6)  =7.65 
(dd, J = 9.0, 1.8 Hz, 4H), 6.75 (t, J = 9.1 Hz, 4H), 4.80 (t, J = 5.4 Hz, 1H), 3.70 – 3.36 (m, 10H), 
1.12 (t, J = 6.9 Hz, 9H); 13C-NMR (75 MHz, DMSO-d6)  = 149.1 (q), 148.7 (q), 142.5 (q), 
142.4 (q), 123.9 (+), 123.8 (+), 111.0 (+), 111.0 (+), 58.4 (−), 52.2 (−), 45.0 (−), 43.9 (−), 12.6 
(+), 12.1 (+); IR (neat)  = 3337, 2971, 2930, 2892, 1592, 1558, 1510, 1394, 1346, 1267, 
1193, 1144, 1070, 999, 943, 820, 783, 731 cm-1; HRMS (ESI) calcd. for C20H29N4O (M+H)+ 
m/z = 341.2336; found 341.2343. 
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(E)-N,N,N-Triethyl-2-((4-((4-(ethyl(2-hydroxyethyl)amino)phenyl)diazenyl)phenyl) 
amino) -2-oxoethan-1-aminium (44) 
Oxalyl chloride (123 µL, 1.43 mmol, 1.1 eq.) in anhydrous CH2Cl2 (0.7 mL) was added 
dropwise to 2-triethylammonio acetate (228 mg, 1.43 mmol, 1.1 eq.) in anhydrous MeCN 
(7 mL) and anhydrous DMF (50 µL). After stirring for 1 h at room temperature all volatiles 
were removed in vacuo. The residue was suspended in a mixture of anhydrous MeCN 
(3 mL) and anhydrous DMF (3 mL) and then added dropwise to a solution of azo 
compound 42 (370 mg, 1.30 mmol, 1.0 eq.) and DIPEA (2.26 mL, 13.00 mmol, 10.0 eq.) in 
anhydrous DMF (20 mL) at 0 °C. After stirring for 16 h at room temperature all volatiles 
were removed in vacuo. The residue was purified by automated flash column 
chromatography (CH2Cl2/MeOH, 3% - 25% MeOH) and subsequent preparative HPLC 
(3% - 75% MeCN in 10 min, tR = 8.0 min) yielding compound 44 trifluoroacetate (235 mg, 
33%) as dark purple glassy solid. Rf 0.20 (CH2Cl2/MeOH 9:1); m.p. 77 °C; 1H-NMR 
(400 MHz, DMSO-d6)  = 10.98 (s, 1H), 7.84 – 7.70 (m, 6H), 6.82 (d, J = 9.3 Hz, 2H), 4.24 (s, 
2H), 3.62 – 3.45 (m, 12H), 1.28 (t, J = 7.2 Hz, 9H), 1.14 (t, J = 7.0 Hz, 3H); 13C-NMR (101 MHz, 
DMSO-d6)  = 162.1 (q), 158.3 (q, quartet), 150.5 (q), 149.0 (q), 142.2 (q), 138.7 (q), 124.9 
(+), 122.6 (+), 120.1 (+), 116.1 (q, quartet) , 111.2 (+), 58.4 (−), 56.4 (−), 54.1 (−), 52.2 (−), 
45.1 (−), 12.0 (+), 7.5 (+); IR (neat)  = 3463, 3060, 2989, 1741, 1689, 1595, 1551, 1424, 
1387, 1346, 1320, 1249, 1118, 1066, 1010, 910, 828, 705 cm-1; HRMS (ESI) calcd. for 
C24H36N5O2 M+ m/z = 426.2864; found 426.2872. 
 
(E)-4-((4-(Ethyl(2-hydroxyethyl)amino)phenyl)diazenyl)-1-methylpyridin-1-ium (47) 
A mixture of azo compound 46 (243 mg, 0.90 mmol, 1.0 eq.) and iodomethane (3.08 mL, 
49.50 mmol, 55.0 eq.) in CH2Cl2 (10 mL) was stirred for 3 h at room temperature. The 
precipitate was collected by filtration, washed several times with a minimum amount of 
cold PE and was dried in vacuo affording compound 47 iodide (367 mg, 99%) as purple 
solid. Rf 0.25 (CH2Cl2/MeOH 9:1); m.p. 181 °C; 1H-NMR (300 MHz, DMSO-d6)  = 8.88 (d, J 
= 7.1 Hz, 2H), 8.10 (d, J = 7.1 Hz, 2H), 7.90 (d, J = 9.3 Hz, 2H), 7.01 (d, J = 9.5 Hz, 2H), 6.55 
(bs, 1H), 4.27 (s, 3H), 3.78 – 3.49 (m, 6H), 1.19 (t, J = 7.0 Hz, 3H); 13C-NMR (75 MHz, DMSO-
d6)  = 161.0 (q), 154.6 (q), 146.6 (+), 143.6 (q), 118.1 (+), 112.9 (+), 58.6 (−), 52.5 (−), 46.7 
(+), 46.0 (−), 12.2 (+); IR (neat)  = 3340, 3034, 2960, 2863, 1633, 1595, 1521, 1472, 1413, 
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1346, 1297, 1260, 1111, 988, 842, 775 cm-1; HRMS (ESI) calcd. for C16H21N4O M+ m/z = 
285.1710; found 285.1714. 
 
(E)-4-((4-(Ethyl(2-hydroxyethyl)amino)phenyl)diazenyl)-1-(3-(triethylammonio)propyl) 
pyridin-1-ium (48) 
A solution of azo compound 46 (30 mg, 0.11 mmol, 1.0 eq.) and 3-bromopropyl 
triethylammonium bromide (100 mg, 0.33 mmol, 3.0 eq.) in anhydrous DMF (3 mL) was 
heated to 80 °C for 30 h in a crimp top vial under nitrogen atmosphere. After drying in 
vacuo the residue was purified by preparative HPLC (3% - 98% MeCN in 15 min, tR = 
6.2 min) yielding 48 bis-trifluoroacetate salt (40 mg, 56%) as purple highly hygroscopic 
solid. Rf 0.08 (CH2Cl2/MeOH 9:1); 1H-NMR (300 MHz, D2O)  = 8.59 (d, J = 7.2 Hz, 2H), 7.88 
(d, J = 7.0 Hz, 4H), 7.46 (d, J = 10.1 Hz, 2H), 4.51 (t, J = 7.5 Hz, 2H), 4.14 (t, J = 5.2 Hz, 2H), 
4.10 – 3.92 (m, 4H), 3.29 (q, J = 7.2 Hz, 8H), 2.47 – 2.32 (m, 2H), 1.40 (t, J = 7.2 Hz, 3H), 
1.23 (t, J = 7.2 Hz, 9H); 13C-NMR (75 MHz, D2O)  = 162.9 (q, quartet), 161.8 (q), 154.3 (q), 
144.6 (+), 141.9 (q), 116.3 (q, quartet), 113.0 (+), 59.1 (−), 56.2 (−), 55.3 (−), 53.0 (−), 52.7 
(−), 50.1 (−), 23.1 (−), 12.7 (+), 6.6 (+); IR (neat)  = 3314, 2989, 2706, 1677, 1636, 1595, 
1502, 1409, 1301, 1264, 1197, 1103, 1025, 824, 716 cm-1; HRMS (ESI) calcd. for C24H39N5O 
M2+ m/z = 206.6572; found 206.6583. 
 
(E)-3-(2-((4-((4-(Diethylamino)phenyl)diazenyl)phenyl)(ethyl)amino)ethyl) 5-methyl 
2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (50) 
Thionyl chloride (7 µL, 0.09 mmol, 1.1 eq.) was added to a suspension of carboxylic acid 
49 (29 mg, 0.09 mmol, 1.0 eq.) in anhydrous CH2Cl2 (180 µL) and anhydrous DMF (50 µL) 
at 0°C under nitrogen atmosphere. After stirring the mixture for 1 h at 0 °C the solvent 
was removed in vacuo. Then a solution of azo compound 40 (30 mg, 0.09 mmol, 1.0 eq.) 
in anhydrous CH2Cl2 (50 µL) was added dropwise to the residue. The stirring was 
continued for 3 h at 0 °C and then for 24 h at room temperature. After addition of CH2Cl2 
(10 mL) the organic solution was washed with a saturated aqueous solution of NaHCO3 
(10 mL) and brine (10 mL). The organic layer was separated, dried over Na2SO4, filtered 
and the solvent was removed under reduced pressure. The residue was purified by 
preparative HPLC (MilliQ water/MeCN, 75% - 98% MeCN in 9 min, 98% MeCN for further 
6 min, tR = 10.3 min) affording compound 50 (26 mg, 46%) as orange solid. Rf 0.09 
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(CH2Cl2/Et3N 99:1); m.p. 78 °C; 1H-NMR (400 MHz, DMSO-d6)  = 9.07 (s, 1H), 7.99 (ddd, J 
= 8.0, 2.4, 1.2 Hz, 1H), 7.96 (t, J = 1.8 Hz, 1H), 7.69 – 7.54 (m, 5H), 7.51 (t, J = 7.8 Hz, 1H), 
6.75 (dd, J = 9.0, 5.1 Hz, 4H), 5.01 (s, 1H), 4.24 – 4.11 (m, 2H), 3.58 (t, J = 6.0 Hz, 2H), 3.54 
(s, 3H), 3.42 (q, J = 7.1 Hz, 4H), 3.36 (dd, J = 7.3, 2.3 Hz, 2H), 2.27 (s, 6H), 1.13 (t, J = 7.0 Hz, 
6H), 1.05 (t, J = 6.9 Hz, 3H); 13C-NMR (101 MHz, DMSO-d6)  = 166.9 (q), 166.6 (q), 149.8 
(q), 148.8 (q), 148.7 (q), 147.7 (q), 147.1 (q), 146.5 (q), 142.9 (q), 142.4 (q) 133.9 (+), 129.6 
(+), 123.9 (+), 123.7 (+), 121.5 (+), 121.2 (+), 111.3 (+), 111.0 (+), 100.9 (q), 100.6 (q), 60.8 
(−), 50.8 (+), 48.1 (−), 44.4 (−), 43.9 (−), 38.8 (+), 18.3 (+), 18.2 (+), 12.5 (+), 11.9 (+); IR 
(neat) = 3355, 3079, 2971, 2896, 1700, 1651, 1595, 1513, 1379, 1346, 1271, 1211, 1148, 
1014, 824, 783, 746, 705 cm-1; HRMS (ESI) calcd. for C36H43N6O6 (M+H)+ m/z = 655.3239; 
found 655.3248. 
 
(E)-N,N,N-Triethyl-2-((4-((4-(ethyl(2-((5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitro-
phenyl)-1,4-dihydropyridine-3-carbonyl)oxy)ethyl)amino)phenyl)diazenyl)phenyl) 
amino)-2-oxoethan-1-aminium (51) 
Thionyl chloride (16 µL, 0.22 mmol, 1.1 eq.) was added to a suspension of carboxylic acid 
49 (67 mg, 0.20 mmol, 1.0 eq.) in anhydrous CH2Cl2 (500 µL) and anhydrous DMF (150 µL) 
at 0°C under nitrogen atmosphere. After stirring the mixture for 1 h at 0 °C and 1 h at 
room temperature the solvent was removed in vacuo. Then a solution of azo compound 
44 (110 mg, 0.20 mmol, 1.0 eq.) in anhydrous DMF (2 mL) and DIPEA (104 µL) was added 
dropwise to the residue suspended in anhydrous CH2Cl2 (500 µL). The stirring was 
continued for 3 h at 0 °C and then for 20 h at room temperature. All volatiles were 
removed in vacuo. The residue was purified by automated flash column chromatography 
(CH2Cl2/MeOH, 3% - 100% MeOH) and subsequent preparative HPLC (3% - 98% MeCN in 
25 min, tR = 16.8 min) yielding compound 51 trifluoroacetate salt (34 mg, 20%) as purple 
solid. Rf 0.30 (CH2Cl2/MeOH 9:1); m.p. 88 °C; 1H-NMR (400 MHz, DMSO-d6)  = 10.98 (s, 
1H), 9.10 (s, 1H), 7.99 (ddd, J = 8.0, 2.4, 1.2 Hz, 1H), 7.94 (t, J = 2.0 Hz, 1H), 7.82 – 7.73 (m, 
4H), 7.70 (d, J = 9.1 Hz, 2H), 7.56 (dt, J = 7.7, 1.4 Hz, 1H), 7.50 (t, J = 7.8 Hz, 1H), 6.80 (d, J = 
9.3 Hz, 2H), 4.99 (s, 1H), 4.28 – 4.20 (m, 3H), 4.15 (dt, J = 11.5 Hz, 1H), 3.62 (t, J = 5.9 Hz, 
2H), 3.59 – 3.51 (m, 9H), 3.39 (dq, J = 9.8, 4.9 Hz, 2H), 2.27 (s, 3H), 2.26 (s, 3H), 1.28 (t, J = 
7.2 Hz, 9H), 1.07 (t, J = 7.0 Hz, 3H); 13C-NMR (101 MHz, DMSO-d6)  = 166.9 (q), 166.6 (q), 
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162.1 (q), 158.1 (q, quartet), 150.2 (q), 149.8 (q), 148.9 (q), 147.6 (q), 147.2 (q), 146.5 (q), 
142.5 (q), 138.8 (q), 133.9 (+), 129.6 (+), 124.7 (+), 122.7 (+), 121.5 (+), 121.2 (+), 120.1 (+), 
111.3 (+), 100.9 (q), 100.5 (q), 60.8 (−), 56.4 (−), 54.1 (−), 50.8 (+), 48.1 (−), 44.5 (−), 38.7 
(+), 18.3 (+), 18.2 (+), 11.9 (+), 7.5 (+); IR (neat)  = 3273, 3071, 2982, 1674, 1595, 1528, 
1424, 1383, 1349, 1249, 1200, 1133, 1018, 828, 719 cm-1; HRMS (ESI) calcd. for C40H50N7O7 
M+ m/z = 740.3766; found 740.3770. 
 
(E)-3-(2-(Ethyl(4-(pyridin-4-yldiazenyl)phenyl)amino)ethyl) 5-methyl 2,6-dimethyl-4-(3-
nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (52) 
Thionyl chloride (16 µL, 0.22 mmol, 1.1 eq.) was added to a suspension of carboxylic acid 
49 (67 mg, 0.20 mmol, 1.0 eq.) in anhydrous CH2Cl2 (360 µL) and anhydrous DMF (100 µL) 
at 0°C under nitrogen atmosphere. After stirring the mixture for 1 h at 0 °C the solvent 
was removed in vacuo. Then a solution of azo compound 46 (55 mg, 0.20 mmol, 1.0 eq.) 
in anhydrous CH2Cl2 (100 µL) and Et3N (50 µL) was added dropwise to the residue. The 
stirring was continued for 3 h at 0 °C and then for 24 h at room temperature. All volatiles 
were removed in vacuo and purification by preparative HPLC (MilliQ water/MeCN, 
50% - 98% MeCN in 10 min, 98% MeCN for further 5 min, tR = 9.9 min) afforded compound 
52 (20 mg, 17%) as orange solid. Rf 0.15 (CH2Cl2/Et3N 99:1); m.p. 83 °C (decomposition); 
1H-NMR (400 MHz, DMSO-d6)  = 9.07 (s, 1H), 8.76 – 8.66 (m, 2H), 7.98 (ddd, J = 8.0, 2.4, 
1.2 Hz, 1H), 7.92 (t, J = 2.0 Hz, 1H), 7.81 – 7.71 (m, 2H), 7.68 – 7.61 (m, 2H), 7.55 (dt, J = 
7.8, 1.5 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 6.84 (d, J = 9.3 Hz, 2H), 4.97 (s, 1H), 4.27 (dt, J = 
11.4, 5.7 Hz, 1H), 4.17 (dt, J = 11.5, 5.8 Hz, 1H), 3.67 (t, J = 5.8 Hz, 2H), 3.53 (s, 3H), 3.43 
(dq, J = 7.1, 3.4 Hz, 2H), 2.26 (s, 3H), 2.25 (s, 3H), 1.08 (t, J = 7.0 Hz, 3H); 13C-NMR 
(101 MHz, DMSO-d6)  = 166.9 (q), 166.5 (q), 157.4 (q), 151.6 (q), 150.8 (+), 149.7 (q), 
147.6 (q), 147.2 (q), 146.4 (q), 142.5 (q), 133.9 (+), 129.6 (+), 126.0 (+), 121.4 (+), 121.2 (+), 
115.7 (+), 111.5 (+), 101.0 (q), 100.4 (q), 60.7 (−), 50.8 (+), 48.1 (−), 44.5 (−), 38.7 (+), 18.3 
(+), 18.2 (+), 11.9 (+); IR (neat)  = 3299, 3198, 3083, 2952, 1681, 1588, 1513, 1439, 1379, 
1349, 1312, 1271, 1211, 1118, 1096, 1021, 828, 742, 705 cm-1; HRMS (ESI) calcd. for 
C31H33N6O6 (M+H)+ m/z = 585.2456; found 585.2459. 
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(E)-4-((4-(Ethyl(2-((5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-
pyridine-3-carbonyl)oxy)ethyl)amino)phenyl)diazenyl)-1-methylpyridin-1-ium (53) 
Thionyl chloride (8 µL, 0.10 mmol, 1.1 eq.) was added to a suspension of carboxylic acid 
49 (33 mg, 0.10 mmol, 1.0 eq.) in anhydrous CH2Cl2 (150 µL) and anhydrous DMF (50 µL) 
at 0 °C under nitrogen atmosphere. After stirring the mixture for 1 h at 0 °C and 1 h at 
room temperature the solvent was removed in vacuo. Then a solution of azo compound 
47 (42 mg, 0.10 mmol, 1.0 eq.) in anhydrous DMF (1 mL) and DIPEA (52 µL) was added 
dropwise to the residue suspended in anhydrous CH2Cl2 (150 µL). The stirring was 
continued for 3 h at 0 °C and then for 20 h at room temperature. All volatiles were 
removed in vacuo and purification by preparative HPLC (10% - 75% MeCN in 10 min, then 
75% - 98% MeCN in 2 min, tR = 9.1 min) afforded compound 53 trifluoroacetate salt 
(31 mg, 46%) as purple solid. Rf 0.09 (CH2Cl2/MeOH 9:1); m.p. 92 °C; 1H-NMR (400 MHz, 
DMSO-d6)  = 9.13 (s, 1H), 8.92 (d, J = 7.1 Hz, 2H), 8.12 (d, J = 7.1 Hz, 2H), 7.95 (ddd, J = 
7.8, 2.4, 1.4 Hz, 1H), 7.88 (t, J = 2.0 Hz, 1H), 7.82 (d, J = 9.3 Hz, 2H), 7.55 – 7.43 (m, 2H), 
6.94 (d, J = 9.5 Hz, 2H), 4.93 (s, 1H), 4.43 – 4.12 (m, 5H), 3.79 (t, J = 5.7 Hz, 2H), 3.57 – 3.47 
(m, 5H), 2.26 (s, 3H), 2.23 (s, 3H), 1.12 (t, J =7.04 Hz, 3H); 13C-NMR (75 MHz, DMSO-d6)  = 
166.9 (q), 166.5 (q), 161.0 (q), 154.3 (q), 149.6 (q), 147.6 (q), 147.5 (q), 146.8 (+), 146.5 
(q), 143.6 (q), 133.9 (+), 129.6 (+), 121.4 (+), 121.2 (+), 118.3 (+), 112.6 (+), 101.0 (q), 100.3 
(q), 60.7 (−), 50.9 (+), 48.5 (−), 46.9 (+), 45.0 (−), 38.6 (+), 18.4 (+), 18.2 (+), 12.1 (+); IR 
(neat)  = 3045, 2933, 1689, 1636, 1349, 1301, 1271, 1208, 1115, 1014, 846, 775, 738, 
705 cm-1; HRMS (ESI) calcd. for C32H35N6O6 M+ m/z = 599.2613; found 599.2618; purity: 
90% (254 nm), 93% (220 nm). 
 
3-(2-(Ethyl(phenyl)amino)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-
pyridine-3,5-dicarboxylate (54) 
Thionyl chloride (144 µL, 1.98 mmol, 1.1 eq.) was added to a suspension of carboxylic acid 
49 (598 mg, 1.80 mmol, 1.0 eq.) in anhydrous CH2Cl2 (4 mL) and anhydrous DMF (1 mL) at 
0°C under nitrogen atmosphere. After stirring the mixture for 1 h at 0 °C a solution of 2-
N-ethylanilino ethanol (303 mg, 1.84 mmol, 1.0 eq.) in anhydrous CH2Cl2 (1 mL) was 
added dropwise. The stirring was continued for 3 h at 0 °C and then for 24 h at room 
temperature. The solvent was removed in vacuo and the residue dissolved in EtOAc 
(10 mL). The organic solution was washed with brine (10 mL) and a saturated aqueous 
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solution of NaHCO3 (10 mL). The organic layer was separated, dried over Na2SO4, filtered 
and the solvent was removed under reduced pressure. The residue was purified by 
automated flash column chromatography (CH2Cl2 + 1% Et3N /MeOH, 3% - 10% MeOH) and 
subsequent preparative HPLC (MilliQ water/MeCN, 75% - 98% MeCN in 9 min, tR = 
6.7 min) yielding compound 54 (364 mg, 42%) as yellow solid. Rf 0.11 (CH2Cl2/Et3N 99:1); 
m.p. 121 °C; 1H-NMR (400 MHz, DMSO-d6)  = 9.08 (s, 1H), 8.00 (ddd, J = 8.0, 2.4, 1.1 Hz, 
1H), 7.96 (t, J = 2.0 Hz, 1H), 7.59 (dt, J = 7.7, 1.4 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.11 (dd, J 
= 8.7, 7.2 Hz, 2H), 6.69 – 6.61 (m, 2H), 6.56 (t, J = 7.2 Hz, 1H), 5.02 (s, 1H), 4.10 (td, J = 6.0, 
4.4 Hz, 2H), 3.55 (s, 3H), 3.44 (t, J = 6.2 Hz, 2H), 3.27 (q, J = 6.9 Hz, 2H), 2.28 (s, 3H), 2.28 
(s, 3H), 0.99 (t, J = 7.0 Hz, 3H); 13C-NMR (101 MHz, DMSO-d6)  = 167.0 (q), 166.6 (q), 149.8 
(q), 147.7 (q), 147.3 (q), 147.0 (q), 146.5 (q), 134.0 (+), 129.7 (+) , 129.1 (+), 121.5 (+), 121.2 
(+), 115.5 (+), 111.6 (+), 100.9 (q), 100.7 (q), 60.8 (−), 50.9 (+), 48.1 (−), 44.3 (−), 38.8 (+), 
18.3 (+), 18.3 (+), 11.8 (+); IR (neat)  = 3355, 3094, 2952, 2885, 1703, 1648, 1595, 1528, 
1507, 1484, 1379, 1346, 1290, 1215, 1122, 1044, 1014, 895, 828, 787, 742, 693 cm-1; 
HRMS (ESI) calcd. for C26H30N3O6 (M+H)+ m/z = 480.2129; found 480.2141. 
 
3.4.2 X-ray Crystallography 
 
Crystallographic data of 6. 
Chemical formula C15H13N3O·CH4O 
Mr 283.32 
Crystal system, space group Monoclinic, P21/c 
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Temperature (K) 123 
a, b, c (Å) 8.8058 (1), 15.9096 (2), 10.3309 (1) 
β (°) 90.198 (1) 
V (Å3) 1447.32 (3) 
Z 4 
Radiation type Cu Kα 
µ (mm−1) 0.71 
Crystal size (mm) 0.17 × 0.16 × 0.13 
Data collection 
Diffractometer SuperNova, Single source at offset, Atlas 
Absorption correction 
Multi-scan  
CrysAlis PRO, Agilent Technologies, Version 
1.171.37.31 (release 14-01-2014 CrysAlis171 .NET) 
(compiled Jan 14 2014,18:38:05) Empirical absorption 
correction using spherical harmonics, implemented in 
SCALE3 ABSPACK scaling algorithm. Empirical 
absorption correction using spherical harmonics, 
implemented in SCALE3 ABSPACK scaling algorithm. 
Tmin, Tmax 0.838, 1.000 
No. of measured, independent 
and observed [I > 2σ(I)] 
reflections 
82319, 2915, 2679 
Rint 0.031 
(sin θ/λ)max (Å−1) 0.623 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.037, 0.102, 1.02 
No. of reflections 2915 
No. of parameters 197 
H-atom treatment 
H atoms treated by a mixture of independent and 
constrained refinement 
Δρmax, Δρmin (e Å−3) 0.25, −0.24 
 
Computer programs: CrysAlis PRO, Agilent Technologies, Version 1.171.37.31 (release 14-
01-2014 CrysAlis171 .NET) (compiled Jan 14 2014, 18:38:05), SHELXS (Sheldrick, 2008), 
SHELXL (Sheldrick, 2008), Olex2 (Dolomanov et al., 2009). 
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Crystallographic data of 46. 
Chemical formula C15H18N4O 
Mr 270.33 
Crystal system, space group Orthorhombic, Pna21 
Temperature (K) 123 
a, b, c (Å) 12.7730 (3), 14.7900 (3), 7.47602 (18) 
V (Å3) 1412.31 (6) 
Z 4 
Radiation type Cu Kα 
µ (mm−1) 0.67 
Crystal size (mm) 0.15 × 0.06 × 0.04 
Data collection 
Diffractometer SuperNova, Single source at offset, Atlas 
Absorption correction 
Gaussian  
CrysAlis PRO 1.171.38.42b (Rigaku Oxford Diffraction, 
2015) Numerical absorption correction based on 
gaussian integration over a multifaceted crystal model 
Empirical absorption correction using spherical 
harmonics, implemented in SCALE3 ABSPACK scaling 
algorithm. 
Tmin, Tmax 0.988, 0.995 
No. of measured, independent 
and observed [I > 2σ(I)] 
reflections 
9497, 2721, 2510  
Rint 0.032 
(sin θ/λ)max (Å−1) 0.622 
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Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.033, 0.084, 1.05 
No. of reflections 2721 
No. of parameters 183 
No. of restraints 1 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin (e Å−3) 0.13, −0.14 
Absolute structure 
Flack x determined using 1030 quotients 
[(I+)-(I-)]/[(I+)+(I-)] (Parsons, Flack and Wagner, Acta 
Cryst. B69 (2013) 249-259). 
Absolute structure parameter −0.02 (18) 
 
Computer programs: CrysAlis PRO 1.171.38.42b (Rigaku OD, 2015), SHELXT (Sheldrick, 
2015), SHELXL (Sheldrick, 2015), Olex2 (Dolomanov et al., 2009). 
 
3.4.3 ElectrophysiologyD 
Electrophysiological recordings in whole-cell configuration were conducted on CHO-K1 
cells at room temperature (20 - 25°C) using an EPC-9 amplifier (HEKA Elektronic, 
Germany). Cells were continuously superfused with external solution containing (mM): 
NaCl 140, CaCl2 2, KCl 2.8, MgCl2 1, HEPES 20, glucose 10; pH 7.4; 320-330 mOsm. The 
patch pipette solution contained (mM): KCl 140, MgCl2, MgATP 2, HEPES 10, BAPTA 2; pH 
7.3; 290 mOsm. All recordings were performed at Vhold -30 mV. 
To express homomeric glycine-receptors cells were transfected with cDNA of one of its 
subunits: 1 zebrafish, 1 human, 2 zebrafish, 2 mouse, 1 human G254A mutant or α3 
human; to express GABAA-receptors cells were transfected with cDNA of 1, 2 and 2 
subunits simultaneously. The Lipofectamine 3000 protocol (Life Technology, USA) was 
used for transfection. Activation of glycine and GABAA-receptors was induced by 
application of agonists of different concentration (glycine and GABA, respectively). For 
rapid application of compounds a system of parallel rectangular tubes (100 µm in 
diameter), located at the distance of 40-50 µm from the tested cell, was used. The 
                                                     
D All electrophysiological investigations were performed in the group of Prof. Dr. Piotr Bregestovski by 
Galyna Maleeva at the Aix-Marseille University, France. 
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movement of the tubes was controlled by a computer-driven fast exchange system (SF77A 
Perfusion Fast-Step, Warner, USA). 
UV illumination (365 nm) has been applied using a light emitting diode (Thorlabs). 
 
3.4.4 Behavioral Tests in Zebrafish LarvaeE 
Zebrafish larvae (Danio rerio, Tupfel-long strain) at their 7th day post fertilization were 
habituated for 45 minutes inside the Zebrabox (ViewPoint high throughput monitoring 
system) under dark conditions into 200 µL of clean water. Continuously, 100 µL of water 
were extracted carefully from each well with a 12 multichannel pipette and rapidly 
substituted with 100 µL of a solution with a double final concentration of each treatment. 
To the wells with the control only 100 µL of clean water was added. The time between the 
first and last treatment addition never exceeded more than 40 seconds and experimental 
recording started as soon as all animals were refilled with their treatments. 
In total, 96 larval zebrafish were recorded for 32 minutes and analysed into 6 treatment 
groups: 
1. Control: 12 zebrafishes were kept as control animals swimming in 200 µL of clean 
water 
2. DMSO: 12 zebrafishes were exposed to 200 µL of clean water with 1% of DMSO 
3. Compound 26: 12 zebrafishes were exposed to 100 µM of 26 in 200 µL of clean 
water with 1% of DMSO 
4. Compound 27: 12 zebrafishes were exposed to 100 µM of 27 in 200 µL of clean 
water with 1% of DMSO 
5. Compound 29: 12 zebrafishes were exposed to 100 µM of 29 in 200 µL of clean 
water with 1% of DMSO. 
6. Compound 29: 12 zebrafishes were exposed to 50 µM of 29 in 200 µL of clean 
water with 1% of DMSO 
                                                     
E All in vivo experiments were carried out in the group of Prof. Dr. Pau Gorostiza by Alexandre Gomila and 
Dr. Núria Camarero at the Institute of Bioengineering of Catalonia, Barcelona, Spain. 
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All photoswitchable azo benzodiazepines were initially used in their thermal equilibrium 
thus in their trans configuration. 
Experimental procedure: 
For the first 20 minutes (relaxation period) of the experiment, the animals were kept in 
dark conditions with no light changes or mechanic stimuli. After that the animals were 
exposed to UV/blue light cycles for in total 12 minutes with alternating continuous 
illumination for 2 minutes of 365 nm and 2 minutes of 455 nm. LEDs preinstalled in the 
Zebrabox were used as light sources. 
For the figures a One-way ANOVA analysis was conducted with Dunnette’s multiple 
comparisons test against the control animal group, establishing a p-value of 0’05 for 
significance. P-value > 0’05 (ns), p<0’05 (*), p<0’01 (**), p<0’001 (***) and p<0’0001 
(****). 
 
3.4.5 Molecular DockingF 
All compounds were optimized with Gaussian09 (G09) software package[73] in B3LYP/6-
31+G** level of theory. Used receptor structures: the GABAAR homology model,[70] the 
available crystal structures of 1 and 3 GlyRs[15, 71] and a homology model of 3 GlyR open 
state created using Modeller.[74] Hydrogens and missing atoms were added using 
psfgen[75] and MolProbity.[76] Rigid and flexible dockings were done using Autodock 
Vina.[77] All images were generated using VMD (version 1.9.2).[78] 
  
                                                     
F All molecular docking experiments were performed in the group of Prof. Dr. Carme Rovira by Alba Nin-Hill 
and Dr. Mercedes Alfonso-Prieto at the University of Barcelona, Spain. 
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3.5 Supporting Information 
Photochromic data 
 
Compound 26 
 
Figure S1. Photochromic data of compound 26. a) UV-Vis spectra of azo benzodiazepine 26 (50 µM in PBS + 
0.1% DMSO) from the trans isomer, the PSS at irradiation with UV-light of 365 nm and the PSS at irradiation 
with blue light of 455 nm. b) Cycle performance of azo benzodiazepine 26 (50 µM in PBS + 0.1% DMSO). 
Changes in absorption at max of the trans isomer were measured during alternate irradiation with light of 
365 nm and 455 nm. c), d) Determination of the thermal half-lives of compound 26 at 25 °C (c: 50 µM in 
DMSO; d: 50 µM in PBS + 0.1% DMSO). 
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Compound 27 
 
Figure S2. Photochromic data of compound 27. a), b) UV-Vis spectra of azo benzodiazepine 27 (a: 50 µM in 
DMSO; b: 30 µM in PBS + 3% DMSO) from the trans isomer, the PSS at irradiation with UV-light of 365 nm 
and the PSS at irradiation with blue light of 455 nm. c), d) Cycle performance of azo benzodiazepine 27 (c: 
50 µM in DMSO; d: 30 µM in PBS + 3% DMSO). Changes in absorption at max of the trans isomer were 
measured during alternate irradiation with light of 365 nm and 455 nm. e), f) Determination of the thermal 
half-lives of compound 27 at 25 °C (e: 50 µM in DMSO; f: 30 µM in PBS + 3% DMSO).  
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Compound 28 
 
Figure S3. Photochromic data of compound 28. a) UV-Vis spectra of azo benzodiazepine 28 (50 µM in DMSO) 
from the trans isomer, the PSS at irradiation with UV-light of 365 nm and the PSS at irradiation with blue 
light of 455 nm. b) Cycle performance of azo benzodiazepine 28 (50 µM in DMSO). Changes in absorption 
at max of the trans isomer were measured during alternate irradiation with light of 365 nm and 455 nm. c) 
Determination of the thermal half-life of compound 28 at 25 °C (50 µM in DMSO).  
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Compound 29 
 
Figure S4. Photochromic data of compound 29. a), b) UV-Vis spectra of azo benzodiazepine 29 (a: 50 µM in 
DMSO; b: 50 µM in PBS + 0.1% DMSO) from the trans isomer, the PSS at irradiation with UV-light of 365 nm 
and the PSS at irradiation with blue light of 455 nm. c), d) Cycle performance of azo benzodiazepine 29 (c: 
50 µM in DMSO; d: 50 µM in PBS + 0.1% DMSO). Changes in absorption at max of the trans isomer were 
measured during alternate irradiation with light of 365 nm and 455 nm. e), f) Determination of the thermal 
half-lives of compound 29 at 25 °C (e: 50 µM in DMSO; f: 50 µM in PBS + 0.1% DMSO).  
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Compound 30 
 
Figure S5. Photochromic data of compound 30. a), b) UV-Vis spectra of azo benzodiazepine 30 (a: 50 µM in 
DMSO; b: 50 µM in PBS + 0.1% DMSO) from the trans isomer, the PSS at irradiation with UV-light of 365 nm 
and the PSS at irradiation with blue light of 530 nm. c), d) Cycle performance of azo benzodiazepine 30 (c: 
50 µM in DMSO; d: 50 µM in PBS + 0.1% DMSO). Changes in absorption at max of the trans isomer were 
measured during alternate irradiation with light of 365 nm and 530 nm. e), f) Determination of the thermal 
half-lives of compound 30 at 25 °C (e: 50 µM in DMSO; f: 50 µM in PBS + 0.1% DMSO). Determination in PBS 
was not possible due to precipitation or decomposition. 
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Compound 31 
 
Figure S6. Photochromic data of compound 31. a), b) UV-Vis spectra of azo benzodiazepine 31 (a: 50 µM in 
DMSO; b: 50 µM in PBS + 1% DMSO) from the trans isomer, the PSS at irradiation with UV-light of 365 nm 
and the PSS at irradiation with blue light of 455 nm. c), d) Cycle performance of azo benzodiazepine 31 (c: 
50 µM in DMSO; d: 50 µM in PBS + 1% DMSO). Changes in absorption at max of the trans isomer were 
measured during alternate irradiation with light of 365 nm and 455 nm. e), f) Determination of the thermal 
half-lives of compound 31 at 25 °C (e: 50 µM in DMSO; f: 50 µM in PBS + 1% DMSO). 
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Compound 32 
 
Figure S7. Photochromic data of compound 32. a), b) UV-Vis spectra of azo benzodiazepine 32 (a: 50 µM in 
DMSO; b: 50 µM in PBS + 1% DMSO) from the trans isomer, the PSS at irradiation with UV-light of 365 nm 
and the PSS at irradiation with blue light of 455 nm. c), d) Cycle performance of azo benzodiazepine 32 (c: 
50 µM in DMSO; d: 50 µM in PBS + 1% DMSO). Changes in absorption at max of the trans isomer were 
measured during alternate irradiation with light of 365 nm and 455 nm. e), f) Determination of the thermal 
half-lives of compound 32 at 25 °C (e: 50 µM in DMSO; f: 50 µM in PBS + 1% DMSO). 
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Compound 50 
 
Figure S8. Photochromic data of compound 50. a) UV-Vis spectra of azo nicardipine 50 (10 µM in DMSO) 
from the trans isomer, the PSS at irradiation with blue light of 455 nm and the PSS at irradiation with orange 
light of 590 nm. b) Cycle performance of azo nicardipine 50 (10 µM in DMSO). Changes in absorption at max 
of the trans isomer were measured during alternate irradiation with light of 455 nm and 590 nm. c) 
Determination of the thermal half-life of compound 50 at 25 °C (10 µM in DMSO). 
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Compound 51 
 
Figure S9. Photochromic data of compound 51. a) UV-Vis spectra of azo nicardipine 51 (25 µM in PBS + 1% 
DMSO) from the trans isomer and the PSS at irradiation with blue light of 455 nm. b) Cycle performance of 
azo nicardipine 51 (25 µM in PBS + 1% DMSO). Changes in absorption at max of the trans isomer were 
measured during alternate irradiation with light of 455 nm and thermal relaxation c), d) Determination of 
the thermal half-lives of compound 51 at 25 °C (c: 25 µM in DMSO; d: 25 µM in PBS + 1% DMSO). The thermal 
half-life in PBS could not properly be determined due to the described aggregation effect and additionally 
a very short thermal half-life. By comparison to the measurement in DMSO the half-life in PBS has to be < 
0.3 s. 
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Compound 52 
 
Figure S10. Photochromic data of compound 52. a) UV-Vis spectra of azo nicardipine 52 (25 µM in DMSO) 
from the trans isomer, the PSS at irradiation with blue light of 455 nm and the PSS at irradiation with UV-
light of 385 nm. b) Cycle performance of azo nicardipine 52 (25 µM in DMSO). Changes in absorption at max 
of the trans isomer were measured during alternate irradiation with light of 455 nm and 385 nm. c) 
Determination of the thermal half-life of compound 52 at 25 °C (25 µM in DMSO). 
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Compound 53 
 
Figure S11. a), b) UV-Vis spectra of the trans isomer of azo nicardipine 53 (a: 15 µM in DMSO; b: 15 µM in 
PBS + 1% DMSO). 
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1H- and 13C-NMR spectra  
Compound 6  
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Compound 8  
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Compound 26  
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Compound 27  
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Compound 28  
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Compound 29  
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Compound 30  
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Compound 31 
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Compound 32  
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Compound 40  
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Compound 44 
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Compound 47 
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Compound 48 
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Compound 50 
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Compound 51 
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Compound 52 
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Compound 53 
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Compound 54 
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4.1 Introduction 
Triplex DNA has recently received increasing attention in different fields of research due 
to its variety of biological activities including DNA damage, DNA repair, mutagenesis and 
even diseases.[1-2] The formation of triplex DNA was initially described in 1957.[3] Triplexes 
are formed by Hoogsteen or reverse Hoogsteen hydrogen bonds either intramolecularly 
whereby the third strand originates from the same DNA molecule or intermolecularly by 
binding of a separate triplex forming oligonucleotide (TFO) to the major groove of double 
stranded DNA (dsDNA) on the so called triplex target site (TTS).[4-5] Latter approach of a 
site-specific recognition of duplex DNA by TFOs was shown to be a useful approach for 
the modification of gene structure and functions both in vitro and in vivo providing a 
useful tool for gene-specific manipulation of DNA.[6]  
The cyanine dye thiazole orange (TO) is very well-known for its interaction with DNA and 
nucleic acids in general.[7] The intrinsic fluorescence of TO is rather neglectable, but upon 
intercalation in DNA enhanced dramatically by a factor of more than 1000.[8] Therefore, it 
is commonly used to stain DNA in gels[9] and capillary electrophoresis[10] or to stain 
residual RNA in blood cells.[11] Recent investigations showed that thiazole orange exhibits 
an enhanced specific high-affinity binding to triplex DNA compared to dsDNA building 
stable complexes which do even not dissociate during chromatography and gel 
electrophoresis.[12] Hence, we envisioned that functionalizing thiazole orange with a biotin 
moiety via a linker could yield a specific probe for the isolation and purification of triplex 
DNA by utilizing the biotin/streptavidin or avidin affinity, respectively. 
 
Figure 1. Structure of the cyanine dye thiazole orange (TO) and common structure of the targeted 
biotinylated thiazole orange. 
The interaction of biotinylated molecules with streptavidin or avidin is one of the most 
useful and applied tools for purification in biochemical and biomedical research due to 
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the high affinity and specificity of the vitamin biotin towards the proteins streptavidin and 
avidin.[13-14] For that reason the biotinylated thiazole orange should enable an isolation of 
only triplexes from complex mixtures of different oligonucleotides. It can also be used to 
finally extract specific dsDNA by adding a defined TFO to a mixture of dsDNA, which forms 
triplexes only with the targeted dsDNA bearing an appropriate TTS. Herein, we discuss the 
synthesis and preliminary biological evaluations of our biotinylated thiazole orange 
derivative (TO-Biotin). 
 
4.2 Results and Discussion 
4.2.1 Synthesis 
Different approaches to functionalize TO with a biotin label were attempted. Thereby, the 
initial trial to directly attach the biotin moiety at the thiazole orange core via Friedel-Crafts 
acylation was not successful. Also the synthesis of a TO derivative bearing an amino group 
for functionalization with biotin by amide coupling was problematic due to occurring side 
reactions during condensation of the two aromatic precursors to the core scaffold of the 
dye. Finally, a biotinylated thiazole orange was successfully synthesized as depicted in 
Scheme 1. 
 
Scheme 1. Preparation of TO-Biotin 6. 
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After methylation of benzothiazole 1 with methyl p-toluenesulfonate[15] and alkylation of 
lepidine (3) with propagyl bromide[16] thiazole orange derivative 5 was prepared by 
condensing the two afforded precursors 2 and 4 under basic conditions according to a 
reported procedure.[16] Subsequent copper catalyzed 1,3-dipolar cycloaddition of 
compound 5 with a commercially available azide-PEG3-biotin conjugate yielded target 
structure 6 in good yield of 76%. The yield is based on a calculation with tosylate as 
quantitative counterion, which has the highest molecular weight of all possible 
counterions. However, we are aware that according to the proton NMR analysis only 
approximately 20% of the anions are tosylates. Due to the final purification by preparative 
HPLC with aqueous TFA as eluent we could also detect trifluoroacetate as counterion by 
fluorine NMR, but not quantify the overall amount. From the synthetic procedure, also 
bromide, sulfate or hydroxyl salts are conceivable, respectively, which all are not 
detectable by standard proton and carbon NMR measurements. Nevertheless, we used 
the obtained compound with mixed counterions for preliminary biological investigations 
using a molecular weight of 945.18 grams per mole (quantitative tosylate) for preparing 
stock solutions. By using the highest possible molecular weight we could obtain false 
higher affinity values (lower EC50s) in the measurements, but in the first initial 
experiments we just wanted to check the influence of the modification we made on the 
dye structure and if the biotinylated thiazole still coordinates with higher selectivity to 
triplexes than dsDNA. Obtaining promising results in the initial biological investigations, 
we could convert the mixture of salts to a defined one by ion exchange chromatography. 
 
4.2.2 Biological InvestigationsA 
First, the ability of the investigated probes to form triplexes was verified by an 
electrophoretic mobility shift assay. Like depicted in Figure 2a the amount of triplexes is 
increasing with increasing concentration of the triplex forming oligonucleotide (TFO) up 
to 500 nM at which all TTS (dsDNA) is transformed into triplexes. The determination of 
the half-maximal effective concentrations (EC50) of the TFO to the TTS, TO to TTS and 
triplexes as well as TO-Biotin to TTS and triplexes was accomplished by using microscale 
                                                     
A All biological investigations were performed in the group of Prof. Dr. Gernot Längst by Dr. Rodrigo 
Maldonado at the University of Regensburg, Germany. 
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thermophoresis (MST). This is an immobilization-free technology using the different 
mobility of fluorescent labeled biomolecules along a temperature gradient depending on 
a variety of molecular properties such as size, charge, hydration shell or conformation.[17] 
By plotting the fluorescent intensities against the different concentrations of unlabeled 
ligands the EC50 value as well as the unbound and bound states can be determined. Thus, 
an EC50 of 54.2 nM for the TFO binding to the TTS was measured (Figure 2b).  
 
Figure 2. a) Triplex forming oligonucleotide (TFO, ssDNA of 29 bases) titration for triplex annealing. 
Increasing concentrations of non-labeled TFO (1.95 nM – 500 nM, specified above the gel image) were 
incubated with 20 nM of Cy5-labeled triplex targeting site (TTS, dsDNA of 29 base pairs) at 37 °C for 30 min. 
Then the samples were separated on a 15% polyacrylamide gel and visualized on a fluorescence scanner. As 
a control the TTS was incubated in the absence of the TFO (first lane −). b) Triplex formation analysis by 
microscale thermophoresis (MST). A fixed concentration of Cy5-labeled TTS (20 nM) was incubated with 
increasing amounts of non-labeled TFO (from 0.05 nM to 4 µM, 30 min at 37 °C) revealing an EC50 of 
54.2 nM. 
We could prove that TO exhibits a higher binding affinity to triplexes (EC50 = 0.87 µM, 
Figure 3b) compared to dsDNA (EC50 = 3.2 µM, Figure 3a). Prepared TO-Biotin 6 slightly 
lost affinity to dsDNA (EC50 = 4.8 µM, Figure 3c) but unfortunately also lost overall and 
relative affinity to triplexes (EC50 = 2.1 µM, Figure 3d). Therefore, we could not further 
utilize compound 6 for the purification of triplexes. 
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Figure 3. Analysis of thiazole orange (TO) and biotinylated thiazole orange (TO-Biotin) binding to dsDNA and 
triplex DNA by MST. a), b) Fixed concentrations of Cy5-labeled TTS (20 nM, a) and Cy5-labeled triplex (20 nM 
Cy5-TTS + 2 µM TFO, b) were incubated with increasing amounts of TO (0.005 nM – 25 nM for c; 
0.02 nM – 12.5 nM for d) revealing an EC50 of 3.2 µM for dsDNA and an EC50 of 0.87 µM for triplexes. c), d) 
Fixed concentrations of Cy5-labeled TTS (20 nM, c) and Cy5-labeled triplex (20 nM Cy5-TTS + 2 µM TFO, d) 
were incubated with increasing amounts of TO-Biotin (0.061 nM – 20 µM) revealing an EC50 of 4.8 µM for 
dsDNA and an EC50 of 2.1 µM for triplexes. 
Interestingly and in contrast to the loss of affinity, TO-Biotin 6 maintained the ability to 
stabilize triplexes known from thiazole orange as depicted in Figure 4. By adding a 
competitor oligonucleotide which is complementary to the TFO (anti_TFO) we could still 
detect triplexes in the lanes with TO-Biotin and TO, respectively. The lanes without any 
TO contained no triplexes any more, just duplexes consisting of TFO and anti_TFO. 
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Figure 4. Stabilization of triplexes by TO and TO-Biotin. Triplexes were annealed by incubating a Cy5-labeled 
TFO and a non-labeled TTS using a ratio TTS:TFO of 1:4 (50 nM:200 nM) for 30 min at 37 °C (lane 3). In order 
to destabilize the triplexes a competitor oligonucleotide that is complementary to the TFO (anti_TFO, lane 
2) was titrated after triplex annealing and incubated for 15 min at 37 °C (lane 4-6). To examine the 
stabilization of the triplexes by TO and TO-Biotin the triplexes were incubated with 50 µM of both 
compounds for 10 min at 25 °C prior to the titration of the anti_TFO. All samples were separated on a 12% 
polyacrylamide gel and visualized on a fluorescence scanner. 
4.3 Conclusion 
In summary, we designed a thiazole orange derivative functionalized with a biotin moiety 
for purification and isolation of triplex DNA. The target compound was synthesized 
connecting a thiazole orange derivative to a commercial biotin conjugate by azide-alkyne 
click chemistry in good yield. However, preliminary biological investigations showed that 
the prepared biotinylated thiazole orange lost overall affinity and specificity to triplex DNA 
compared to the non-functionalized thiazole orange. For this reason, our biotinylated 
thiazole orange could not be utilized for a selective purification of triplex DNA. In contrast, 
further investigations indicated that the prepared thiazole orange derivative kept the 
ability to stabilize triplexes against competitor oligonucleotides, which is a known feature 
for unfunctionalized thiazole orange. 
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4.4 Experimental 
4.4.1 General Information 
Compounds 2,[15] 4,[16] 5,[16] were synthesized according to reported procedures. 
Commercial reagents and starting materials were purchased from Acros Organics, Alfa-
Aesar, Fisher Scientific, Sigma Aldrich or VWR and used without any further purification. 
Solvents were used in p.a. quality. The melting point was measured with a Stanford 
Research Systems OptiMelt MPA 100 device and is uncorrected. NMR spectra were 
recorded on a Bruker Avance III 600 (1H 600.25 MHz, 13C 150.95 MHz) instrument. The 
spectra are referenced against the NMR-solvent (DMSO-d6: H = 2.50 ppm, C = 
39.52 ppm) and chemical shifts  are reported in ppm. Abbreviations for resonance 
multiplicity: s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). Carbon NMR 
signals are reported using a 1H-13C HSQC spectrum with (+) for primary/tertiary, (−) for 
secondary and (q) for quaternary carbons. An Agilent Q-TOF 6540 UHD (ESI-MS) 
instrument was used for measuring mass spectra. A Knauer system (two Knauer K-1001 
pumps with a Knauer K-2600 UV-detector; column: Phenomenex Luna 10 µM C18(2) 
100 Å, 250 x 21.2 mm; flow: 11.0 mL/min at room temperature; solvent A: MilliQ water 
with 0.05 % vol. TFA; solvent B: MeCN) was used for purification by preparative HPLC. 
Analytical HPLC measurements for reaction monitoring and a final purity test were 
performed on an Agilent 1220 Infinity LC (column: Phenomenex Luna 3 µM C18(2) 100 Å, 
150 x 2.00 mm; flow: 0.3 mL/min at 30 °C; solvent A: MilliQ water with 0.05 % vol. TFA; 
solvent B: MeCN). A purity of 96% for biotinylated thiazole orange 6 (gradient: 10% - 98% 
MeCN in 25 min, 98% MeCN for further 5 min, tR = 10.9 min) of 96% with detection at 
254 nm was measured. 
 
4.4.2 Synthesis and Characterization of TO-Biotin 
4-((3-Methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-1-((1-(13-oxo-17-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-
triazol-4-yl)methyl)quinolin-1-ium (6) 
A reaction vessel was equipped with biotin-PEG3-azide (105 mg, 0.24 mmol, 1.0 eq.), 
thiazole orange 5 (354 mg, 0.71 mmol, 3.0 eq.), CuSO4 x 5 H2O (177 mg, 0.71 mmol, 
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3.0 eq.), TBTA (438 mg, 0.83 mmol, 3.5 eq.) and sodium ascorbate (234 mg, 1.18 mmol, 
5.0 eq.). Then a solution of H2O/MeCN (1:1, 5 mL) was added and the mixture was stirred 
at room temperature for 3 d. After removal of the solvent by evaporation under reduced 
pressure and lyophilization the crude product was purified by preparative HPLC 
(10% - 95% MeCN in 25 min, tR = 13.4 min) affording TO 6 (170 mg, 76%) as an orange-red 
fluffy solid. m.p. 188 °C; 1H-NMR (600 MHz, MeOH-d4) = 8.82 - 8.76 (m, 2H), 8.27 (s, 1H), 
8.23 (d, J = 8.6 Hz, 1H), 8.08 (dd, J = 7.9, 0.8 Hz 1H), 7.94 (ddd, J = 8.5, 7.0, 1.2 Hz, 1H), 7.83 
(d, J = 8.3 Hz, 1H), 7.80 (t, J = 5.6 Hz, 1H), 7.72 (ddd, J = 8.1, 7.4, 1.2 Hz, 1H), 7.64 (ddd, J = 
8.4, 7.4, 1.2 Hz, 1H), 7.48 – 7.44 (m, 2H), 6.97 (s, 1H), 6.39 (s, 1H), 6.35 (s, 1H), 5.92 (s, 2H), 
4.51 (t, J = 5.1 Hz, 2H), 4.29 (dd, J = 7.8, 5.0 Hz, 1H), 4.10 (ddd, J = 7.8, 4.5, 1.8 Hz, 1H), 4.05 
(s, 3H), 3.77 (t, J = 5.2 Hz, 2H), 3.46 (dd, J = 5.9, 3.4 Hz, 2H), 3.43 – 3.40 (m, 6H), 3.37 – 3.36 
(m, 2H), 3.16 (q, J = 5.9 Hz, 2H), 3.06 (ddd, J = 8.6, 6.2, 4.4 Hz, 1H), 2.80 (dd, J = 12.4, 5.1 Hz, 
1H), 2.56 (d, J = 12.4 Hz, 1H), 2.04 (t, J = 7.4 Hz, 2H), 1.63 – 1.54 (m, 1H), 1.52 – 1.40 (m, 
3H), 1.32 – 1.23 (m, 2H).; 13C-NMR (151 MHz, MeOH-d4) = 172.1 (q), 162.7 (q), 160.7 (q), 
148.7 (q), 144.6 (+), 140.9 (q), 140.5 (q), 137.1 (q), 133.1 (+), 128.3 (+), 126.8 (+), 125.7 (+), 
124.7 (+), 124.5 (+), 124.2 (q), 124.0 (q), 122.9 (+), 118.3 (+), 113.2 (+), 107.8 (+), 88.6 (+), 
69.6 (−), 69.6 (−), 69.5 (−), 69.5 (−), 69.1 (−), 68.6 (−), 61.0 (+), 59.2 (+), 55.4 (+), 49.6 (−), 
49.0 (−), 40.1 (−), 38.4 (−), 35.1 (−), 34.0 (+), 28.2 (−), 28.0 (−), 25.2 (−); HRMS (ESI) calcd. 
for C39H49N8O5S2 M+ m/z = 773.3262; found 773.3267. 
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4.5 Supporting Information 
1H- and 13C-NMR spectra of compound 6 
 
 
Signals marked with * result from tosylate as partial counterion. 
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5 Summary  
 
The major part of this thesis (Chapter 1 – 3) focuses on the functionalization of different 
photochromic scaffolds for biological applications. Chapter 4 deals with a modified dye 
for purification of triplex DNA. 
Chapter 1 describes different synthetic routes to photochromic dithienylmaleimides 
functionalized either at each of the thiophene moieties or at the maleimide nitrogen. A 
Perkin-type condensation of two independently prepared thiophene precursors was 
successfully employed as the key step to assemble the maleimide core for non-symmetric 
diarylmaleimides. Thus, a photoswitchable amino acid was obtained and a variety of 
aromatic substituted dithienylmaleimides were synthesized by applying a Suzuki coupling 
strategy prior to the condensation. A different synthetic approach gave access to 
photochromic labeled natural amino acids as well as maleimide protected 
dithienylmaleimides by the reaction of a dithienylmaleic anhydride with amines or 
hydrazines. All prepared photoswitchable compounds exhibited reversible 
photochromism in polar organic solvents. 
Photoswitchable histone deacetylase (HDAC) inhibitors are presented in Chapter 2. These 
inhibitors were gained by equipping dithienylethenes (DTEs) and fulgimides with 
hydroxamic acids to enable binding to zinc dependent HDACs. The control of these 
enzymes is of high biomedical interest in anticancer research and epigenetics due to their 
crucial role in numerous biological processes. While the photochromic performance of the 
two prepared classes of DTEs was only moderate in polar solvents the fulgimides featured 
excellent reversible photochromism even in aqueous buffer with very high 
photostationary states. All synthesized target compounds showed the anticipated 
inhibitory effect on the tested hHDAC1, hHDAC6, hHDAC8 and smHDAC8 with best IC50 
values in the low nanomolar range. However, the corresponding photoisomers showed 
only a maximum four-fold difference in inhibitory ability. The differences in activity 
observed in the in vitro experiments could be rationalized by molecular dockings. 
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Chapter 3 reports the synthesis and biological evaluation of photochromic ligands for 
modulation of -aminobutyric acid (GABA) and glycine-receptors by light. Therefore, 
photochromic ligands were synthesized by merging structural elements of nitrazepam and 
nicardipine, which are well-known pharmacophores for ion channels, with 
photoswitchable azobenzenes. The photochromic properties of the ligands were 
outstanding with very good fatigue resistance and high photostationary states. Initial in 
vitro electrophysiological investigations identified one azo benzodiazepine as very 
promising ligand. This compound acted not only as a UV sensitive blocker of GABAA-
receptors, but also as subtype specific photoswitchable modulator of glycine-receptors. 
Preliminary molecular dockings could partly explain these experimental effects. 
Furthermore, in vivo investigations of the photochromic ligands were performed and 
another azo benzodiazepine showed photoswitchable influence on the activity of 
zebrafish larvae. 
The attempt to purify triplex DNA with a biotinylated thiazole orange derivative, which 
was synthesized by azide-alkyne click chemistry, is described in Chapter 4. Biological 
investigations of the functionalized compound could prove that the prepared thiazole 
orange kept the ability to stabilize triplexes against competitor oligonucleotides. 
However, a loss of overall affinity and specificity to triplex DNA was observed, which 
disqualified the biotinylated thiazole orange for a utilization to purify triplexes. 
Overall, this thesis presents functionalized synthetic compounds for biological 
applications. In particular, the contributions of this work are relevant for the future 
development of novel molecular tools to light-control cellular processes or living 
organisms. 
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6 Zusammenfassung  
 
Der Großteil dieser Arbeit (Kapitel 1 – 3) befasst sich mit der Funktionalisierung 
photochromer Strukturen und deren biologischen Anwendungen. Kapitel 4 diskutiert die 
Synthese und Eigenschaften eines modifizierten Farbstoffs für die Aufreinigung von 
Triplex-DNA. 
In Kapitel 1 werden verschiedene Syntheserouten zu photochromen Dithienylmaleimiden 
beschrieben, die entweder an jedem Thiophen oder am Maleimid-Stickstoff 
funktionalisiert sind. Eine Perkin-Kondensationsreaktion von zwei unabhängig 
voneinander hergestellten Thiophenvorstufen wurde als Schlüsselschritt zum Aufbau der 
Maleimid-Grundstruktur unsymmetrische Diarylmaleimde verwendet. Damit konnte eine 
photoschaltbare Aminosäure hergestellt werden, sowie verschiedene, aromatisch 
substituierte Dithienylmaleimide. Letzteres gelang durch eine Funktionalisierung der 
Vorstufen mittels Suzuki-Kupplung vor der Kondensation. Ein weiterer synthetischer 
Ansatz der Reaktion eines Dithienylmaleimidanhydrids mit Aminen oder Hydrazinen 
lieferte photochrom markierte natürliche Aminosäuren und Stickstoff-geschützte 
Dithienylmalemide. Alle hergestellten photoschaltbaren Verbindungen zeigten reversible 
Photochromie in polaren organischen Lösungsmitteln. 
Kapitel 2 befasst sich mit photoschaltbaren Inhibitoren für Histon-Deacetylasen (HDACs). 
Diese Inhibitoren wurden durch Derivatisierung von Dithienylethenen (DTEs) und 
Fulgimiden mit Hydroxamsäuren erhalten, welche eine Bindung an HDACs mit einem 
Zinkion im katalytischen Zentrum ermöglichen. Die Kontrolle dieser Enzyme ist wegen 
ihrer entscheidenden Rolle in einer Vielzahl von biologischen Prozessen von hohem 
biomedizinischem Interesse in der Anti-Krebs-Forschung und auf dem Gebiet der 
Epigenetik. Während die photochromen Eigenschaften der zwei verschiedenen Klassen 
von verwendeten DTEs in polaren Lösungsmitteln nur mäßig waren, zeigten hingegen die 
Fulgimide sogar in wässrigen Puffersystemen ausgezeichnetes und reversibles 
photochromes Verhalten mit sehr hohen photostationären Zuständen. Alle 
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synthetisierten Zielstrukturen zeigten eine erwartete Inhibition der getesteten hHDAC1, 
hHDAC6, hHDAC8 und smHDAC8 mit den besten IC50-Werten im zweistelligen 
nanomolaren Bereich. Die entsprechenden Photoisomere unterschieden sich jedoch nur 
maximal vierfach in ihrer Inhibitionswirkung. Die beobachteten Inhibitionsunterschiede 
konnten durch molekulares Docking erklärt werden. 
Die Synthese und biologische Untersuchung von photochromen Liganden für die 
Regulierung von -Aminobuttersäure- (GABA) und Glycinrezeptoren mittels Licht ist in 
Kapitel 3 dargestellt. Für die Herstellung dieser Liganden wurden Strukturelemente von 
Nitrazepam und Nicardipin, die bekannte Pharmakophore für Ionenkanäle sind, mit der 
von Azobenzolen verschmolzen. Die photochromen Eigenschaften der Liganden waren 
herausragend mit sehr guter Stabilität und hohen photostationären Zuständen. Erste 
elektrophysiologische Untersuchungen in vitro identifizierten ein Azo-Benzodiazepin als 
vielversprechenden Liganden. Dieser wirkte nicht nur als UV-sensitiver Blocker von 
GABAA-Kanälen, sondern auch als subtypspezifischer, photoschaltbarer Modulator an 
Glycinrezeptoren. Vorläufige molekulare Dockings konnten diese experimentellen 
Befunde teilweise erklären. Außerdem wurden die ersten photochromen Liganden auch 
in vivo untersucht und dabei zeigte ein weiteres Azo-Benzodiazepin photoschaltbaren 
Einfluss auf die Aktivität von Zebrafischlarven. 
Kapitel 4 beschreibt den Versuch der Aufreinigung von Triplex-DNA mittels eines Thiazol 
Orange Derivats, das mit Hilfe einer Azid-Alkin-Cycloaddition mit Biotin funktionalisiert 
wurde. Biologische Untersuchungen zeigten, dass die hergestellte Verbindung zwar auch 
wie Thiazol Orange die Eigenschaft hat Triplex-DNA gegenüber konkurrierende 
Oligonucleotide zu stabilisieren, jedoch insgesamt nicht mehr so affin und spezifisch an 
Triplex-DNA bindet. Damit konnte das funktionalisierte Thiazol Orange nicht wie weiter 
angedacht zur Aufreinigung von Triplex-DNA verwendet werden. 
Zusammengefasst beschreibt diese Arbeit synthetische, funktionalisierte Verbindungen 
für biologische Anwendungen. Die erzielten Erkenntnisse sind insbesondere für die 
zukünftige Entwicklung von neuen molekularen Werkzeugen relevant, um zelluläre 
Prozesse oder neurophysiologische Prozesse in Lebewesen mit Licht zu steuern. 
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7 Appendix 
 
7.1 Abbreviations 
A      absorbance 
Alloc     allyloxycarbonyl 
APCI     atmospheric pressure chemical ionization 
Ar      aryl 
BZD     benzodiazepine 
calcd.    calculated 
Cbz     carboxybenzyl 
CDI     1,1’-carbonyldiimadazole 
CMC     critical micelle concentration 
conc.     concentration 
dba     dibenzylideneacetone 
DEPT     distortionless enhancement by polarization transfer 
DIPEA    N,N-diisopropylethylamine  
DMF     N,N-dimethylformamide 
DMSO    dimethyl sulfoxide 
DNA     deoxyribonucleic acid 
dsDNA    double stranded deoxyribonucleic acid 
DTE     dithienylethene 
      molar extinction coefficient
EC50     half-maximal effective concentration 
eq.     equivalent(s) 
ESI     electrospray ionization 
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Fmoc     fluorenylmethyloxycarbonyl 
GABA    -aminobutyric acid 
GABAAR    -aminobutyric acid A-receptor 
Gly     glycine 
GlyR     glycine-receptor 
HDAC    histone deacetylates  
HDACi    histone deacetylates inhibitor 
HPLC     high performance liquid chromatography 
HR-MS    high-resolution mass spectrometry 
HSQC     heteronuclear single-quantum correlation 
IC50     half-maximal inhibitory concentration 
IR      infrared spectroscopy 
J      coupling constant 
      wavelength 
LAH     lithium aluminum hydride 
LC-MS    liquid chromatography–mass spectrometry 
LED     light-emitting diode 
Lys     lysine 
m.p.     melting point 
max     maximum 
MCPBA    meta-chloroperoxybenzoic acid 
MOE     Molecular Operating Environment 
MST     MicroScale Thermophoresis 
n.i.     no inhibition 
NBS     N-bromosuccinimide 
NMR     nuclear magnetic resonance 
Oxone    potassium peroxysulfate 
p.a.     pro analysi 
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PBS     phosphate-buffered saline 
PCL     photochromic ligand 
Pd/C     palladium on charcoal 
PDB     Protein Data Bank 
PE      petroleum ether 
PEG     polyethylene glycol 
PSS     photostationary state 
PTL     photochromic tethered ligand 
PyBOP    benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
Rf      retention factor 
ssDNA    double stranded deoxyribonucleic acid 
t1/2     half-life 
TBTA     tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amin 
TFA     trifluoroacetic acid 
TFO     triplex forming oligonucleotide 
THF     tetrahydrofuran 
TICT     twisted intramolecular charge transfer 
TO     thiazole orange 
tR      retention time 
tra.     trans 
TTN     thallium trinitrate 
TTS     triplex target site 
UV     ultraviolet 
Vis     visible  
WT     wild type 
XPhos    2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl 
ZMAL    (S)-[5-acetylamino-1-(4-methyl-2-oxo-2H-chromen-7-ylcarbamoyl)- 
pentyl]-carbamic acid benzyl ester 
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